<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC6579862</article-id><article-id pub-id-type="pmcid-ver">PMC6579862.1</article-id><article-id pub-id-type="pmcaid">6579862</article-id><article-id pub-id-type="pmcaiid">6579862</article-id><article-id pub-id-type="pmid">31244856</article-id><article-id pub-id-type="doi">10.3389/fimmu.2019.01317</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The Humoral Immune Response to BCG Vaccination</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tanner</surname><given-names initials="R">Rachel</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/565939/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Villarreal-Ramos</surname><given-names initials="B">Bernardo</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vordermeier</surname><given-names initials="HM">H. Martin</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McShane</surname><given-names initials="H">Helen</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/137687/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>The Jenner Institute, Nuffield Department of Medicine, University of Oxford</institution>, <addr-line>Oxford</addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Bacteriology, Animal and Plant Health Agency</institution>, <addr-line>Addlestone</addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><sup>3</sup><institution>Institute of Biological, Environmental and Rural Sciences, Aberystwyth University</institution>, <addr-line>Aberystwyth</addr-line>, <country>United Kingdom</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Jeffrey K. Actor, University of Texas Health Science Center at Houston, United States</p></fn><fn fn-type="edited-by"><p>Reviewed by: Christine Benn, State Serum Institute (SSI), Denmark; Steven Anthony Porcelli, Albert Einstein College of Medicine, United States</p></fn><corresp id="c001">*Correspondence: Rachel Tanner <email>rachel.tanner@ndm.ox.ac.uk</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>11</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">328186</issue-id><elocation-id>1317</elocation-id><history><date date-type="received"><day>09</day><month>4</month><year>2019</year></date><date date-type="accepted"><day>23</day><month>5</month><year>2019</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2019</year></date></event><event event-type="pmc-live"><date><day>26</day><month>06</month><year>2019</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-10-11 12:25:21.200"><day>11</day><month>10</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2019 Tanner, Villarreal-Ramos, Vordermeier and McShane.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Tanner, Villarreal-Ramos, Vordermeier and McShane</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-10-01317.pdf"/><abstract><p>Bacillus Calmette Gu&#233;rin (BCG) is the only currently available vaccine against tuberculosis (TB), but it confers incomplete and variable protection against pulmonary TB in humans and bovine TB (bTB) in cattle. Insights into the immune response induced by BCG offer an underexploited opportunity to gain knowledge that may inform the design of a more efficacious vaccine, which is urgently needed to control these major global epidemics. Humoral immunity in TB and bTB has been neglected, but recent studies supporting a role for antibodies in protection against TB has driven a growing interest in determining their relevance to vaccine development. In this manuscript we review what is known about the humoral immune response to BCG vaccination and re-vaccination across species, including evidence for the induction of specific B cells and antibodies; and how these may relate to protection from TB or bTB. We discuss potential explanations for often conflicting findings and consider how factors such as BCG strain, manufacturing methodology and route of administration influence the humoral response. As novel vaccination strategies include BCG prime-boost regimens, the literature regarding off-target immunomodulatory effects of BCG vaccination on non-specific humoral immunity is also reviewed. Overall, reported outcomes to date are inconsistent, but indicate that humoral responses are heterogeneous and may play different roles in different species, populations, or individual hosts. Further study is warranted to determine whether a new TB vaccine could benefit from the targeting of humoral as well as cell-mediated immunity.</p></abstract><kwd-group><kwd>humoral immunity</kwd><kwd>BCG vaccine</kwd><kwd>antibodies</kwd><kwd>B cells</kwd><kwd>tuberculosis</kwd><kwd>bovine TB</kwd></kwd-group><counts><fig-count count="0"/><table-count count="3"/><equation-count count="0"/><ref-count count="224"/><page-count count="18"/><word-count count="17112"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Tuberculosis (TB), caused by <italic toggle="yes">Mycobacterium tuberculosis</italic> (<italic toggle="yes">M.tb</italic>), continues to pose a major global health threat with 10 million new cases and 1.6 million deaths per year (<xref rid="B1" ref-type="bibr">1</xref>). Bovine TB (bTB), caused mainly by the related <italic toggle="yes">Mycobacterium bovis</italic> (<italic toggle="yes">M.bovis</italic>), is one of the principal diseases reducing livestock production and thus wealth in Africa, South Asia and South America, with an estimated global annual impact of US $3 billion (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>). bTB also has public health implications, and in 2017 the World Health Organization (WHO), Food and Agriculture Organization of the United Nations (FAO), World Organization for Animal Health (OIE), and Union against Tuberculosis and Lung Disease published a roadmap to combat zoonotic TB (<xref rid="B4" ref-type="bibr">4</xref>). Bacillus Calmette Gu&#233;rin (BCG) is the only currently available vaccine against TB and potentially bTB, but confers incomplete and variable protection against pulmonary TB in humans and against bTB in cattle (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>&#8211;<xref rid="B7" ref-type="bibr">7</xref>).</p><p>Due to the ability of mycobacteria to survive the intracellular environment of phagocytic cells, and the demonstration of specific T cells as the pillar of acquired immunity to TB (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>), immunology studies and TB/bTB vaccine development to date have focused on cell-mediated immunity. Indeed, there is ample evidence that the cellular response is necessary for protection, notably the increased susceptibility to TB in mice and humans lacking elements of T cell immunity (<xref rid="B10" ref-type="bibr">10</xref>&#8211;<xref rid="B12" ref-type="bibr">12</xref>). T cell responses to BCG vaccination have been described, indicating the induction of robust Th1 responses in adults and infants (<xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>). However, the association between vaccine-induced cell-mediated immunity and protection against TB is unclear (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). The TB vaccine candidate MVA85A did not demonstrate protective efficacy in a recent Phase IIb trial despite inducing an IFN&#947;-secreting CD4<sup>+</sup> T cell response (<xref rid="B17" ref-type="bibr">17</xref>). It is not known whether protection requires a more potent cellular response or qualitatively different immunogenicity. A role for unconventional T cells and trained innate immunity in BCG-mediated protection against TB has recently been proposed (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>), as well as the potential involvement of humoral immunity (<xref rid="B20" ref-type="bibr">20</xref>).</p><p>The humoral immune response in the context of TB and bTB has been understudied, but recent evidence suggests that B cells and antibodies may play a more significant role than previously appreciated (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B21" ref-type="bibr">21</xref>). An antibody response to the Ag85 complex was associated with superior outcome in a cohort of <italic toggle="yes">M.tb</italic>-infected Mexican Indians (<xref rid="B22" ref-type="bibr">22</xref>). Furthermore, low titers of antibodies against the mycobacteria surface glycolipid lipoarabinomannan (LAM) have been associated with disseminated TB in children (<xref rid="B23" ref-type="bibr">23</xref>), and some evidence suggests that monoclonal antibodies against arabinomannan (AM; the sugar component of LAM) are protective in mouse infection models (<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>). Lu et al. recently applied a systems serology approach to identify antibody features that distinguished active TB patients from individuals with latent <italic toggle="yes">M.tb</italic> infection (LTBI), indicating a role for antibody effector functions in control of infection (<xref rid="B26" ref-type="bibr">26</xref>). Exposed but healthy healthcare workers have also been shown to make antibodies that offer moderate protection against <italic toggle="yes">M.tb</italic> infection in both mouse aerosol challenge and <italic toggle="yes">in vitro</italic> models (<xref rid="B27" ref-type="bibr">27</xref>).</p><p>The antibody response to BCG vaccination has widely been considered of little relevance to protection (<xref rid="B13" ref-type="bibr">13</xref>). However, in a recent <italic toggle="yes">post-hoc</italic> correlates of risk analysis using samples from the MVA85A efficacy trial, levels of Ag85A-specific IgG were associated with reduced risk of TB disease in BCG-vaccinated South African infants (<xref rid="B28" ref-type="bibr">28</xref>). Though increased following MVA85A vaccination in the BCG-MVA85A group, levels of these antibodies were also increased in the BCG-only placebo group at this time-point, suggesting that protective antibodies may be induced by BCG vaccination (<xref rid="B28" ref-type="bibr">28</xref>). Potential mechanisms of antibody-mediated immunity against <italic toggle="yes">M.tb</italic> include enhanced phagocytosis, increased phagolysosome formation, bacterial neutralization, enhanced inflammasome activation, and enhanced cytotoxic NK cell activity (<xref rid="B29" ref-type="bibr">29</xref>). Antibodies may also interact with T cells to promote immunity, for example through forming bacterial-antibody complexes that result in increased processing and presentation of <italic toggle="yes">M.tb</italic> antigens to CD4<sup>+</sup> T cells by phagocytes, thus increasing T cell activation and enhancing cytotoxic responses (<xref rid="B29" ref-type="bibr">29</xref>).</p><p>We review what is known about the humoral immune response to BCG vaccination and re-vaccination across species, including evidence for the induction of specific B cells and antibodies and how these may relate to protection from TB or bTB. We consider how factors such as BCG strain, manufacturing methodology and route of administration influence the humoral response, as well as the immunomodulatory effects of BCG vaccination on non-specific humoral immunity. Insights into the BCG-induced specific immune response may aid in informing the design of an efficacious new TB vaccine which could benefit from the targeting of humoral, as well as cell-mediated, immunity. Understanding the off-target effects of BCG is also important in the context of TB vaccine development, as novel candidates in the current pipeline include both homologous and heterologous BCG prime-boost regimens. Understanding the mechanisms of non-specific immunity opens the possibility of replicating or boosting beneficial responses to the host advantage, or conversely of avoiding exacerbation of undesirable effects.</p></sec><sec id="s2"><title>The B Cell Response to BCG Vaccination</title><p>B cells are observed in the lungs of TB patients, in the granulomas of mice and non-human primates (NHPs) infected with <italic toggle="yes">M.tb</italic>, and in cattle infected with <italic toggle="yes">M.bovis</italic>; these cells may act to orchestrate and modulate the immune environment of the infected lung (<xref rid="B30" ref-type="bibr">30</xref>&#8211;<xref rid="B33" ref-type="bibr">33</xref>). There is evidence of a role for B cells in the granuloma producing <italic toggle="yes">M.tb</italic>-specific antibodies, acting as antigen presenting cells (APCs) and reducing immunopathology (<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>). Humans with pulmonary TB disease have been shown to have lower peripheral B cell counts than asymptomatic individuals with or without <italic toggle="yes">M.tb</italic> infection (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>). Vordermeier et al. demonstrated an increased susceptibility to TB in B cell deficient mice, although interestingly specific T cell responses or protection conferred by BCG vaccination were not impaired (<xref rid="B38" ref-type="bibr">38</xref>). Bosio et al. also reported that although B cell deficient mice had comparable bacterial loads in the lungs following low-dose infection with an <italic toggle="yes">M.tb</italic> clinical isolate, there was less severe lesion formation and delayed dissemination of bacteria (<xref rid="B39" ref-type="bibr">39</xref>). It was later shown that adoptive transfer of B cells into B cell knock-out (KO) mice reversed the enhanced susceptibility to infection and immunopathology observed (<xref rid="B40" ref-type="bibr">40</xref>). However, others have reported no role for B cells in such models, which may reflect differences in genetic backgrounds or strain and dose of <italic toggle="yes">M.tb</italic> used for infection (<xref rid="B39" ref-type="bibr">39</xref>&#8211;<xref rid="B42" ref-type="bibr">42</xref>). The B cell compartment may even be involved in disease progression, with an abundance of antibodies in sera of patients with active disease suggesting that B cells are involved in immunopathology (<xref rid="B34" ref-type="bibr">34</xref>), although the direction of causality is unclear.</p><p>There is a paucity of literature on the B cell response to BCG vaccination (<xref rid="B13" ref-type="bibr">13</xref>), although it has been demonstrated in mice that B cell deficiency results in a diminished BCG vaccine-induced Th1 response. Using a series of elegant experiments, the authors proposed that B cells regulate neutrophilia during <italic toggle="yes">M.tb</italic> infection and BCG vaccination by modulating the IL-17 response, and that exuberant early neutrophilia (as observed in B cell deficient mice) can adversely affect the vaccine-induced Th1 response by impairment of dendritic cell (DC) migration to draining lymph nodes, thus compromising CD4<sup>+</sup> T cell priming (<xref rid="B43" ref-type="bibr">43</xref>).</p><p>A clinical study of 79 BCG-vaccinated and 14 unvaccinated human volunteers found a significantly higher frequency of PPD-specific memory B cells in PBMC from BCG-vaccinated compared with unvaccinated volunteers (<xref rid="B44" ref-type="bibr">44</xref>). A lack of B cell reactivity to either ESAT-6 or CFP-10 indicated that the increased B cell response was not due to <italic toggle="yes">M.tb</italic> exposure. Donors received BCG vaccination between 13 and 45 years prior to enrolment, suggesting a long duration of the memory B cell response (<xref rid="B44" ref-type="bibr">44</xref>). Conversely, in a randomized trial of 118 Danish infants, there was limited overall impact of neonatal BCG vaccination on a range of measured B or T cell subset frequencies (<xref rid="B45" ref-type="bibr">45</xref>). However, it should be noted that proportions of cells present in the peripheral blood may not correlate linearly with specific immunity, and that effects of antigen-specific cells may be masked where total populations are measured.</p></sec><sec id="s3"><title>The Specific Antibody Response to BCG Vaccination</title><sec><title>BCG Vaccination in Humans</title><p>There have been several studies measuring the specific antibody response to BCG vaccination, a summary of which is provided in <xref rid="T1" ref-type="table">Table 1</xref>. Early investigations utilized haemagglutination assays; the first serodiagnostic test for TB described by Middlebrook and Dubos in 1948 (<xref rid="B78" ref-type="bibr">78</xref>). Lagercrantz and Enell reported a large study of 248 healthy Swedish children aged 8&#8211;15 years who were BCG-vaccinated during their first year at school. Sixty-five percent of the children had a haemagglutination titer of at least 1/8; a level comparable to that observed during <italic toggle="yes">M.tb</italic> infection (<xref rid="B46" ref-type="bibr">46</xref>). Titer values at 3 months post-vaccination were significantly higher than at 1&#8211;5 years post-vaccination, and were higher than those found in children vaccinated at birth (<xref rid="B46" ref-type="bibr">46</xref>, <xref rid="B79" ref-type="bibr">79</xref>). While other studies in the 1950s using this assay failed to observe elevated antibody activity following routine BCG vaccination (<xref rid="B61" ref-type="bibr">61</xref>), some achieved positive results using alternative methods such as agar gel diffusion and the bentonite flocculation test (<xref rid="B47" ref-type="bibr">47</xref>, <xref rid="B80" ref-type="bibr">80</xref>).</p><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Summary of studies discussed in this review measuring specific antibody responses to BCG by route of administration.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-10-01317-i0001.jpg"/><table-wrap-foot><p><italic toggle="yes">Human studies are indicated by black text, cattle studies are indicated by blue text, murine studies are indicated by red text and non-human primate studies are indicated by green text. Studies in any other species are indicated by light blue text</italic>.</p></table-wrap-foot></table-wrap><p>The 1980s saw the development of an enzyme-linked immunosorbent assay (ELISA) to measure antibody responses in TB using plasma-membrane antigen from <italic toggle="yes">M.tb</italic> (<xref rid="B62" ref-type="bibr">62</xref>). In addition to investigating the activity of specific antibody in sera from TB cases, Krambovitis considered the effect of BCG vaccination. Sera were collected from five healthy TST negative adults at baseline and 2 months post-BCG vaccination, and from a further two adults at 2 years post-vaccination. There was no marked change in specific IgG following vaccination in any of the volunteers, although the small sample size is a notable limitation (<xref rid="B62" ref-type="bibr">62</xref>). Consistent with this finding, there was no effect of previous BCG vaccination on the levels of <italic toggle="yes">M.tb</italic>-specific IgG, IgM, or IgA by ELISA in a separate study of 250 healthy volunteers (<xref rid="B63" ref-type="bibr">63</xref>).</p><p>However, later studies have more frequently observed induction of specific antibody following BCG vaccination. Turneer et al. reported a small but significant increase in levels of both IgM and IgG following BCG vaccination in 75 adults using a PPD-specific ELISA (<xref rid="B48" ref-type="bibr">48</xref>). In a study of 66 infants in Turkey, half of whom received BCG vaccination in the first month and half in the second month after birth, there was a significant increase in PPD-specific IgM during the 15 month post-vaccination study period with a higher titer at 2 and 4 months post-vaccination in infants who were vaccinated in the second month of life. IgG levels decreased at 2 months post-vaccination (which the authors propose may be due to loss of maternally-transferred antibody) but rose progressively thereafter (<xref rid="B49" ref-type="bibr">49</xref>). In a separate study of 50 Indian children aged 1&#8211;10 years, there were significantly higher levels of antibody to BCG-CF in BCG-vaccinated compared with unvaccinated children or TB patients, which were directed mostly toward the low molecular weight proteins (<xref rid="B51" ref-type="bibr">51</xref>). Nabeshima and colleagues reported a significant increase in antibodies directed against anti-tuberculous glycolipid antigen (TBGL) at 2, 4, and 8 weeks following BCG vaccination in 20 TST-negative Japanese healthcare workers, although antibody levels had reduced by 1 year post-vaccination (<xref rid="B50" ref-type="bibr">50</xref>).</p><p>Brown et al. went on to investigate antigenic targets of specific antibodies in serum from subjects before and after BCG vaccination and from TB patients, conducting ELISAs with 20 different mycobacterial antigen preparations including recombinant MPT63, MPT64, KatG, MPT51, ESAT-6, MTC28, 14kDa protein, 38kDa protein, CFP-10, TbDP, LAM, and Ag85. Only LAM-reactive IgG was significantly increased among BCG-vaccinated subjects compared with a PPD-negative control group. The proportion of subjects with positive LAM responses in the BCG-vaccinated group was similar to that in the active TB group (<xref rid="B52" ref-type="bibr">52</xref>). Given that LAM is a major component of the mycobacterial cell wall and has several immunosuppressive effects that favor mycobacterial survival in the host (including downregulation of DC function through interaction with the DC-SIGN receptor), it follows that neutralizing antibodies to LAM or its component AM may contribute to host defense against mycobacterial infection (<xref rid="B81" ref-type="bibr">81</xref>, <xref rid="B82" ref-type="bibr">82</xref>). Indeed, studies have now indicated a protective role for monoclonal antibodies against AM, and partial protection conferred by antibodies induced by vaccination with AM-protein conjugates (<xref rid="B25" ref-type="bibr">25</xref>, <xref rid="B83" ref-type="bibr">83</xref>). Furthermore, an inverse correlation between the titer of LAM-specific antibodies and risk of disseminated disease has been reported in humans (<xref rid="B23" ref-type="bibr">23</xref>).</p><p>De Valli&#232;re et al. also reported significant induction of LAM-specific IgG following both primary and secondary BCG vaccination in 10 healthy volunteers (<xref rid="B53" ref-type="bibr">53</xref>). To our knowledge, this is one of only two studies to have investigated the functional mechanism of action of BCG-induced antibodies. Using GFP-expressing BCG, it was demonstrated that internalization of BCG by neutrophils and monocytes/macrophages was significantly enhanced using post-vaccination compared with pre-vaccination serum (<xref rid="B53" ref-type="bibr">53</xref>). Furthermore, the inhibitory effects of these phagocytic cells on mycobacterial growth were significantly enhanced by BCG-induced antibodies; an effect which was reversed by preabsorption of IgG. Vaccine-induced antibodies also enhanced proliferation and IFN-&#947; production in mycobacterium-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, highlighting interdependence between the humoral and cellular arms (<xref rid="B53" ref-type="bibr">53</xref>). Similarly, Chen et al. observed a significant increase in AM-specific IgG at 4&#8211;8 weeks post-BCG vaccination which was able to opsonize BCG and <italic toggle="yes">M.tb</italic>. When BCG was opsonized with post-vaccination sera, there was significant enhancement of phagocytosis, phagolysosomal fusion and intracellular growth inhibition. Reduction of BCG growth in THP-1 cells correlated significantly with post-vaccination AM-specific IgG, suggesting a role for an Fc&#947;R-mediated effect (<xref rid="B54" ref-type="bibr">54</xref>). Such evidence supports a protective function for BCG-induced antibodies, as summarized in <xref rid="T2" ref-type="table">Table 2</xref>.</p><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Summary of studies discussed in this review providing evidence for or against a protective function of BCG-induced antibodies.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-10-01317-i0002.jpg"/><table-wrap-foot><p><italic toggle="yes">Human studies are indicated by black text, cattle studies are indicated by blue text, murine studies are indicated by red text and non-human primate studies are indicated by green text</italic>.</p></table-wrap-foot></table-wrap></sec><sec><title>BCG Vaccination in Cattle</title><p>Induction of specific antibody following BCG vaccination is rarely observed in cattle, despite BCG being similarly partially protective in this species. Buddle et al. vaccinated 20 calves with BCG within 8 h of birth, 10 of which received a BCG boost at 6 weeks of age. A further 10 calves received BCG vaccination at 6 weeks only, and 10 matched animals were unvaccinated controls (<xref rid="B65" ref-type="bibr">65</xref>). There was no induction of antibody to <italic toggle="yes">M.bovis</italic> culture filtrate in any group at 2, 4, 6, 9, or 12 weeks of age. There was, however, a significant increase in antibody levels in all of the animals following challenge with <italic toggle="yes">M.bovis</italic> (<xref rid="B65" ref-type="bibr">65</xref>). Additional studies by the same authors reported that antibody responses to <italic toggle="yes">M.bovis</italic> culture filtrate were low or absent in all groups following low- and medium-dose BCG vaccination and subsequent challenge with <italic toggle="yes">M.bovis</italic>, and following BCG vaccination by the respiratory or subcutaneous (SC) routes (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B85" ref-type="bibr">85</xref>).</p><p>Lyashchenko et al. described a study of six calves aged 6 months that received two immunisations with BCG Pasteur 6 weeks apart. No IgG responses were detected to any of the antigens tested (ESAT-6, CFP-10, MPB70, MBP59, MPB64, MPB83, Acr1, or PstS-1) for 7 weeks post-booster vaccination (<xref rid="B66" ref-type="bibr">66</xref>). Furthermore, in a study of 12 healthy bovine neonates aged under 1 month in Ethiopia, there was no detectable antibody in the na&#239;ve or BCG-vaccinated groups for 13 weeks post-vaccination (<xref rid="B67" ref-type="bibr">67</xref>). In a more recent report of 24 healthy mixed-breed <italic toggle="yes">Bos taurus</italic> calves aged 4&#8211;6 months of age, animals were vaccinated with either live or inactivated BCG. There were no significant differences in the antibody responses by IDEXX TB ELISA between na&#239;ve animals and those vaccinated with live or inactivated BCG for 9 weeks post-vaccination (<xref rid="B68" ref-type="bibr">68</xref>).</p><p>It may be of importance that all of these studies were conducted in young calves. When LAM-specific IgG responses to primary and secondary BCG vaccination were measured in calves and young adults, the young adults demonstrated a significant increase in antibody at 9 and 11 weeks post primary vaccination and 1 and 3 weeks after secondary vaccination, while such a response was absent in the calves. Furthermore, PPD-B stimulated cells from vaccinated young adults secreted significantly more antibody than cells from unvaccinated calves in a cell culture system (<xref rid="B86" ref-type="bibr">86</xref>). This suggests that young calves may be limited in their capacity to mount an antibody response to BCG, possibly associated with immaturity of the neonatal immune system (<xref rid="B87" ref-type="bibr">87</xref>). Furthermore, the passive transfer of maternal antibody to neonates may mask vaccine responses or actively interfere with postnatal activation of the calf's own immune system and capacity to mount a protective response to vaccination or infection (<xref rid="B87" ref-type="bibr">87</xref>&#8211;<xref rid="B89" ref-type="bibr">89</xref>).</p></sec><sec><title>BCG Vaccination in Preclinical Models</title><p>Preclinical models offer the opportunity to explore novel vaccine candidates or regimens, and to relate induced immune responses to protection from subsequent experimental mycobacterial challenge. In a murine study comparing different doses of BCG, levels of anti-CFP IgG increased following vaccination at all doses, with the highest levels seen in mice vaccinated with the highest dose of BCG, although there was no influence of dose on protection following <italic toggle="yes">M.tb</italic> challenge (<xref rid="B55" ref-type="bibr">55</xref>). A recent murine study of an AM-protein conjugate vaccine demonstrated induction of an AM-specific antibody response, prolonged survival and enhanced control of extrapulmonary dissemination in immunized compared with control animals (<xref rid="B84" ref-type="bibr">84</xref>). Interestingly, a serum passive transfer experiment resulted in a significant reduction in lung and spleen bacterial burden following transfer of serum from mice vaccinated with the AM conjugate vaccine constructs but not from mice vaccinated with BCG (<xref rid="B84" ref-type="bibr">84</xref>). In a study of mice vaccinated with either PBS, BCG, a proteoliposome from BCG (PLBCG) or PLBCG with alum hydroxide (PLBCG-AL), there was significant induction of specific IgG (all subclasses combined) and IgG1 in all groups receiving vaccines compared with PBS, and significant induction of IgG2a in the BCG-vaccinated group only at 6 weeks post-vaccination (<xref rid="B56" ref-type="bibr">56</xref>).</p><p>Guinea pigs are a useful model for TB due to ability to reproducibly infect animals with <italic toggle="yes">M.tb</italic> and remarkable similarities to humans in the course of disease following pulmonary infection (<xref rid="B90" ref-type="bibr">90</xref>). Consistent with findings in humans, significant induction of LAM-specific IgG has been reported in guinea pigs who had been BCG-vaccinated compared with those receiving a sham vaccination (<xref rid="B91" ref-type="bibr">91</xref>). Romain et al. collected sera from BCG-vaccinated guinea pigs and used it to detect mycobacterial antigens present in BCG or <italic toggle="yes">M.tb</italic> culture medium filtrate which are recognized by antibodies raised against live BCG. They identified and purified a complex of 45- and 47-kDa major molecules (Apa), a cell-surface adhesion and secretory glycoprotein produced by all members of the <italic toggle="yes">M.tb</italic> complex, which was found to be an immunodominant target triggering an antibody response following BCG vaccination (<xref rid="B59" ref-type="bibr">59</xref>). Several Apa-subunit or DNA vaccines have since been shown to confer significant protection against <italic toggle="yes">M.tb</italic> challenge, consistent across vaccination strategies and animal models (<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B96" ref-type="bibr">96</xref>).</p><p>While non-human primates (NHPs) are considered the most relevant animal model for human TB vaccine development due to susceptibility to <italic toggle="yes">M.tb</italic> infection and partial protectiveness of BCG (<xref rid="B97" ref-type="bibr">97</xref>, <xref rid="B98" ref-type="bibr">98</xref>), there is very little literature on the antibody response to BCG in this model. An early study described detection of antibody in monkeys following BCG vaccination or <italic toggle="yes">M.tb</italic> infection using a gel double-diffusion test (<xref rid="B47" ref-type="bibr">47</xref>). In a more recent comparison of BCG vaccination in different species, a weak <italic toggle="yes">M.tb</italic>-specific IgG response was observed in rhesus but not cynomolgus macaques at 14 weeks post-BCG vaccination (although it should be noted that animals were treated with a 3-week course of daily oral isoniazid and rifadin treatment at 8 weeks post-vaccination). Interestingly, cynomolgus macaques appeared better protected against subsequent <italic toggle="yes">M.tb</italic> challenge, which draws into question the relevance of the specific IgG response to protection (<xref rid="B60" ref-type="bibr">60</xref>). An increase in anti-PPD antibody titers following aerosol BCG vaccination in macaques has recently been reported, as described in the section Aerosol BCG (<xref rid="B75" ref-type="bibr">75</xref>).</p></sec><sec><title>BCG Re-vaccination</title><p>Several human epidemiological studies, as well as a large randomized controlled trial in Brazil, have previously indicated that BCG re-vaccination confers no additional protection to neonatal vaccination (<xref rid="B99" ref-type="bibr">99</xref>&#8211;<xref rid="B101" ref-type="bibr">101</xref>), as well as a large randomized controlled trial in Brazil (<xref rid="B100" ref-type="bibr">100</xref>). However, a recent Phase II prevention-of-infection trial in South African adolescents found that while BCG re-vaccination did not demonstrate efficacy in preventing initial <italic toggle="yes">M.tb</italic> infection (defined as QFT conversion at an IFN-&#947; level of &#8805;0.35 IU per ml after day 84), it did result in significantly reduced rates of sustained QFT conversion (defined as three consecutive positive QFT results after day 84) (<xref rid="B102" ref-type="bibr">102</xref>). The authors suggest that as initial acquisition of infection is not averted by the innate immune response, antigen is trafficked to the draining lymph nodes triggering adaptive immunity (as indicated by initial QFT conversion), followed by enhanced bacterial control or clearance in protected individuals (<xref rid="B102" ref-type="bibr">102</xref>). The inconsistency in outcomes between this and previous BCG re-vaccination trials may reflect different enrolment criteria, as the recent study excluded adolescents who were not QFT-negative at baseline and BCG efficacy is thought to be greatest in individuals without previous mycobacterial exposure (<xref rid="B103" ref-type="bibr">103</xref>). These findings have fuelled renewed interest in the potential utility of BCG re-vaccination, although it is not clear to what extent cellular and/or humoral immunity contribute to this protection.</p><p>In the murine model, mice vaccinated with a repeat dose of BCG demonstrated an increased titer of anti-BCG IgG (<xref rid="B57" ref-type="bibr">57</xref>, <xref rid="B58" ref-type="bibr">58</xref>). In a study of na&#239;ve and historically BCG-vaccinated UK volunteers, there was no significant difference between groups in the total IgG response at baseline or 4 weeks after BCG vaccination (which represented a re-vaccination for the historically BCG-vaccinated individuals). However, the group receiving a re-vaccination had significantly higher levels of IgG2 at both time-points (<xref rid="B54" ref-type="bibr">54</xref>). Increases in AM-specific IgA and IgM titers were significant after secondary but not primary vaccination, and re-vaccination induced more pronounced IgG responses to AM oligosaccharide (OS) epitopes than primary vaccination (<xref rid="B54" ref-type="bibr">54</xref>). In the de Valli&#232;re et al. study described in the section BCG Vaccination in Humans, 8 of the 10 volunteers were given a BCG re-vaccination 6 months following primary vaccination. There was a significant increase in levels of LAM-specific IgG following primary vaccination which was further increased at 8 and 28 weeks post-boost. As described, these antibodies were found to be capable of enhancing both innate and cell-mediated immune responses to mycobacteria (<xref rid="B53" ref-type="bibr">53</xref>).</p><p>Use of an <italic toggle="yes">in vitro</italic> model of human PBMC induced with a repeat dose of BCG at 24 and 72 h of cell culture demonstrated increased anti-BCG IgG levels in supernatants compared to the pre-boost and control groups (<xref rid="B104" ref-type="bibr">104</xref>). Re-vaccination of cattle with BCG 2 years after first vaccination restored protection from <italic toggle="yes">M.bovis</italic> challenge compared with calves receiving only a single vaccination 2.5 years previously (<xref rid="B69" ref-type="bibr">69</xref>). However, the serum antibody responses to <italic toggle="yes">M.bovis</italic> culture filtrate protein or Ag85A peptides measured following re-vaccination and challenge were not significantly different between the BCG-vaccinated, re-vaccinated or unvaccinated groups. Interestingly, immune responses in cattle re-vaccinated with TB protein vaccines were biased toward induction of antibody, but this was not associated with improved protection from <italic toggle="yes">in vivo</italic> challenge (<xref rid="B69" ref-type="bibr">69</xref>).</p></sec></sec><sec id="s4"><title>BCG by Other Routes of Administration</title><sec><title>Oral BCG</title><p>BCG was originally administered by the oral route, but this was largely replaced by intradermal vaccination following (a) the observation that oral administration produced no allergic skin response (considered at the time evidence of immunity against TB), (b) the L&#252;beck disaster (when neonates were mistakenly given oral BCG vaccine contaminated with <italic toggle="yes">M.tb</italic>) and (c) association with cervical adenitis (<xref rid="B105" ref-type="bibr">105</xref>, <xref rid="B106" ref-type="bibr">106</xref>). However, oral BCG has been shown to induce greater mucosal and systemic immune responses compared with intradermal vaccination in mice (<xref rid="B107" ref-type="bibr">107</xref>), and there has been renewed interest in this route of delivery (<xref rid="B106" ref-type="bibr">106</xref>). Lagranderie et al. reported the induction of PPD-specific IgG, IgM, and IgA in sera, intestinal secretions and BAL fluids of mice following oral vaccination with various BCG strains (<xref rid="B71" ref-type="bibr">71</xref>).</p><p>In the Brown et al. study described in the section BCG Vaccination in Humans (<xref rid="B52" ref-type="bibr">52</xref>), mucosal specimens were harvested from 8 volunteers before and after two oral BCG vaccinations administered at an interval of 6 months. There was a significant increase in LAM-specific (but not Ag85- or <italic toggle="yes">M.tb</italic> whole lysate-specific) IgA antibodies in tears at 6 months post-primary oral BCG vaccination and at 1 week and 6 weeks post-secondary oral BCG vaccination (<xref rid="B52" ref-type="bibr">52</xref>). A second study reported induction of specific IgG that peaked between 10 and 14 days after oral BCG vaccination. Two volunteers who received boosting with oral BCG showed an alteration in the humoral immune response with a shift of isotype from IgG to IgA, independent of the route used for primary vaccination (<xref rid="B70" ref-type="bibr">70</xref>). This supports the suggestion by Hoft et al. that a combination of intradermal and oral routes for BCG vaccination may induce mucosal and systemic immunity against initial infection and systemic progression (<xref rid="B108" ref-type="bibr">108</xref>).</p><p>Significant wildlife reservoir hosts exist for <italic toggle="yes">M.bovis</italic> infection of cattle including badgers in the UK, white-tailed deer in the US, and wild boar and red deer in Spain (<xref rid="B2" ref-type="bibr">2</xref>). Oral delivery of vaccines would be the most practical and cost-effective means of vaccinating wildlife, and oral vaccines have been successfully used to protect foxes against rabies (<xref rid="B109" ref-type="bibr">109</xref>). In a study of 20 wild boar piglets aged 3&#8211;4 months, there was no increase in PPD-B or MPB83 antigen-specific antibody levels following oral BCG vaccination for 8 weeks post-vaccination (<xref rid="B72" ref-type="bibr">72</xref>). However, oral vaccination with heat-inactivated <italic toggle="yes">M.bovis</italic> in wild boar has been shown to induce specific antibody responses that may be associated with protection from <italic toggle="yes">M.bovis</italic> challenge (<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B110" ref-type="bibr">110</xref>).</p></sec><sec><title>Respiratory BCG</title><p>Since TB is primarily a pulmonary infection, targeting delivery of BCG directly to the respiratory mucosa (either by intranasal, aerosol or pulmonary administration) may be physiologically and immunologically beneficial (<xref rid="B111" ref-type="bibr">111</xref>). Furthermore, intranasal or aerosol routes could offer practical advantages for vaccine administration and negate the risk of cross-contamination due to needle re-use, particularly in developing countries.</p><sec><title>Intranasal BCG</title><p>Recent studies have demonstrated that intranasal (IN) vaccination with BCG results in superior protection of mice against challenge with <italic toggle="yes">M.tb</italic> or <italic toggle="yes">M.bovis</italic> (<xref rid="B112" ref-type="bibr">112</xref>, <xref rid="B113" ref-type="bibr">113</xref>). Intranasally administered BCG has been shown to induce secretion of total (specific and non-specific) IgA and <italic toggle="yes">M.tb</italic>-specific IgA in the lungs in an IL-17A-dependent manner at levels significantly higher than in unvaccinated mice or those vaccinated with BCG subcutaneously. This was associated with protection against pulmonary <italic toggle="yes">M.tb</italic> challenge following IN but not subcutaneous BCG in the TB-susceptible DBA/2 mouse strain (<xref rid="B73" ref-type="bibr">73</xref>). In a separate study in BALB/c mice, IN BCG induced significantly higher levels of specific IgA, IgG1, and IgG2a antibodies in the nasal lavage compared with subcutaneously vaccinated or unvaccinated mice and resulted in a lower bacterial load in the lungs following <italic toggle="yes">M.tb</italic> challenge (<xref rid="B74" ref-type="bibr">74</xref>). However, it has been noted that extent of granuloma formation is associated with level of protection in the lungs following IN BCG vaccination, and that dosage needs balancing to avoid undue pathology (<xref rid="B114" ref-type="bibr">114</xref>). The use of IN vaccination in humans has raised safety concerns following association of facial nerve paralysis (Bell's palsy) with three separate IN vaccines administered with the <italic toggle="yes">E.coli</italic> heat labile toxin adjuvant (ELT) (<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>).</p></sec><sec><title>Aerosol BCG</title><p>The aerosol route of vaccination has been explored for other respiratory pathogens including influenza and measles, in which boosting with an aerosolised vaccine evoked a stronger and more durable antibody response than injected measles vaccine and was effective and well-tolerated (<xref rid="B117" ref-type="bibr">117</xref>, <xref rid="B118" ref-type="bibr">118</xref>). BCG administered by aerosol has been demonstrated to induce a greater degree of protection against challenge with virulent <italic toggle="yes">M.tb</italic> than subcutaneous BCG vaccination in Rhesus macaques and guinea pigs (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B120" ref-type="bibr">120</xref>). In a separate NHP study, median anti-PPD IgG titers in the serum increased following aerosol BCG vaccination at both a standard and low-dose relative to baseline (<xref rid="B75" ref-type="bibr">75</xref>). Although aerosol vaccination with BCG has been described in humans, the antibody response was not measured (<xref rid="B121" ref-type="bibr">121</xref>). Interestingly, anti-vector antibodies to the TB vaccine candidate MVA85A were reported in the serum after ID but not aerosol administration in humans, suggesting that aerosol vaccination may overcome detrimental pre-existing humoral immunity against the vaccine vector (<xref rid="B122" ref-type="bibr">122</xref>).</p></sec><sec><title>Pulmonary BCG</title><p>The intratracheal (IT) and endobronchial routes may be favored for preclinical respiratory BCG studies as they allow for accurate delivery of defined vaccine doses. Although IT BCG vaccination in mice has been shown to confer superior protection to the SC route, to our knowledge there are no descriptions of the humoral response (<xref rid="B123" ref-type="bibr">123</xref>). In cattle, Buddle et al. reported superior protection to <italic toggle="yes">M.bovis</italic> challenge following BCG vaccination by the IT route compared with the SC route or with ID vaccination using heat-killed <italic toggle="yes">M.vaccae</italic>. However, the proportions of animals showing positive responses in an antibody ELISA against <italic toggle="yes">M.bovis</italic> culture filtrate did not differ between groups (<xref rid="B85" ref-type="bibr">85</xref>).</p><p>Dijkman et al. conducted a controlled NHP study in which BCG vaccination was administered by the standard ID route or by endobronchial installation into the left lower lung lobe (BCG.muc) (<xref rid="B76" ref-type="bibr">76</xref>). There was a significant but modest increase in PPD-specific pan-immunoglobulin in the serum following BCG vaccination by both routes compared with unvaccinated controls. IgA was significantly increased by more than 1 log in the BAL (but not the serum) at 8 weeks following BCG.muc compared with unvaccinated controls or animals receiving ID BCG vaccination. BCG.muc was able to prevent infection with repeated low-dose <italic toggle="yes">M.tb</italic> challenge (RLD), as evidenced by lack of IGRA conversion or TB-associated pathology in some of the animals. BCG.muc also elicited superior protection from RLD compared with ID BCG (~1.5 vs. ~1 log reduction in primary lung lobe CFU and ~3 vs. ~1 log reduction in BAL CFU), and importantly IgA was identified as a correlate of local protective immunity (<xref rid="B76" ref-type="bibr">76</xref>). IgA is the most abundantly produced natural antibody isotype in mucosal tissue, and may play an important role in the host's early defense against pathogens invading the respiratory tract (<xref rid="B124" ref-type="bibr">124</xref>). Indeed, it has been shown that IgA can prevent the adsorption of bacteria at the mucosal epithelium (<xref rid="B125" ref-type="bibr">125</xref>&#8211;<xref rid="B127" ref-type="bibr">127</xref>) and block the entrance of mycobacteria into the lungs (<xref rid="B128" ref-type="bibr">128</xref>). While endobronchial installation may not be a deployable vaccine strategy in humans, the protective signal offers a valuable opportunity to identify immune correlates of protection to aid in development of improved TB vaccines.</p></sec><sec><title>Intravenous BCG</title><p>There has been a resurgence of interest in intravenous (IV) BCG given the recent NHP study demonstrating superior protection against virulent <italic toggle="yes">M.tb</italic> challenge following vaccination by this route compared with ID or ID with an intratracheal mucosal boost (ID+IT) (<xref rid="B129" ref-type="bibr">129</xref>). This finding supports several reports published in the 1970s indicating improved protection conferred by the IV route of administration (<xref rid="B119" ref-type="bibr">119</xref>, <xref rid="B130" ref-type="bibr">130</xref>&#8211;<xref rid="B132" ref-type="bibr">132</xref>). One early NHP study comparing BCG administered intracutaneously (IC), IV or by aerosol inhalation detected precipitating antibodies during the post-vaccination period only in the IV group; this increase was associated with marked increases in serum IgG, IgA, and IgM, although corresponding levels of protection were not measured (<xref rid="B77" ref-type="bibr">77</xref>). IgG, IgA, and IgM PPD-specific antibody responses were also analyzed in mice receiving IV BCG vaccination and re-vaccination 1 month later. IgG and IgM responses were detected at 1 month post-primary BCG vaccination and were further boosted by re-vaccination, remaining stable until the end of the experiment. IgA responses remained low even after two BCG vaccinations (<xref rid="B71" ref-type="bibr">71</xref>).</p></sec></sec></sec><sec id="s5"><title>Variation in BCG Efficacy</title><p>In addition to directing improved TB vaccine design, better characterization of the overall BCG-induced immune response may aid in understanding the observed variability in vaccine efficacy. This is essential if we are to avoid a new generation of vaccines being subject to the same pitfall. Although previous exposure to non-tuberculous mycobacteria (NTM) resulting in &#8220;masking&#8221; or &#8220;blocking&#8221; of the BCG-induced immune response is the leading hypothesis for variation in vaccine efficacy, a range of other factors such as genetic or nutritional differences between host populations, environmental influences, and viral or helminth infections at time of vaccination have been implicated (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B133" ref-type="bibr">133</xref>, <xref rid="B134" ref-type="bibr">134</xref>).</p><p>Variation in BCG strain may also play a role, with some evidence of a divergence in protective immunity conferred by different strains (<xref rid="B135" ref-type="bibr">135</xref>, <xref rid="B136" ref-type="bibr">136</xref>). Interestingly, a comparative analysis of human B cell epitopes based on BCG genomes indicated strain-specific differences which the authors hypothesize may contribute to variability in BCG vaccine efficacy (<xref rid="B137" ref-type="bibr">137</xref>). In one study comparing oral immunization of mice using BCG Pasteur, Glaxo, Japanese, Russian or Prague strains, the highest IgG and IgA anti-PPD antibody responses were observed in sera of mice immunized with the Pasteur and Russian strains (<xref rid="B71" ref-type="bibr">71</xref>). After IV vaccination, the Japanese strain induced only very low levels of anti-PPD specific antibodies compared with the other strains but no correlation was observed between induction of antibody and stimulation of protective immunity as measured by ability to eliminate rBCG expressing &#946;-glacatosidase (<xref rid="B71" ref-type="bibr">71</xref>).</p><p>Using the Moreau strain, Petricevich et al. investigated whether differences in methodology for vaccine manufacture influenced the capacity of BCG to induce a humoral immune response in mice. They found that BCG bacilli cultured in Sauton-asparagine medium multiplied more and induced a stronger humoral immune response (with higher titers of BCG-specific antibody and a higher number of antibody-producing spleen cells) compared with bacilli grown in Sauton-starch/bacto-peptone-enriched medium (<xref rid="B138" ref-type="bibr">138</xref>). The mycobacterial capsule is enriched in polysaccharides and lipids and includes some immunologically active secreted proteins (<xref rid="B139" ref-type="bibr">139</xref>). Prados-Rosales et al. used specific antibodies to the major capsule polysaccharides, AM and &#945;-glucan, to demonstrate that growing BCG in the presence of detergent strips the capsule. While un-encapsulated BCG induced predominantly IgM responses following vaccination, encapsulated BCG grown in the absence of detergent was better at eliciting higher titers of class-switched antibody. Encapsulated BCG was also more effective at generating IFN-&#947; and polyfunctional T cell responses and together this enhanced immunogenicity was associated with a lower bacterial burden following <italic toggle="yes">M.tb</italic> challenge (<xref rid="B140" ref-type="bibr">140</xref>).</p></sec><sec id="s6"><title>Off-Target Humoral Immunomodulatory Effects of BCG Vaccination</title><sec><title>Infectious Diseases and Heterologous Vaccines</title><p>There is a growing body of literature proposing non-specific benefits of BCG vaccination including a reduction in all-cause infant mortality and protection against unrelated infectious diseases (<xref rid="B141" ref-type="bibr">141</xref>&#8211;<xref rid="B144" ref-type="bibr">144</xref>). Although IV BCG has been reported to protect mice against challenge with <italic toggle="yes">Babesia</italic> and <italic toggle="yes">Plasmodium</italic> spp., this is not thought to be associated with antibody specific for surface antigens of the parasites (<xref rid="B145" ref-type="bibr">145</xref>). Furthermore, resistance of BCG-infected mice to superinfection with <italic toggle="yes">Salmonella typhimurium</italic> is not associated with a greater or more rapid antibody response (<xref rid="B146" ref-type="bibr">146</xref>). It is thought that protection beyond the target pathogen could rather be promoted by heterologous lymphocyte activation or innate immune memory (<xref rid="B147" ref-type="bibr">147</xref>). Interestingly, in a recent trial in Denmark, BCG vaccination was associated with a reduced rate of infant hospitalization for infection, but only in infants of mothers who were BCG-vaccinated (<xref rid="B148" ref-type="bibr">148</xref>). This observation was supported by a similar finding in Guinea-Bissau, where the reduction in all-cause mortality was 66% (95% CI, 33&#8211;83%) if the mother also had a BCG scar (<xref rid="B149" ref-type="bibr">149</xref>). Vaccinating against measles in the presence of maternal antibody is associated with reduced child mortality (<xref rid="B150" ref-type="bibr">150</xref>), and it is possible that a similar mechanism acts to enhance the non-specific effects of BCG vaccination. Indeed, studies have demonstrated that maternal BCG vaccination modifies the immunological response to BCG in the infant (<xref rid="B151" ref-type="bibr">151</xref>, <xref rid="B152" ref-type="bibr">152</xref>). In the BCG re-vaccination trial described in the section BCG Re-vaccination, a decrease in unrelated respiratory tract infections was observed in BCG re-vaccinated individuals compared with the H4:IC31 vaccinated or placebo groups (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B153" ref-type="bibr">153</xref>). Although the immune mechanism remains unclear, BCG re-vaccination, like maternal priming, represents a situation in which the presence of (possibly antibody-related) pre-existing immunity enhances non-specific effects.</p><p>There is some evidence that BCG vaccination enhances the humoral immune response to other unrelated childhood vaccinations, essentially acting as an adjuvant. Ota et al. reported that infants vaccinated at birth with BCG had, upon vaccination against hepatitis, significantly higher levels of IgG against hepatitis B vaccine antigens. Furthermore, BCG vaccination given at the time of oral polio vaccine boosting improved the antibody response to polio, indicating an effect of BCG at the systemic level (<xref rid="B154" ref-type="bibr">154</xref>). An Australian study of 56 BCG-vaccinated and 52 non-BCG vaccinated infants found that BCG vaccination was associated with significantly higher IgG titers against pneumococcal capsular polysaccharide antigens, <italic toggle="yes">H.influenzae</italic> type b polysaccharide and tetanus toxoid following routine immunisations later in infancy (<xref rid="B155" ref-type="bibr">155</xref>). Conversely, in a study of 300 children in a high-income setting, no overall effect of neonatal BCG vaccination was observed on antibody levels induced by the routine vaccinations DiTeKiPol/Act-Hib and Prevnar 13. However, a possible enhancing effect of BCG on antibodies against <italic toggle="yes">B. pertussis</italic> and all pneumococcal serotypes was identified when stratifying by age of randomization to BCG vaccination or no BCG vaccination suggesting that the timing of BCG vaccination may be important (<xref rid="B156" ref-type="bibr">156</xref>).</p></sec><sec><title>Atopic Disorders and IgE</title><p>The hygiene hypothesis proposes that the increasing occurrence of allergies in the developed world may be associated with reduced incidence of microbial infections, including TB, which would otherwise bias the developing immune system toward a Th1 response. The resulting Th1-Th2 imbalance with an increase in Th2 cells favors IgE antibody production and the establishment of allergic reactivity (<xref rid="B157" ref-type="bibr">157</xref>). In such a situation, it is plausible that BCG early in life could provide Th1 stimulation that mimics mycobacterial infection and reduces the incidence of atopy. Indeed, positive tuberculin responses were associated with lower serum IgE levels, cytokine profiles biased toward a Th1 type and lower incidence of asthma in a retrospective study of over 800 Japanese schoolchildren (<xref rid="B158" ref-type="bibr">158</xref>). In Italian volunteers with allergic rhinitis, there was a significant decrease in total and allergen-specific IgE levels following BCG vaccination (<xref rid="B159" ref-type="bibr">159</xref>). A further study indicated that BCG vaccination was associated with downregulation of spontaneous and stimulated <italic toggle="yes">in vitro</italic> IgE secretion from PBMC of atopic children with asthma (<xref rid="B160" ref-type="bibr">160</xref>). Atopy (defined as skin test reactivity to <italic toggle="yes">Dermatophagoides pteronyssinus, D. farinae</italic> or cockroach) was reduced in African children given BCG vaccination early in infancy, although IgE levels were not measured in this study (<xref rid="B161" ref-type="bibr">161</xref>). That BCG vaccination is associated with a reduction in allergen-specific antibodies and a beneficial effect on atopic disorders is supported by several preclinical studies (<xref rid="B162" ref-type="bibr">162</xref>&#8211;<xref rid="B165" ref-type="bibr">165</xref>).</p><p>However, others report no marked effect of BCG vaccination on IgE levels or risk of development or symptoms of atopic disease (<xref rid="B166" ref-type="bibr">166</xref>&#8211;<xref rid="B171" ref-type="bibr">171</xref>). While there are several studies describing repeated administration of inactivated BCG for the management of asthma (<xref rid="B172" ref-type="bibr">172</xref>&#8211;<xref rid="B174" ref-type="bibr">174</xref>), a randomized double-blind placebo-controlled study in adults with moderately severe asthma and house dust mite allergy showed no efficacy of four injections with heat-inactivated BCG and no reduction in IgE compared with the placebo group (<xref rid="B175" ref-type="bibr">175</xref>). Differences in outcome may be related to time of, or since, BCG vaccination (<xref rid="B176" ref-type="bibr">176</xref>, <xref rid="B177" ref-type="bibr">177</xref>) or host genetic factors (<xref rid="B178" ref-type="bibr">178</xref>, <xref rid="B179" ref-type="bibr">179</xref>). Safety concerns have been raised regarding the use of BCG as a tool for the prevention and therapy of allergic airway disease, as Ahrens et al. noted that BCG-induced suppression of Th2-type allergic airway inflammation in the OVA-sensitized mouse also stimulated Th1-associated neutrophilic airway inflammation (<xref rid="B180" ref-type="bibr">180</xref>).</p></sec><sec><title>Autoantibodies</title><p>Autoantibodies have been found at high frequency in the blood of patients infected with mycobacteria (<xref rid="B181" ref-type="bibr">181</xref>), suggesting cross-reactivity between mycobacterial and host antigens. A recent study of sera obtained from healthy adults post-BCG vaccination reported IgG recognition of host peptides that peaked at 8 weeks post-vaccination and diminished over time (<xref rid="B182" ref-type="bibr">182</xref>). IgG responses primarily demonstrated increased reactivity to ion transporters, cytokine receptors, ribonucleoprotein and enzymes. The authors suggest that the modification of the host immunological and non-immunological landscape in this way may influence disease-specific immune responses previously reported in TB, autoimmune disease and cancer (<xref rid="B182" ref-type="bibr">182</xref>). Indeed, autoantibodies associated with autoimmune diseases such as systemic lupus erythematosus (SLE) have been shown to recognize mycobacterial antigens (<xref rid="B183" ref-type="bibr">183</xref>, <xref rid="B184" ref-type="bibr">184</xref>). In non-obese diabetic (NOD) mice, heat-killed BCG was shown to prevent diabetes but precipitated a systemic lupus erythematous (SLE)-like syndrome associated with increased titers of antinuclear autoantibodies (<xref rid="B185" ref-type="bibr">185</xref>).</p><p>Insulin-dependent diabetes mellitus, or type 1 diabetes (T1D), is an autoimmune condition in which insulin-producing pancreatic islet cells undergo immune-mediated destruction. BCG vaccination has been reported to prevent the onset of T1D in mice and result in clinical remission or a long-term reduction in blood sugar levels in T1D patients (<xref rid="B186" ref-type="bibr">186</xref>&#8211;<xref rid="B189" ref-type="bibr">189</xref>). T1D is a predominantly T cell-mediated disease, and the mechanism of action of BCG in this context is thought to be through induction of tumor necrosis factor (TNF) resulting in selective death of autoreactive T cells and expansion of beneficial regulatory T cells that restore immune balance (<xref rid="B190" ref-type="bibr">190</xref>). Autoantibodies may also play a role and BCG vaccination has been associated with a significant reduction of autoantibodies to the 65-kDa isoform of glutamate decarboxylase (GAD65) and islet tyrosine phosphatase (I-A2) in southern Indian diabetic patients (<xref rid="B191" ref-type="bibr">191</xref>). However, a separate prospective study of German infants born to parents with T1D found no evidence that BCG vaccination reduced GAD65, I-A2 or insulin autoantibody levels by age 2 or 5 years, and suggested that neonatal BCG vaccination may in fact accelerate progression from autoimmunity to diabetes in autoantibody-positive children (<xref rid="B192" ref-type="bibr">192</xref>). Furthermore, BCG vaccination has been linked to an increased risk of developing high levels of anti-IA-2 autoantibodies, although the authors note that the number of vaccinated children was relatively small and not representative of the general population (<xref rid="B193" ref-type="bibr">193</xref>). Outcomes have been shown to differ widely from individual to individual (<xref rid="B194" ref-type="bibr">194</xref>).</p><p>Multiple sclerosis (MS) is an autoimmune-mediated inflammatory disease affecting the central nervous system. It has been postulated that BCG vaccination may be beneficial in suppressing autoimmune responses in the animal model of MS (experimental autoimmune encephalomyelitis) and human MS (<xref rid="B195" ref-type="bibr">195</xref>, <xref rid="B196" ref-type="bibr">196</xref>), and conversely that it could initiate autoimmunity through molecular mimicry (<xref rid="B197" ref-type="bibr">197</xref>). Interestingly, a seroprevalence study measuring antibodies against the host encephalitogenic myelin oligodendrocyte glycoprotein (MOG)<sub>35&#8722;55</sub> epitope and two mycobacterial peptides sharing sequence homology showed a significant difference between MS patients and healthy controls in levels of antibody positivity for MOG<sub>35&#8722;55</sub> but not for the BCG-derived homologous peptides (<xref rid="B198" ref-type="bibr">198</xref>). A possible role for antibody responses to mycobacterial hsp65 (and equivalent human or bacterial proteins) has been proposed in rheumatoid arthritis (RA), although findings are conflicting (<xref rid="B199" ref-type="bibr">199</xref>&#8211;<xref rid="B201" ref-type="bibr">201</xref>). Increased levels of anti-BCG antibodies have also been reported in RA and SLE patients compared with healthy controls (<xref rid="B202" ref-type="bibr">202</xref>), and BCG therapy for cancer has been associated with systemic autoimmune phenomena such as inflammatory arthritis or immune-related toxicity, likely through molecular mimicry (<xref rid="B203" ref-type="bibr">203</xref>&#8211;<xref rid="B205" ref-type="bibr">205</xref>).</p></sec><sec><title>Cancer Immunotherapy</title><p>The relationship between mycobacteria and cancer was first recognized almost a century ago, with animal studies demonstrating that BCG-infected mice were resistant to transplantation of tumor cells leading to the discovery of Tumor Necrosis Factor (TNF) (<xref rid="B206" ref-type="bibr">206</xref>&#8211;<xref rid="B208" ref-type="bibr">208</xref>). Numerous attempts were consequently made to apply BCG as a therapy for various cancers including leukemia and melanoma; the efficacy of BCG therapy for bladder cancer has since been confirmed and it is now the standard of care for high-risk non-muscle-invasive disease (<xref rid="B209" ref-type="bibr">209</xref>). It is generally considered that CD4<sup>+</sup> and CD8<sup>+</sup> T cells, NK cells and granulocytes are the main players in mediating the immunotherapeutic effect of BCG in this context, but important humoral factors have been identified and it is possible that antibodies contribute to the immune activation observed (<xref rid="B210" ref-type="bibr">210</xref>). While some early studies in melanoma and bladder cancer patients reported an increase in BCG-specific antibody following therapy which was tentatively associated with reduced rates of recurrence (<xref rid="B211" ref-type="bibr">211</xref>&#8211;<xref rid="B213" ref-type="bibr">213</xref>), others did not confirm these findings (<xref rid="B214" ref-type="bibr">214</xref>, <xref rid="B215" ref-type="bibr">215</xref>). Interestingly, parenteral exposure to BCG prior to intravesical treatment has been associated with improved response to therapy, and patients with sustained pre-existing immunity to BCG showed significant improvement in recurrence-free survival (<xref rid="B216" ref-type="bibr">216</xref>). This is in line with the observations regarding the beneficial effects of maternal priming and BCG re-vaccination on non-specific effects of BCG described in the section Infectious Diseases and Heterologous Vaccines.</p><p>Antibodies raised against mycobacterial antigens with a high degree of homology to proteins found on the surface of tumor cells may be of direct relevance to clinical outcome. Early work on cross-reactivity demonstrated that guinea pigs immunized with BCG developed antibody in their sera to the transplantable guinea pig hepatoma line 10 (but not line 1) (<xref rid="B217" ref-type="bibr">217</xref>). The mycobacterial heat shock protein hsp65 induces a strong cellular and humoral immune response, and hsp65 from BCG has been shown to enhance recognition of tumor-associated antigens (<xref rid="B218" ref-type="bibr">218</xref>). It has been reported that titers of IgG against hsp65 and the native protein P64 in bladder cancer patients increase after BCG intravesical therapy, but that increased antibody responses against P64 may be associated with a higher rate of tumor recurrence (<xref rid="B215" ref-type="bibr">215</xref>, <xref rid="B219" ref-type="bibr">219</xref>). In a murine model of transplantable methylcholanthrene-induced fibrosarcoma, BCG treatment of tumor-bearing mice stimulated formation of antibodies against tumor-specific antigens but these antibodies enhanced tumor growth (<xref rid="B220" ref-type="bibr">220</xref>). A summary of the off-target humoral immunomodulatory effects (both beneficial and detrimental) of BCG vaccination is provided in <xref rid="T3" ref-type="table">Table 3</xref>.</p><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Summary of evidence for off-target humoral immunomodulatory effects of BCG vaccination discussed in this review.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-10-01317-i0003.jpg"/><table-wrap-foot><p><italic toggle="yes">Human studies are indicated by black text, murine studies are indicated by red text and studies in any other species are indicated by light blue text</italic>.</p></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="s7"><title>Conclusions</title><p>Until relatively recently, a simplistic paradigm has prevailed of a mutually-exclusive immunological duality with the cellular and humoral arms of immunity conferring protection against intracellular and extracellular pathogens respectively. However, this was challenged by Casadevall and others who pointed to a role for humoral immunity in preventing infection with some intracellular pathogens (<xref rid="B221" ref-type="bibr">221</xref>). It is now recognized that there is extensive synergy between the two arms of immunity with, for example, B cells modulating the T cell response via cytokine production and participating in T cell priming through antigen capture and presentation (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B222" ref-type="bibr">222</xref>). A dual requirement for both cell-mediated and humoral immunity in the development of an effective response to both intracellular and extracellular pathogens is increasingly recognized. Furthermore, with accumulating evidence supporting a contribution of trained innate immunity to protection (<xref rid="B19" ref-type="bibr">19</xref>), the key to a more successful TB vaccine may lie in the stimulation of the innate immune system and harnessing of humoral immunity in concert with a potent cell-mediated response.</p><p>In light of this, together with recent evidence supporting a role for antibodies in immunity against TB and questioning the sufficiency of the cell-mediated response alone to confer protection (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B26" ref-type="bibr">26</xref>&#8211;<xref rid="B28" ref-type="bibr">28</xref>), understanding humoral immunity in TB has become increasingly pertinent. As the only vaccine currently available against TB, and offering partial protection against the transmissible pulmonary form of disease, BCG offers an opportunity to identify and characterize the protective components of vaccine-induced humoral immunity. Such insights may aid in the design of new more efficacious TB and bTB vaccine candidates, especially when related to functional properties <italic toggle="yes">in vitro</italic> and protection from mycobacterial challenge or natural infection <italic toggle="yes">in vivo</italic>. Alternatively, given the recent findings regarding the non-specific benefits of BCG (<xref rid="B141" ref-type="bibr">141</xref>&#8211;<xref rid="B144" ref-type="bibr">144</xref>), the influence of maternal priming (<xref rid="B148" ref-type="bibr">148</xref>&#8211;<xref rid="B152" ref-type="bibr">152</xref>) and the efficacy of BCG re-vaccination in reducing sustained infection (<xref rid="B102" ref-type="bibr">102</xref>), control of the TB epidemic may in fact be achieved through wiser use of the BCG vaccine itself.</p><p>However, the humoral immune response to BCG vaccination remains poorly defined. Evidence for the induction of specific antibody responses is variable and the relevance to protection is unclear, as summarized in <xref rid="T2" ref-type="table">Table 2</xref>. Many of the cited studies suffer from small sample sizes and unspecified/different sampling time-points or duration of follow-up. Outcomes may also be influenced by assay methods, dose and strain of BCG vaccine, species/strain of animal or population of humans and baseline characteristics such as mycobacterial exposure, co-infections or genetic factors. Age at time of vaccination is also important; the presence of maternal antibody in early infancy may complicate studies of humoral immunity to neonatal vaccination and durability of induced antibody responses is more limited than at older ages. In particular, when literature is consolidated, it is apparent that BCG-induced antibody is observed more consistently in humans than cattle. However, findings in cattle, at least in the earlier studies, may be confounded by the use of high doses of BCG which are now known to be less effective than lower doses, and that studies were often performed in regions with very high prevalence of <italic toggle="yes">M.bovis</italic> or in neonatal calves with immature immune systems and presence of maternal antibody (<xref rid="B2" ref-type="bibr">2</xref>).</p><p>Recently, large randomized controlled trials using standardized assays have more consistently observed induction of antibody following BCG vaccination, with convincing evidence for a functional role of LAM- or AM-specific IgG <italic toggle="yes">in vitro</italic> (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B54" ref-type="bibr">54</xref>). It is clear from several studies that BCG induces antibody directed against LAM and AM, and that vaccine constructs based on these antigens can be protective in mice (<xref rid="B84" ref-type="bibr">84</xref>). However, other antigen targets are not well-defined and protective epitopes may not necessarily be on the cell surface, be immunodominant or induce the highest antibody titers. This area warrants further investigation, including consideration of other measures of antibody efficacy such as avidity and affinity which may associate more strongly with protection than titer alone.</p><p>Inability to observe a correlation with protection does not rule out antibody responses as a contributing factor; humoral immunity may be necessary but not sufficient for protection, or may be relevant for some hosts but not others. Furthermore, the overwhelming majority of studies investigating anti-mycobacterial humoral responses have sampled the periphery, which may not reflect the situation at the site of infection. As different routes of vaccination are explored, particularly targeting the respiratory mucosa, the induction of localized humoral immunity may become increasingly relevant. IgA, the predominant antibody isotype present in the mucosal tissue, is widely considered to be involved in defense against viral and bacterial infections at these sites, and it has been demonstrated that IgA-deficient mice have increased susceptibility to IN mycobacterial infection (<xref rid="B223" ref-type="bibr">223</xref>). Furthermore, Balu et al. reported protection against <italic toggle="yes">M.tb</italic> in mice using an immunotherapeutic human IgA monoclonal antibody (<xref rid="B224" ref-type="bibr">224</xref>).</p><p>Better characterization of the BCG-induced immune response may also aid in understanding the observed variability in vaccine efficacy, which is essential if we are to avoid a new generation of TB vaccines being subject to the same pitfall as BCG. Differences in the humoral immune response observed between BCG strains and vaccine manufacture methods may be one contributing factor. It would also be of interest to compare BCG-induced antibody responses between populations where BCG varies in efficacy and determine potential associations with NTM exposure. A study by Sebina et al. found no differences in mycobacteria-specific antibody levels between volunteers with or without travel history to <italic toggle="yes">M.tb</italic> endemic areas, but indicated that some unvaccinated uninfected individuals possess cross-reactive antibodies and memory B cells likely induced by exposure to NTMs or other pathogens (<xref rid="B44" ref-type="bibr">44</xref>).</p><p>It has long been recognized that BCG has complex and diverse immunomodulatory influences ranging from effects on autoimmune disease to atopic disorders and cancer. Such off-target effects are relevant in the context of vaccination as a TB vaccine candidate designed to replace BCG should ideally be non-inferior in non-specific as well as specific efficacy. Furthermore, as novel candidates in the current pipeline include both homologous and heterologous BCG prime-boost regimens, understanding the mechanism of non-specific immunity opens the possibility of boosting such responses to the host advantage. However, study findings are often divergent, and subject to the same confounders as those of specific responses to BCG such as time of, or since, vaccination and additional external influences on the immune system. While it is clear that the effect of BCG vaccination on IgE antibody responses and atopic disorders is beneficial in at least some populations, heterologous humoral immune responses in other contexts may represent a double-edged sword leading to autoimmunity through molecular mimicry.</p><p>In conclusion, as we begin to appreciate a role for the humoral immune response in protection from TB, further studies should be aimed at elucidating the nature and relevance of the humoral immune response to BCG vaccination and how this may be harnessed to better design novel candidate vaccines for TB and bTB.</p></sec><sec id="s8"><title>Author Contributions</title><p>RT wrote the first draft of the manuscript. BV-R, HMV, and HM wrote sections of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.</p><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> This work was supported by the GCRF Networks in Vaccines Research and Development VALIDATE Network, which was co-funded by the MRC and BBSRC (MR/R005850/1). This UK funded award is part of the EDCTP2 programme supported by the European Union. HM is a Wellcome Trust Investigator (WT 206331/Z/17/Z). This work was also supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Center (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>World Health Organisation Annual TB Report 2017</source>. (<year>2018</year>).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waters</surname><given-names>WR</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>MV</given-names></name><name name-style="western"><surname>Buddle</surname><given-names>BM</given-names></name><name name-style="western"><surname>Vordermeier</surname><given-names>HM</given-names></name></person-group>. <article-title>Bovine tuberculosis vaccine research: historical perspectives and recent advances</article-title>. <source>Vaccine.</source> (<year>2012</year>) <volume>30</volume>:<fpage>2611</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.02.018</pub-id><pub-id pub-id-type="pmid">22342705</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>OIE</collab></person-group> (<year>2018</year>). Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.oie.int/en/animal-health-in-the-world/animal-diseases/bovine-tuberculosis/">http://www.oie.int/en/animal-health-in-the-world/animal-diseases/bovine-tuberculosis/</ext-link></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab><italic toggle="yes">Roadmap for Zoonotic Tuberculosi.</italic></collab></person-group> (<year>2017</year>) Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fao.org/3/a-i7807e.pdf">http://www.fao.org/3/a-i7807e.pdf</ext-link>; <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fao.org/3/a-i7807e.pdf">http://www.fao.org/3/a-i7807e.pdf</ext-link></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fine</surname><given-names>PE</given-names></name></person-group>. <article-title>Variation in protection by BCG: implications of and for heterologous immunity</article-title>. <source>Lancet.</source> (<year>1995</year>) <volume>346</volume>:<fpage>1339</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(95)92348-9</pub-id><pub-id pub-id-type="pmid">7475776</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lombardi</surname><given-names>C</given-names></name><name name-style="western"><surname>Pedrazzani</surname><given-names>ES</given-names></name><name name-style="western"><surname>Pedrazzani</surname><given-names>JC</given-names></name><name name-style="western"><surname>Filho</surname><given-names>PF</given-names></name><name name-style="western"><surname>Zicker</surname><given-names>F</given-names></name></person-group>. <article-title>Protective efficacy of BCG against leprosy in Sao Paulo</article-title>. <source>Bull Pan Am Health Organ.</source> (<year>1996</year>) <volume>30</volume>:<fpage>24</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="pmid">8919722</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merle</surname><given-names>CS</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>SS</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>LC</given-names></name></person-group>. <article-title>BCG vaccination and leprosy protection: review of current evidence and status of BCG in leprosy control</article-title>. <source>Expert Rev Vaccines.</source> (<year>2010</year>) <volume>9</volume>:<fpage>209</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1586/erv.09.161</pub-id><pub-id pub-id-type="pmid">20109030</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orme</surname><given-names>IM</given-names></name></person-group>. <article-title>Characteristics and specificity of acquired immunologic memory to <italic toggle="yes">Mycobacterium tuberculosis</italic> infection</article-title>. <source>J Immunol.</source> (<year>1988</year>) <volume>140</volume>:<fpage>3589</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="pmid">3129497</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jasenosky</surname><given-names>LD</given-names></name><name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Hanekom</surname><given-names>WA</given-names></name><name name-style="western"><surname>Goldfeld</surname><given-names>AE</given-names></name></person-group>. <article-title>T cells and adaptive immunity to <italic toggle="yes">Mycobacterium tuberculosis</italic> in humans</article-title>. <source>Immunol Rev.</source> (<year>2015</year>) <volume>264</volume>:<fpage>74</fpage>&#8211;<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12274</pub-id><pub-id pub-id-type="pmid">25703553</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caruso</surname><given-names>AM</given-names></name><name name-style="western"><surname>Serbina</surname><given-names>N</given-names></name><name name-style="western"><surname>Klein</surname><given-names>E</given-names></name><name name-style="western"><surname>Triebold</surname><given-names>K</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>BR</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>JL</given-names></name></person-group>. <article-title>Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis</article-title>. <source>J Immunol.</source> (<year>1999</year>) <volume>162</volume>:<fpage>5407</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="pmid">10228018</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flynn</surname><given-names>JL</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J</given-names></name><name name-style="western"><surname>Triebold</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Dalton</surname><given-names>DK</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>TA</given-names></name><name name-style="western"><surname>Bloom</surname><given-names>BR</given-names></name></person-group>. <article-title>An essential role for interferon gamma in resistance to <italic toggle="yes">Mycobacterium tuberculosis</italic> infection</article-title>. <source>J Exp Med.</source> (<year>1993</year>) <volume>178</volume>:<fpage>2249</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1084/jem.178.6.2249</pub-id><pub-id pub-id-type="pmid">7504064</pub-id><pub-id pub-id-type="pmcid">PMC2191274</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geldmacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A</given-names></name><name name-style="western"><surname>Hoelscher</surname><given-names>M</given-names></name></person-group>. <article-title>Interaction between HIV and <italic toggle="yes">Mycobacterium tuberculosis</italic>: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis</article-title>. <source>Curr Opin HIV AIDS.</source> (<year>2012</year>) <volume>7</volume>:<fpage>268</fpage>&#8211;<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1097/COH.0b013e3283524e32</pub-id><pub-id pub-id-type="pmid">22495739</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dockrell</surname><given-names>HM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SG</given-names></name></person-group>. <article-title>What Have We Learnt about BCG Vaccination in the Last 20 Years?</article-title><source>Front Immunol.</source> (<year>2017</year>) <volume>8</volume>:<fpage>1134</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.01134</pub-id><pub-id pub-id-type="pmid">28955344</pub-id><pub-id pub-id-type="pmcid">PMC5601272</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marchant</surname><given-names>A</given-names></name><name name-style="western"><surname>Goetghebuer</surname><given-names>T</given-names></name><name name-style="western"><surname>Ota</surname><given-names>MO</given-names></name><name name-style="western"><surname>Wolfe</surname><given-names>I</given-names></name><name name-style="western"><surname>Ceesay</surname><given-names>SJ</given-names></name><name name-style="western"><surname>De Groote</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Newborns develop a Th1-type immune response to <italic toggle="yes">Mycobacterium bovis</italic> bacillus Calmette-Guerin vaccination</article-title>. <source>J Immunol.</source> (<year>1999</year>) <volume>163</volume>:<fpage>2249</fpage>&#8211;<lpage>55</lpage>. <pub-id pub-id-type="pmid">10438968</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kagina</surname><given-names>BM</given-names></name><name name-style="western"><surname>Abel</surname><given-names>B</given-names></name><name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Keyser</surname><given-names>A</given-names></name><name name-style="western"><surname>Soares</surname><given-names>A</given-names></name><etal/></person-group><article-title>Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Gu&#233;rin vaccination of newborns</article-title>. <source>Am J Respir Crit Care Med.</source> (<year>2010</year>) <volume>182</volume>:<fpage>1073</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201003-0334OC</pub-id><pub-id pub-id-type="pmid">20558627</pub-id><pub-id pub-id-type="pmcid">PMC2970848</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittr&#252;cker</surname><given-names>HW</given-names></name><name name-style="western"><surname>Steinhoff</surname><given-names>U</given-names></name><name name-style="western"><surname>K&#246;hler</surname><given-names>A</given-names></name><name name-style="western"><surname>Krause</surname><given-names>M</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>D</given-names></name><name name-style="western"><surname>Mex</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2007</year>) <volume>104</volume>:<fpage>12434</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0703510104</pub-id><pub-id pub-id-type="pmid">17640915</pub-id><pub-id pub-id-type="pmcid">PMC1941486</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tameris</surname><given-names>MD</given-names></name><name name-style="western"><surname>Hatherill</surname><given-names>M</given-names></name><name name-style="western"><surname>Landry</surname><given-names>BS</given-names></name><name name-style="western"><surname>Scriba</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Snowden</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial</article-title>. <source>Lancet.</source> (<year>2013</year>) <volume>381</volume>:<fpage>1021</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(13)60177-4</pub-id><pub-id pub-id-type="pmid">23391465</pub-id><pub-id pub-id-type="pmcid">PMC5424647</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zufferey</surname><given-names>C</given-names></name><name name-style="western"><surname>Germano</surname><given-names>S</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>B</given-names></name><name name-style="western"><surname>Ritz</surname><given-names>N</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name></person-group>. <article-title>The contribution of non-conventional T cells and NK cells in the mycobacterial-specific IFN&#947; response in Bacille Calmette-Gu&#233;rin (BCG)-immunized infants</article-title>. <source>PLoS ONE.</source> (<year>2013</year>) <volume>8</volume>:<fpage>e77334</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0077334</pub-id><pub-id pub-id-type="pmid">24098583</pub-id><pub-id pub-id-type="pmcid">PMC3789697</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koeken</surname><given-names>VACM</given-names></name><name name-style="western"><surname>Verrall</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>Hill</surname><given-names>PC</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R</given-names></name></person-group>. <article-title>Trained innate immunity and resistance to <italic toggle="yes">Mycobacterium tuberculosis</italic> infection</article-title>. <source>Clin Microbiol Infect.</source> (<year>2019</year>). <fpage>S1198</fpage>-<lpage>743X</lpage>:<fpage>30081</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2019.02.015</pub-id><pub-id pub-id-type="pmid">30807849</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Achkar</surname><given-names>JM</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name></person-group>. <article-title>B cells and antibodies in the defense against <italic toggle="yes">Mycobacterium tuberculosis</italic> infection</article-title>. <source>Immunol Rev.</source> (<year>2015</year>) <volume>264</volume>:<fpage>167</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12276</pub-id><pub-id pub-id-type="pmid">25703559</pub-id><pub-id pub-id-type="pmcid">PMC4629253</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobs</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Mongkolsapaya</surname><given-names>J</given-names></name><name name-style="western"><surname>Screaton</surname><given-names>GR</given-names></name><name name-style="western"><surname>McShane</surname><given-names>H</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>RJ</given-names></name></person-group>. <article-title>Antibodies and tuberculosis</article-title>. <source>Tuberculosis</source>. (<year>2016</year>) <volume>101</volume>:<fpage>102</fpage>&#8211;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2016.08.001</pub-id><pub-id pub-id-type="pmid">27865379</pub-id><pub-id pub-id-type="pmcid">PMC5120988</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanchez-Rodriguez</surname><given-names>C</given-names></name><name name-style="western"><surname>Estrada-Chavez</surname><given-names>C</given-names></name><name name-style="western"><surname>Garcia-Vigil</surname><given-names>J</given-names></name><name name-style="western"><surname>Laredo-Sanchez</surname><given-names>F</given-names></name><name name-style="western"><surname>Halabe-Cherem</surname><given-names>J</given-names></name><name name-style="western"><surname>Pereira-Suarez</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>An IgG antibody response to the antigen 85 complex is associated with good outcome in Mexican Totonaca Indians with pulmonary tuberculosis</article-title>. <source>Int J Tuberc Lung Dis.</source> (<year>2002</year>) <volume>6</volume>:<fpage>706</fpage>&#8211;<lpage>12</lpage>. Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ingentaconnect.com/content/iuatld/ijtld">https://www.ingentaconnect.com/content/iuatld/ijtld</ext-link><pub-id pub-id-type="pmid">12150483</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Costello</surname><given-names>AM</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Narayan</surname><given-names>V</given-names></name><name name-style="western"><surname>Akbar</surname><given-names>MS</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name><name name-style="western"><surname>Abou-Zeid</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Does antibody to mycobacterial antigens, including lipoarabinomannan, limit dissemination in childhood tuberculosis?</article-title><source>Trans R Soc Trop Med Hyg.</source> (<year>1992</year>) <volume>86</volume>:<fpage>686</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/0035-9203(92)90192-F</pub-id><pub-id pub-id-type="pmid">1287946</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamasur</surname><given-names>B</given-names></name><name name-style="western"><surname>Haile</surname><given-names>M</given-names></name><name name-style="western"><surname>Pawlowski</surname><given-names>A</given-names></name><name name-style="western"><surname>Schroder</surname><given-names>U</given-names></name><name name-style="western"><surname>Kallenius</surname><given-names>G</given-names></name><name name-style="western"><surname>Svenson</surname><given-names>SB</given-names></name></person-group>. <article-title>A mycobacterial lipoarabinomannan specific monoclonal antibody and its F(ab') fragment prolong survival of mice infected with <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Clin Exp Immunol.</source> (<year>2004</year>) <volume>138</volume>:<fpage>30</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.2004.02593.x</pub-id><pub-id pub-id-type="pmid">15373902</pub-id><pub-id pub-id-type="pmcid">PMC1809178</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teitelbaum</surname><given-names>R</given-names></name><name name-style="western"><surname>Glatman-Freedman</surname><given-names>A</given-names></name><name name-style="western"><surname>Chen</surname><given-names>B</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>JB</given-names></name><name name-style="western"><surname>Unanue</surname><given-names>E</given-names></name><name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A mAb recognizing a surface antigen of <italic toggle="yes">Mycobacterium tuberculosis</italic> enhances host survival</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>1998</year>) <volume>95</volume>:<fpage>15688</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.95.26.15688</pub-id><pub-id pub-id-type="pmid">9861031</pub-id><pub-id pub-id-type="pmcid">PMC28105</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>LL</given-names></name><name name-style="western"><surname>Chung</surname><given-names>AW</given-names></name><name name-style="western"><surname>Rosebrock</surname><given-names>TR</given-names></name><name name-style="western"><surname>Ghebremichael</surname><given-names>M</given-names></name><name name-style="western"><surname>Yu</surname><given-names>WH</given-names></name><name name-style="western"><surname>Grace</surname><given-names>PS</given-names></name><etal/></person-group>. <article-title>A Functional Role for Antibodies in Tuberculosis</article-title>. <source>Cell.</source> (<year>2016</year>) <volume>167</volume>:<fpage>433</fpage>&#8211;<lpage>43</lpage>.e14. <pub-id pub-id-type="doi">10.1016/j.cell.2016.08.072</pub-id><pub-id pub-id-type="pmid">27667685</pub-id><pub-id pub-id-type="pmcid">PMC5526202</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XX</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Fu</surname><given-names>L</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Latently and uninfected healthcare workers exposed to TB make protective antibodies against <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2017</year>) <volume>114</volume>:<fpage>5023</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1611776114</pub-id><pub-id pub-id-type="pmid">28438994</pub-id><pub-id pub-id-type="pmcid">PMC5441709</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fletcher</surname><given-names>HA</given-names></name><name name-style="western"><surname>Snowden</surname><given-names>MA</given-names></name><name name-style="western"><surname>Landry</surname><given-names>B</given-names></name><name name-style="western"><surname>Rida</surname><given-names>W</given-names></name><name name-style="western"><surname>Satti</surname><given-names>I</given-names></name><name name-style="western"><surname>Harris</surname><given-names>SA</given-names></name><etal/></person-group><article-title>T-cell activation is an immune correlate of risk in BCG vaccinated infants</article-title>. <source>Nat Commun.</source> (<year>2016</year>) <volume>7</volume>:<fpage>11290</fpage><pub-id pub-id-type="doi">10.1038/ncomms11290</pub-id><pub-id pub-id-type="pmid">27068708</pub-id><pub-id pub-id-type="pmcid">PMC4832066</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Javid</surname><given-names>B</given-names></name></person-group>. <article-title>Antibodies and tuberculosis: finally coming of age?</article-title><source>Nat Rev Immunol.</source> (<year>2018</year>) <volume>18</volume>:<fpage>591</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1038/s41577-018-0028-0</pub-id><pub-id pub-id-type="pmid">29872140</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulrichs</surname><given-names>T</given-names></name><name name-style="western"><surname>Kosmiadi</surname><given-names>GA</given-names></name><name name-style="western"><surname>Trusov</surname><given-names>V</given-names></name><name name-style="western"><surname>Jorg</surname><given-names>S</given-names></name><name name-style="western"><surname>Pradl</surname><given-names>L</given-names></name><name name-style="western"><surname>Titukhina</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung</article-title>. <source>J Pathol.</source> (<year>2004</year>) <volume>204</volume>:<fpage>217</fpage>&#8211;<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1002/path.1628</pub-id><pub-id pub-id-type="pmid">15376257</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maglione</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J</given-names></name></person-group>. <article-title>How B cells shape the immune response against <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Eur J Immunol.</source> (<year>2009</year>) <volume>39</volume>:<fpage>676</fpage>&#8211;<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200839148</pub-id><pub-id pub-id-type="pmid">19283721</pub-id><pub-id pub-id-type="pmcid">PMC2760469</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phuah</surname><given-names>JY</given-names></name><name name-style="western"><surname>Mattila</surname><given-names>JT</given-names></name><name name-style="western"><surname>Lin</surname><given-names>PL</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>JL</given-names></name></person-group>. <article-title>Activated B Cells in the Granulomas of Nonhuman Primates Infected with <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Am J Pathol.</source> (<year>2012</year>) <volume>181</volume>:<fpage>508</fpage>&#8211;<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2012.05.009</pub-id><pub-id pub-id-type="pmid">22721647</pub-id><pub-id pub-id-type="pmcid">PMC3409439</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>L</given-names></name><name name-style="western"><surname>Gough</surname><given-names>J</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>Y</given-names></name><name name-style="western"><surname>Hewinson</surname><given-names>G</given-names></name><name name-style="western"><surname>Vordermeier</surname><given-names>M</given-names></name><name name-style="western"><surname>Wangoo</surname><given-names>A</given-names></name></person-group>. <article-title>Immunohistochemical markers augment evaluation of vaccine efficacy and disease severity in bacillus Calmette-Guerin (BCG) vaccinated cattle challenged with <italic toggle="yes">Mycobacterium bovis</italic></article-title>. <source>Vet Immunol Immunopathol.</source> (<year>2006</year>) <volume>111</volume>:<fpage>219</fpage>&#8211;<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.vetimm.2006.01.016</pub-id><pub-id pub-id-type="pmid">16540176</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Valentini</surname><given-names>D</given-names></name><name name-style="western"><surname>Poiret</surname><given-names>T</given-names></name><name name-style="western"><surname>Dodoo</surname><given-names>E</given-names></name><name name-style="western"><surname>Parida</surname><given-names>S</given-names></name><name name-style="western"><surname>Zumla</surname><given-names>A</given-names></name><etal/></person-group><article-title>B in TB: B cells as mediators of clinically relevant immune responses in tuberculosis</article-title>. <source>Clin Infect Dis</source>. (<year>2015</year>) <volume>61</volume>(<issue>Suppl. 3</issue>):<fpage>S225</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ614</pub-id><pub-id pub-id-type="pmcid">PMC4583574</pub-id><pub-id pub-id-type="pmid">26409285</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahman</surname><given-names>S</given-names></name><name name-style="western"><surname>Rehn</surname><given-names>A</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>J</given-names></name><name name-style="western"><surname>Andersson</surname><given-names>J</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>M</given-names></name><name name-style="western"><surname>Brighenti</surname><given-names>S</given-names></name></person-group>. <article-title>Pulmonary tuberculosis patients with a vitamin D deficiency demonstrate low local expression of the antimicrobial peptide LL-37 but enhanced FoxP3+ regulatory T cells and IgG-secreting cells</article-title>. <source>Clin Immunol.</source> (<year>2015</year>) <volume>156</volume>:<fpage>85</fpage>&#8211;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2014.12.003</pub-id><pub-id pub-id-type="pmid">25510482</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corominas</surname><given-names>M</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>V</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>L</given-names></name><name name-style="western"><surname>Cayla</surname><given-names>JA</given-names></name><name name-style="western"><surname>Rufi</surname><given-names>G</given-names></name><name name-style="western"><surname>Mestre</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>B-lymphocytes and co-stimulatory molecules in <italic toggle="yes">Mycobacterium tuberculosis</italic> infection</article-title>. <source>Int J Tuberc Lung Dis.</source> (<year>2004</year>) <volume>8</volume>:<fpage>98</fpage>&#8211;<lpage>105</lpage>. Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ingentaconnect.com/content/iuatld/ijtld">https://www.ingentaconnect.com/content/iuatld/ijtld</ext-link><pub-id pub-id-type="pmid">14974752</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>J</given-names></name><name name-style="western"><surname>Velazquez</surname><given-names>C</given-names></name><name name-style="western"><surname>Valenzuela</surname><given-names>O</given-names></name><name name-style="western"><surname>Robles-Zepeda</surname><given-names>R</given-names></name><name name-style="western"><surname>Ruiz-Bustos</surname><given-names>E</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Low number of peripheral blood B lymphocytes in patients with pulmonary tuberculosis</article-title>. <source>Immunol Invest.</source> (<year>2010</year>) <volume>39</volume>:<fpage>197</fpage>&#8211;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.3109/08820130903586346</pub-id><pub-id pub-id-type="pmid">20380518</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vordermeier</surname><given-names>HM</given-names></name><name name-style="western"><surname>Venkataprasad</surname><given-names>N</given-names></name><name name-style="western"><surname>Harris</surname><given-names>DP</given-names></name><name name-style="western"><surname>Ivanyi</surname><given-names>J</given-names></name></person-group>. <article-title>Increase of tuberculous infection in the organs of B cell-deficient mice</article-title>. <source>Clin Exp Immunol.</source> (<year>1996</year>) <volume>106</volume>:<fpage>312</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2249.1996.d01-845.x</pub-id><pub-id pub-id-type="pmid">8918578</pub-id><pub-id pub-id-type="pmcid">PMC2200584</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosio</surname><given-names>CM</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>D</given-names></name><name name-style="western"><surname>Elkins</surname><given-names>KL</given-names></name></person-group>. <article-title>Infection of B cell-deficient mice with CDC 1551, a clinical isolate of <italic toggle="yes">Mycobacterium tuberculosis</italic>: delay in dissemination and development of lung pathology</article-title>. <source>J Immunol.</source> (<year>2000</year>) <volume>164</volume>:<fpage>6417</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.164.12.6417</pub-id><pub-id pub-id-type="pmid">10843697</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maglione</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Chan</surname><given-names>J</given-names></name></person-group>. <article-title>B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>J Immunol.</source> (<year>2007</year>) <volume>178</volume>:<fpage>7222</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.11.7222</pub-id><pub-id pub-id-type="pmid">17513771</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>CM</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>AM</given-names></name><name name-style="western"><surname>Frank</surname><given-names>AA</given-names></name><name name-style="western"><surname>Bonorino</surname><given-names>CB</given-names></name><name name-style="western"><surname>Wysoki</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Orme</surname><given-names>IM</given-names></name></person-group>. <article-title><italic toggle="yes">Mycobacterium tuberculosis</italic> aerogenic rechallenge infections in B cell-deficient mice</article-title>. <source>Tuber Lung Dis.</source> (<year>1997</year>);<volume>78</volume>:<fpage>257</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/S0962-8479(97)90006-X</pub-id><pub-id pub-id-type="pmid">10209680</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turner</surname><given-names>J</given-names></name><name name-style="western"><surname>Frank</surname><given-names>AA</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>JV</given-names></name><name name-style="western"><surname>Gonzalez-Juarrero</surname><given-names>M</given-names></name><name name-style="western"><surname>Orme</surname><given-names>IM</given-names></name></person-group><article-title>The progression of chronic tuberculosis in the mouse does not require the participation of B lymphocytes or interleukin-4</article-title>. <source>Exp Gerontol.</source> (<year>2001</year>) <volume>36</volume>:<fpage>537</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/S0531-5565(00)00257-6</pub-id><pub-id pub-id-type="pmid">11250124</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozakiewicz</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dunussi-Joannopoulos</surname><given-names>K</given-names></name><name name-style="western"><surname>Ou</surname><given-names>Q</given-names></name><etal/></person-group>. <article-title>B cells regulate neutrophilia during <italic toggle="yes">Mycobacterium tuberculosis</italic> infection and BCG vaccination by modulating the interleukin-17 response</article-title>. <source>PLoS Pathog.</source> (<year>2013</year>) <volume>9</volume>:<fpage>e1003472</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003472</pub-id><pub-id pub-id-type="pmid">23853593</pub-id><pub-id pub-id-type="pmcid">PMC3708864</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sebina</surname><given-names>I</given-names></name><name name-style="western"><surname>Cliff</surname><given-names>JM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>SG</given-names></name><name name-style="western"><surname>Nogaro</surname><given-names>S</given-names></name><name name-style="western"><surname>Webb</surname><given-names>EL</given-names></name><name name-style="western"><surname>Riley</surname><given-names>EM</given-names></name><etal/></person-group>. <article-title>Long-lived memory B-cell responses following BCG vaccination</article-title>. <source>PLoS ONE.</source> (<year>2012</year>) <volume>7</volume>:<fpage>e51381</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0051381</pub-id><pub-id pub-id-type="pmid">23240017</pub-id><pub-id pub-id-type="pmcid">PMC3519837</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Birk</surname><given-names>NM</given-names></name><name name-style="western"><surname>Nissen</surname><given-names>TN</given-names></name><name name-style="western"><surname>Kj&#230;rgaard</surname><given-names>J</given-names></name><name name-style="western"><surname>Hartling</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Th&#248;stesen</surname><given-names>LM</given-names></name><name name-style="western"><surname>Kofoed</surname><given-names>P-E</given-names></name><etal/></person-group>. <article-title>Effects of Bacillus Calmette-Gu&#233;rin (BCG) vaccination at birth on T and B lymphocyte subsets: results from a clinical randomized trial</article-title>. <source>Sci Rep.</source> (<year>2017</year>) <volume>7</volume>:<fpage>12398</fpage>. <pub-id pub-id-type="doi">10.1038/s41598-017-11601-6</pub-id><pub-id pub-id-type="pmid">28963455</pub-id><pub-id pub-id-type="pmcid">PMC5622034</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagercrantz</surname><given-names>R</given-names></name><name name-style="western"><surname>Enell</surname><given-names>H</given-names></name></person-group>. <article-title>Tuberculin-sensitivity and antibodies (agglutinins) after BCG-vaccination</article-title>. <source>Acta Paediatr.</source> (<year>1953</year>) <volume>42</volume>:<fpage>316</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.1953.tb05598.x</pub-id><pub-id pub-id-type="pmid">13079767</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parlett</surname><given-names>RC</given-names></name><name name-style="western"><surname>Youmans</surname><given-names>GP</given-names></name></person-group>. <article-title>An evaluation of the specificty and sensitivity of a gel double-diffusion test for tuberculosis</article-title>. <source>Am Rev Respir Dis.</source> (<year>1959</year>) <volume>80</volume>:<fpage>153</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="pmid">14430545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/arrd.1959.80.2.153</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Turneer</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Vooren</surname><given-names>JP</given-names></name><name name-style="western"><surname>Nyabenda</surname><given-names>J</given-names></name><name name-style="western"><surname>Legros</surname><given-names>F</given-names></name><name name-style="western"><surname>Lecomte</surname><given-names>A</given-names></name><name name-style="western"><surname>Thiriaux</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The humoral immune response after BCG vaccination in humans: consequences for the serodiagnosis of tuberculosis</article-title>. <source>Eur Respir J.</source> (<year>1988</year>) <volume>1</volume>:<fpage>589</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="pmid">3181404</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beyazova</surname><given-names>U</given-names></name><name name-style="western"><surname>Rota</surname><given-names>S</given-names></name><name name-style="western"><surname>Cevheroglu</surname><given-names>C</given-names></name><name name-style="western"><surname>Karsligil</surname><given-names>T</given-names></name></person-group>. <article-title>Humoral immune response in infants after BCG vaccination</article-title>. <source>Tuber Lung Dis.</source> (<year>1995</year>) <volume>76</volume>:<fpage>248</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/S0962-8479(05)80013-9</pub-id><pub-id pub-id-type="pmid">7548909</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nabeshima</surname><given-names>S</given-names></name><name name-style="western"><surname>Murata</surname><given-names>M</given-names></name><name name-style="western"><surname>Kashiwagi</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujita</surname><given-names>M</given-names></name><name name-style="western"><surname>Furusyo</surname><given-names>N</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>J</given-names></name></person-group>. <article-title>Serum antibody response to tuberculosis-associated glycolipid antigen after BCG vaccination in adults</article-title>. <source>J Infect Chemother.</source> (<year>2005</year>) <volume>11</volume>:<fpage>256</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s10156-005-0398-7</pub-id><pub-id pub-id-type="pmid">16258824</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Surekha</surname><given-names>H</given-names></name></person-group><article-title>Rani VVL, Suman G. Latha and K.J.R. Murthy. Post-BCG vaccination check based on serum IgG to culture filtrate antigens</article-title>. <source>Ind J Tuberculosis.</source> (<year>2004</year>) <volume>52</volume>:<fpage>27</fpage>&#8211;<lpage>30</lpage>. Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.journals.elsevier.com/indian-journal-of-tuberculosis">https://www.journals.elsevier.com/indian-journal-of-tuberculosis</ext-link></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>RM</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>O</given-names></name><name name-style="western"><surname>Brennan</surname><given-names>M</given-names></name><name name-style="western"><surname>Gennaro</surname><given-names>ML</given-names></name><name name-style="western"><surname>Schlesinger</surname><given-names>L</given-names></name><name name-style="western"><surname>Skeiky</surname><given-names>YA</given-names></name><etal/></person-group>. <article-title>Lipoarabinomannan-reactive human secretory immunoglobulin A responses induced by mucosal bacille Calmette-Guerin vaccination</article-title>. <source>J Infect Dis.</source> (<year>2003</year>) <volume>187</volume>:<fpage>513</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1086/368096</pub-id><pub-id pub-id-type="pmid">12552438</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de</surname><given-names>Valli&#232;re S</given-names></name><name name-style="western"><surname>Abate</surname><given-names>G</given-names></name><name name-style="western"><surname>Blazevic</surname><given-names>A</given-names></name><name name-style="western"><surname>Heuertz</surname><given-names>RM</given-names></name><name name-style="western"><surname>Hoft</surname><given-names>DF</given-names></name></person-group><article-title>Enhancement of innate and cell-mediated immunity by antimycobacterial antibodies</article-title>. <source>Infect Immun.</source> (<year>2005</year>) <volume>73</volume>:<fpage>6711</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.73.10.6711-6720.2005</pub-id><pub-id pub-id-type="pmid">16177348</pub-id><pub-id pub-id-type="pmcid">PMC1230956</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>C</given-names></name><name name-style="western"><surname>Eder</surname><given-names>AZ</given-names></name><name name-style="western"><surname>Prados-Rosales</surname><given-names>R</given-names></name><name name-style="western"><surname>Souza</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kim</surname><given-names>RS</given-names></name><etal/></person-group>. <article-title>Association of human antibodies to arabinomannan with enhanced <italic toggle="yes">Mycobacterial Opsonophagocytosis</italic> and intracellular growth reduction</article-title>. <source>J Infect Dis.</source> (<year>2016</year>) <volume>214</volume>:<fpage>300</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiw141</pub-id><pub-id pub-id-type="pmid">27056953</pub-id><pub-id pub-id-type="pmcid">PMC4918826</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruppo</surname><given-names>V</given-names></name><name name-style="western"><surname>Orme</surname><given-names>IM</given-names></name></person-group><article-title>Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Tuberculosis.</source> (<year>2002</year>) <volume>82</volume>:<fpage>267</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1054/tube.2002.0340</pub-id><pub-id pub-id-type="pmid">12623269</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvarez</surname><given-names>N</given-names></name><name name-style="western"><surname>Serpa</surname><given-names>D</given-names></name><name name-style="western"><surname>Kadir</surname><given-names>R</given-names></name><name name-style="western"><surname>Tirado</surname><given-names>Y</given-names></name><name name-style="western"><surname>Borrero</surname><given-names>R</given-names></name><name name-style="western"><surname>Fern&#225;ndez</surname><given-names>S</given-names></name><etal/></person-group><article-title>Specific and cross-reactive immune response against <italic toggle="yes">Mycobacterium tuberculosis</italic> antigens in mice immunized with proteoliposomes from <italic toggle="yes">Mycobacterium bovis</italic> BCG</article-title>. <source>Asian Pacific J Trop Biomed.</source> (<year>2017</year>) <volume>7</volume>:<fpage>188</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/j.apjtb.2016.12.013</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>AA</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>RS</given-names></name><name name-style="western"><surname>Kalorey</surname><given-names>DR</given-names></name><name name-style="western"><surname>Warke</surname><given-names>SR</given-names></name><name name-style="western"><surname>Purohit</surname><given-names>HJ</given-names></name><name name-style="western"><surname>Taori</surname><given-names>GM</given-names></name><etal/></person-group>. <article-title>Effect of repeat dose of BCG vaccination on humoral response in mice model</article-title>. <source>Ind J Exp Biol.</source> (<year>2011</year>) <volume>49</volume>:<fpage>7</fpage>&#8211;<lpage>10</lpage>. Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.niscair.res.in/ScienceCommunication/ResearchJournals/rejour/ijeb/ijeb0.asp">https://www.niscair.res.in/ScienceCommunication/ResearchJournals/rejour/ijeb/ijeb0.asp</ext-link><pub-id pub-id-type="pmid">21365989</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Husain</surname><given-names>AA</given-names></name><name name-style="western"><surname>Warke</surname><given-names>SR</given-names></name><name name-style="western"><surname>Kalorey</surname><given-names>DR</given-names></name><name name-style="western"><surname>Daginawala</surname><given-names>HF</given-names></name><name name-style="western"><surname>Taori</surname><given-names>GM</given-names></name><name name-style="western"><surname>Kashyap</surname><given-names>RS</given-names></name></person-group>. <article-title>Comparative evaluation of booster efficacies of BCG, Ag85B, and Ag85B peptides based vaccines to boost BCG induced immunity in BALB/c mice: a pilot study</article-title>. <source>Clin Exp Vaccine Res.</source> (<year>2015</year>) <volume>4</volume>:<fpage>83</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.7774/cevr.2015.4.1.83</pub-id><pub-id pub-id-type="pmid">25649326</pub-id><pub-id pub-id-type="pmcid">PMC4313113</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romain</surname><given-names>F</given-names></name><name name-style="western"><surname>Laqueyrerie</surname><given-names>A</given-names></name><name name-style="western"><surname>Militzer</surname><given-names>P</given-names></name><name name-style="western"><surname>Pescher</surname><given-names>P</given-names></name><name name-style="western"><surname>Chavarot</surname><given-names>P</given-names></name><name name-style="western"><surname>Lagranderie</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Identification of a <italic toggle="yes">Mycobacterium bovis</italic> BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria</article-title>. <source>Infect Immunity.</source> (<year>1993</year>) <volume>61</volume>:<fpage>742</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="pmid">8423100</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.61.2.742-750.1993</pub-id><pub-id pub-id-type="pmcid">PMC302788</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langermans</surname><given-names>JA</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P</given-names></name><name name-style="western"><surname>van</surname><given-names>Soolingen D</given-names></name><name name-style="western"><surname>Vervenne</surname><given-names>RA</given-names></name><name name-style="western"><surname>Frost</surname><given-names>PA</given-names></name><name name-style="western"><surname>van</surname><given-names>der Laan T</given-names></name><etal/></person-group>. <article-title>Divergent effect of bacillus Calmette-Gu&#233;rin (BCG) vaccination on <italic toggle="yes">Mycobacterium tuberculosis</italic> infection in highly related macaque species: implications for primate models in tuberculosis vaccine research</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2001</year>) <volume>98</volume>:<fpage>11497</fpage>&#8211;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.201404898</pub-id><pub-id pub-id-type="pmid">11562492</pub-id><pub-id pub-id-type="pmcid">PMC58758</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fusillo</surname><given-names>MH</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>DL</given-names></name></person-group>. <article-title>Lack of circulating antibodies after BCG immunization as assayed by the globulin titration technique</article-title>. <source>Am Rev Tuberc.</source> (<year>1958</year>) <volume>78</volume>:<fpage>793</fpage>. <pub-id pub-id-type="pmid">13583446</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/artpd.1958.78.5.793</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krambovitis</surname><given-names>E</given-names></name></person-group>. <article-title>Detection of antibodies to <italic toggle="yes">Mycobacterium tuberculosis</italic> plasma membrane antigen by enzyme-linked immunosorbent assay</article-title>. <source>J Med Microbiol.</source> (<year>1986</year>) <volume>21</volume>:<fpage>257</fpage>&#8211;<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1099/00222615-21-3-257</pub-id><pub-id pub-id-type="pmid">3084792</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kardjito</surname><given-names>T</given-names></name><name name-style="western"><surname>Handoyo</surname><given-names>I</given-names></name><name name-style="western"><surname>Grange</surname><given-names>JM</given-names></name></person-group>. <article-title>Diagnosis of active tuberculosis by immunological methods. 1. The effect of tuberculin reactivity and previous BCG vaccination on the antibody levels determined by ELISA</article-title>. <source>Tubercle.</source> (<year>1982</year>) <volume>63</volume>:<fpage>269</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S0041-3879(82)80014-7</pub-id><pub-id pub-id-type="pmid">6820736</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buddle</surname><given-names>BM</given-names></name><name name-style="western"><surname>de Lisle</surname><given-names>GW</given-names></name><name name-style="western"><surname>Pfeffer</surname><given-names>A</given-names></name><name name-style="western"><surname>Aldwell</surname><given-names>FE</given-names></name></person-group>. <article-title>Immunological responses and protection against <italic toggle="yes">Mycobacterium bovis</italic> in calves vaccinated with a low dose of BCG</article-title>. <source>Vaccine.</source> (<year>1995</year>) <volume>13</volume>:<fpage>1123</fpage>&#8211;<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(94)00055-R</pub-id><pub-id pub-id-type="pmid">7491820</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buddle</surname><given-names>BM</given-names></name><name name-style="western"><surname>Wedlock</surname><given-names>DN</given-names></name><name name-style="western"><surname>Parlane</surname><given-names>NA</given-names></name><name name-style="western"><surname>Corner</surname><given-names>LAL</given-names></name><name name-style="western"><surname>de Lisle</surname><given-names>GW</given-names></name><name name-style="western"><surname>Skinner</surname><given-names>MA</given-names></name></person-group>. <article-title>Revaccination of neonatal calves with mycobacterium bovis bcg reduces the level of protection against bovine tuberculosis induced by a single vaccination</article-title>. <source>Infect Immunity.</source> (<year>2003</year>) <volume>71</volume>:<fpage>6411</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.71.11.6411-6419.2003</pub-id><pub-id pub-id-type="pmid">14573662</pub-id><pub-id pub-id-type="pmcid">PMC219550</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyashchenko</surname><given-names>K</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>AO</given-names></name><name name-style="western"><surname>Greenwald</surname><given-names>R</given-names></name><name name-style="western"><surname>Pollock</surname><given-names>JM</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>P</given-names></name><name name-style="western"><surname>Hewinson</surname><given-names>RG</given-names></name><etal/></person-group>. <article-title>Association of tuberculin-boosted antibody responses with pathology and cell-mediated immunity in cattle vaccinated with <italic toggle="yes">Mycobacterium bovis</italic> BCG and infected with M. bovis</article-title>. <source>Infect Immun.</source> (<year>2004</year>) <volume>72</volume>:<fpage>2462</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.72.5.2462-2467.2004</pub-id><pub-id pub-id-type="pmid">15102752</pub-id><pub-id pub-id-type="pmcid">PMC387859</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debebe</surname><given-names>T</given-names></name><name name-style="western"><surname>Ameni</surname><given-names>G</given-names></name></person-group>. <article-title>Immunogenicity of bacillus Calmette-Guerin (BCG) in bovine neonates under traditional farming in central Ethiopia</article-title>. <source>J Immunoassay Immunochem.</source> (<year>2010</year>) <volume>31</volume>:<fpage>160</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1080/15321811003617479</pub-id><pub-id pub-id-type="pmid">20391027</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van der Heijden</surname><given-names>EMDL</given-names></name><name name-style="western"><surname>Chileshe</surname><given-names>J</given-names></name><name name-style="western"><surname>Vernooij</surname><given-names>JCM</given-names></name><name name-style="western"><surname>Gortazar</surname><given-names>C</given-names></name><name name-style="western"><surname>Juste</surname><given-names>RA</given-names></name><name name-style="western"><surname>Sevilla</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Immune response profiles of calves following vaccination with live BCG and inactivated <italic toggle="yes">Mycobacterium bovis</italic> vaccine candidates</article-title>. <source>PLoS ONE.</source> (<year>2017</year>) <volume>12</volume>:<fpage>e0188448</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0188448</pub-id><pub-id pub-id-type="pmid">29155877</pub-id><pub-id pub-id-type="pmcid">PMC5695775</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parlane</surname><given-names>NA</given-names></name><name name-style="western"><surname>Shu</surname><given-names>D</given-names></name><name name-style="western"><surname>Subharat</surname><given-names>S</given-names></name><name name-style="western"><surname>Wedlock</surname><given-names>DN</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>BH</given-names></name><name name-style="western"><surname>de Lisle</surname><given-names>GW</given-names></name><etal/></person-group>. <article-title>Revaccination of cattle with bacille Calmette-Guerin two years after first vaccination when immunity has waned, boosted protection against challenge with <italic toggle="yes">Mycobacterium bovis</italic></article-title>. <source>PLoS ONE.</source> (<year>2014</year>) <volume>9</volume>:<fpage>e106519</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0106519</pub-id><pub-id pub-id-type="pmid">25180583</pub-id><pub-id pub-id-type="pmcid">PMC4152303</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monteiro-Maia</surname><given-names>R</given-names></name><name name-style="western"><surname>Ortig&#227;o-de-Sampaio</surname><given-names>MB</given-names></name><name name-style="western"><surname>Pinho</surname><given-names>RT</given-names></name><name name-style="western"><surname>Castello-Branco</surname><given-names>LRR</given-names></name></person-group>. <article-title>Modulation of humoral immune response to oral BCG vaccination by <italic toggle="yes">Mycobacterium bovis</italic> BCG Moreau Rio de Janeiro (RDJ) in healthy adults</article-title>. <source>J Immune Based Therap Vaccines</source>. (<year>2006</year>) <volume>4</volume>:<fpage>4</fpage>. <pub-id pub-id-type="doi">10.1186/1476-8518-4-4</pub-id><pub-id pub-id-type="pmid">16956404</pub-id><pub-id pub-id-type="pmcid">PMC1569376</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagranderie</surname><given-names>MR</given-names></name><name name-style="western"><surname>Balazuc</surname><given-names>AM</given-names></name><name name-style="western"><surname>Deriaud</surname><given-names>E</given-names></name><name name-style="western"><surname>Leclerc</surname><given-names>CD</given-names></name><name name-style="western"><surname>Gheorghiu</surname><given-names>M</given-names></name></person-group>. <article-title>Comparison of immune responses of mice immunized with five different <italic toggle="yes">Mycobacterium bovis</italic> BCG vaccine strains</article-title>. <source>Infect Immunity.</source> (<year>1996</year>) <volume>64</volume>:<fpage>1</fpage>. <pub-id pub-id-type="pmid">8557324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.64.1.1-9.1996</pub-id><pub-id pub-id-type="pmcid">PMC173719</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garrido</surname><given-names>JM</given-names></name><name name-style="western"><surname>Sevilla</surname><given-names>IA</given-names></name><name name-style="western"><surname>Beltr&#225;n-Beck</surname><given-names>B</given-names></name><name name-style="western"><surname>Minguij&#243;n</surname><given-names>E</given-names></name><name name-style="western"><surname>Ballesteros</surname><given-names>C</given-names></name><name name-style="western"><surname>Galindo</surname><given-names>RC</given-names></name><etal/></person-group>. <article-title>Protection against Tuberculosis in Eurasian Wild Boar Vaccinated with Heat-Inactivated <italic toggle="yes">Mycobacterium bovis</italic></article-title>. <source>PLoS ONE.</source> (<year>2011</year>) <volume>6</volume>:<fpage>e24905</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0024905</pub-id><pub-id pub-id-type="pmid">21935486</pub-id><pub-id pub-id-type="pmcid">PMC3173485</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilo</surname><given-names>N</given-names></name><name name-style="western"><surname>Alvarez-Arguedas</surname><given-names>S</given-names></name><name name-style="western"><surname>Uranga</surname><given-names>S</given-names></name><name name-style="western"><surname>Marinova</surname><given-names>D</given-names></name><name name-style="western"><surname>Monzon</surname><given-names>M</given-names></name><name name-style="western"><surname>Badiola</surname><given-names>J</given-names></name><etal/></person-group><article-title>Pulmonary but not subcutaneous delivery of BCG vaccine confers protection to tuberculosis-susceptible mice by an interleukin 17-dependent mechanism</article-title>. <source>J Infect Dis.</source> (<year>2016</year>) <volume>213</volume>:<fpage>831</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv503</pub-id><pub-id pub-id-type="pmid">26494773</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giri</surname><given-names>PK</given-names></name><name name-style="western"><surname>Verma</surname><given-names>I</given-names></name><name name-style="western"><surname>Khuller</surname><given-names>GK</given-names></name></person-group>. <article-title>Protective efficacy of intranasal vaccination with <italic toggle="yes">Mycobacterium bovis</italic> BCG against airway <italic toggle="yes">Mycobacterium tuberculosis</italic> challenge in mice</article-title>. <source>J Infect.</source> (<year>2006</year>) <volume>53</volume>:<fpage>350</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2005.12.017</pub-id><pub-id pub-id-type="pmid">16442629</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>White</surname><given-names>AD</given-names></name><name name-style="western"><surname>Sarfas</surname><given-names>C</given-names></name><name name-style="western"><surname>West</surname><given-names>K</given-names></name><name name-style="western"><surname>Sibley</surname><given-names>LS</given-names></name><name name-style="western"><surname>Wareham</surname><given-names>AS</given-names></name><name name-style="western"><surname>Clark</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Evaluation of the immunogenicity of <italic toggle="yes">Mycobacterium bovis</italic> BCG delivered by aerosol to the lungs of macaques</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2015</year>) <volume>22</volume>:<fpage>992</fpage>&#8211;<lpage>1003</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00289-15</pub-id><pub-id pub-id-type="pmid">26108288</pub-id><pub-id pub-id-type="pmcid">PMC4550663</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dijkman</surname><given-names>K</given-names></name><name name-style="western"><surname>Sombroek</surname><given-names>CC</given-names></name><name name-style="western"><surname>Vervenne</surname><given-names>RAW</given-names></name><name name-style="western"><surname>Hofman</surname><given-names>SO</given-names></name><name name-style="western"><surname>Boot</surname><given-names>C</given-names></name><name name-style="western"><surname>Remarque</surname><given-names>EJ</given-names></name><etal/></person-group>. <article-title>Prevention of tuberculosis infection and disease by local BCG in repeatedly exposed rhesus macaques</article-title>. <source>Nat Med</source>. (<year>2019</year>) <volume>25</volume>:<fpage>255</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/s41591-018-0319-9</pub-id><pub-id pub-id-type="pmid">30664782</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Janicki</surname><given-names>BW</given-names></name><name name-style="western"><surname>Good</surname><given-names>RC</given-names></name><name name-style="western"><surname>Minden</surname><given-names>P</given-names></name><name name-style="western"><surname>Affronti</surname><given-names>LF</given-names></name><name name-style="western"><surname>Hymes</surname><given-names>WF</given-names></name></person-group>. <article-title>Immune responses in rhesus monkeys after bacillus Calmette-Guerin vaccination and aerosol challenge with <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Am Rev Respir Dis.</source> (<year>1973</year>) <volume>107</volume>:<fpage>359</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="pmid">4632222</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/arrd.1973.107.3.359</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middlebrook</surname><given-names>G</given-names></name><name name-style="western"><surname>Dubos</surname><given-names>RJ</given-names></name></person-group>. <article-title>Specific serum agglutination of erythrocytes sensitized with extracts of <italic toggle="yes">Tubercle Bacilli</italic></article-title>. <source>J Exp Med.</source> (<year>1948</year>) <volume>88</volume>:<fpage>521</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1084/jem.88.5.521</pub-id><pub-id pub-id-type="pmid">18892427</pub-id><pub-id pub-id-type="pmcid">PMC2135841</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagercrantz</surname><given-names>R</given-names></name><name name-style="western"><surname>Peterson</surname><given-names>JC</given-names></name><name name-style="western"><surname>Lind</surname><given-names>J</given-names></name></person-group>. <article-title>Further studies of tuberculin hemagglutination in tuberculous infection, benign and virulent</article-title>. <source>Acta Paediatr.</source> (<year>1953</year>) <volume>42</volume>:<fpage>113</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1111/j.1651-2227.1953.tb05573.x</pub-id><pub-id pub-id-type="pmid">13050390</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diena</surname><given-names>BB</given-names></name></person-group>. <article-title>Serology in tuberculosis and the bentonite flocculation test</article-title>. <source>Can Med Assoc J.</source> (<year>1968</year>) <volume>99</volume>:<fpage>763</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="pmid">5700847</pub-id><pub-id pub-id-type="pmcid">PMC1945337</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chatterjee</surname><given-names>D</given-names></name><name name-style="western"><surname>Khoo</surname><given-names>KH</given-names></name></person-group>. <article-title><italic toggle="yes">Mycobacterial lipoarabinomannan</italic>: an extraordinary lipoheteroglycan with profound physiological effects</article-title>. <source>Glycobiology.</source> (<year>1998</year>) <volume>8</volume>:<fpage>113</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1093/glycob/8.2.113</pub-id><pub-id pub-id-type="pmid">9451020</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geijtenbeek</surname><given-names>TBH</given-names></name><name name-style="western"><surname>Van Vliet</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Koppel</surname><given-names>EA</given-names></name><name name-style="western"><surname>Sanchez-Hernandez</surname><given-names>M</given-names></name><name name-style="western"><surname>Vandenbroucke-Grauls</surname><given-names>CMJE</given-names></name><name name-style="western"><surname>Appelmelk</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Mycobacteria target DC-SIGN to suppress dendritic cell function</article-title>. <source>J Exp Med.</source> (<year>2003</year>) <volume>197</volume>:<fpage>7</fpage>&#8211;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20021229</pub-id><pub-id pub-id-type="pmid">12515809</pub-id><pub-id pub-id-type="pmcid">PMC2193797</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamasur</surname><given-names>B</given-names></name><name name-style="western"><surname>Haile</surname><given-names>M</given-names></name><name name-style="western"><surname>Pawlowski</surname><given-names>A</given-names></name><name name-style="western"><surname>Schroder</surname><given-names>U</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name><name name-style="western"><surname>Hatch</surname><given-names>G</given-names></name><etal/></person-group>. <article-title><italic toggle="yes">Mycobacterium tuberculosis</italic> arabinomannan-protein conjugates protect against tuberculosis</article-title>. <source>Vaccine.</source> (<year>2003</year>) <volume>21</volume>:<fpage>4081</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(03)00274-3</pub-id><pub-id pub-id-type="pmid">12922145</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prados-Rosales</surname><given-names>R</given-names></name><name name-style="western"><surname>Carreno</surname><given-names>L</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>T</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>C</given-names></name><name name-style="western"><surname>Weinrick</surname><given-names>B</given-names></name><name name-style="western"><surname>Malek</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Enhanced control of <italic toggle="yes">Mycobacterium tuberculosis</italic> extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine</article-title>. <source>PLoS Pathog.</source> (<year>2017</year>) <volume>13</volume>:<fpage>e1006250</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1006250</pub-id><pub-id pub-id-type="pmid">28278283</pub-id><pub-id pub-id-type="pmcid">PMC5360349</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buddle</surname><given-names>BM</given-names></name><name name-style="western"><surname>Keen</surname><given-names>D</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>A</given-names></name><name name-style="western"><surname>Jowett</surname><given-names>G</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>AR</given-names></name><name name-style="western"><surname>Heslop</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protection of cattle from bovine tuberculosis by vaccination with BCG by the respiratory or subcutaneous route, but not by vaccination with killed Mycobacterium vaccae</article-title>. <source>Res Vet Sci.</source> (<year>1995</year>) <volume>59</volume>:<fpage>10</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/0034-5288(95)90023-3</pub-id><pub-id pub-id-type="pmid">8525078</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nonnecke</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Waters</surname><given-names>WR</given-names></name><name name-style="western"><surname>Foote</surname><given-names>MR</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>MV</given-names></name><name name-style="western"><surname>Miller</surname><given-names>BL</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>TE</given-names></name><etal/></person-group>. <article-title>Development of an adult-like cell-mediated immune response in calves after early vaccination with <italic toggle="yes">Mycobacterium bovis</italic> bacillus Calmette-Gu&#233;rin</article-title>. <source>J Dairy Sci.</source> (<year>2005</year>) <volume>88</volume>:<fpage>195</fpage>&#8211;<lpage>210</lpage>. <pub-id pub-id-type="doi">10.3168/jds.S0022-0302(05)72678-3</pub-id><pub-id pub-id-type="pmid">15591383</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niewiesk</surname><given-names>S</given-names></name></person-group>. <article-title>Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies</article-title>. <source>Front Immunol.</source> (<year>2014</year>) <volume>5</volume>:<fpage>446</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2014.00446</pub-id><pub-id pub-id-type="pmid">25278941</pub-id><pub-id pub-id-type="pmcid">PMC4165321</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Endsley</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Roth</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ridpath</surname><given-names>J</given-names></name><name name-style="western"><surname>Neill</surname><given-names>J</given-names></name></person-group><article-title>Maternal antibody blocks humoral but not T cell responses to BVDV</article-title>. <source>Biologicals.</source> (<year>2003</year>) <volume>31</volume>:<fpage>123</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/S1045-1056(03)00027-7</pub-id><pub-id pub-id-type="pmid">12770543</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glezen</surname><given-names>WP</given-names></name></person-group>. <article-title>Effect of maternal antibodies on the infant immune response</article-title>. <source>Vaccine.</source> (<year>2003</year>) <volume>21</volume>:<fpage>3389</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(03)00339-6</pub-id><pub-id pub-id-type="pmid">12850346</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>McMurray</surname><given-names>DN</given-names></name></person-group><article-title>Guinea pig model of tuberculosis</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Bloom</surname><given-names>BR</given-names></name></person-group> editor. <source>Tuberculosis: Pathogenesis, Protection and Control</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Society for Microbiology</publisher-name> (<year>1994</year>). p. <fpage>135</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1128/9781555818357.ch9</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name><name name-style="western"><surname>Watari</surname><given-names>E</given-names></name><name name-style="western"><surname>Matsunaga</surname><given-names>I</given-names></name><name name-style="western"><surname>Hiromatsu</surname><given-names>K</given-names></name><name name-style="western"><surname>Dascher</surname><given-names>CC</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>BCG vaccine elicits both T-cell mediated and humoral immune responses directed against mycobacterial lipid components</article-title>. <source>Vaccine</source>. (<year>2006</year>) <volume>24</volume>:<fpage>5700</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.04.049</pub-id><pub-id pub-id-type="pmid">16725232</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sable</surname><given-names>SB</given-names></name><name name-style="western"><surname>Cheruvu</surname><given-names>M</given-names></name><name name-style="western"><surname>Nandakumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name><name name-style="western"><surname>Bandyopadhyay</surname><given-names>K</given-names></name><name name-style="western"><surname>Kellar</surname><given-names>KL</given-names></name><etal/></person-group>. <article-title>Cellular immune responses to nine <italic toggle="yes">Mycobacterium tuberculosis</italic> vaccine candidates following intranasal vaccination</article-title>. <source>PLoS One.</source> (<year>2011</year>) <volume>6</volume>:<fpage>e22718</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0022718</pub-id><pub-id pub-id-type="pmid">21799939</pub-id><pub-id pub-id-type="pmcid">PMC3143185</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nandakumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kannanganat</surname><given-names>S</given-names></name><name name-style="western"><surname>Dobos</surname><given-names>KM</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>M</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>JS</given-names></name><name name-style="western"><surname>Fang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>O-mannosylation of the <italic toggle="yes">Mycobacterium tuberculosis</italic> adhesin Apa is crucial for T cell antigenicity during infection but is expendable for protection</article-title>. <source>PLoS Pathog.</source> (<year>2013</year>) <volume>9</volume>:<fpage>e1003705</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1003705</pub-id><pub-id pub-id-type="pmid">24130497</pub-id><pub-id pub-id-type="pmcid">PMC3795050</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garapin</surname><given-names>A</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L</given-names></name><name name-style="western"><surname>Pescher</surname><given-names>P</given-names></name><name name-style="western"><surname>Lagranderie</surname><given-names>M</given-names></name><name name-style="western"><surname>Marchal</surname><given-names>G</given-names></name></person-group>. <article-title>Mixed immune response induced in rodents by two naked DNA genes coding for mycobacterial glycosylated proteins</article-title>. <source>Vaccine</source>. (<year>2001</year>) <volume>19</volume>:<fpage>2830</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(01)00012-3</pub-id><pub-id pub-id-type="pmid">11282194</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name><name name-style="western"><surname>Amara</surname><given-names>RR</given-names></name><name name-style="western"><surname>Challu</surname><given-names>VK</given-names></name><name name-style="western"><surname>Chadda</surname><given-names>VK</given-names></name><name name-style="western"><surname>Satchidanandam</surname><given-names>V</given-names></name></person-group>. <article-title>The Apa protein of <italic toggle="yes">Mycobacterium tuberculosis</italic> stimulates gamma interferon-secreting CD4<sup>+</sup> and CD8<sup>+</sup> T cells from purified protein derivative-positive individuals and affords protection in a guinea pig model</article-title>. <source>Infect Immun.</source> (<year>2003</year>) <volume>71</volume>:<fpage>1929</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.71.4.1929-1937.2003</pub-id><pub-id pub-id-type="pmid">12654810</pub-id><pub-id pub-id-type="pmcid">PMC152084</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nandakumar</surname><given-names>S</given-names></name><name name-style="western"><surname>Kannanganat</surname><given-names>S</given-names></name><name name-style="western"><surname>Dobos</surname><given-names>KM</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>M</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>JS</given-names></name><name name-style="western"><surname>Amara</surname><given-names>RR</given-names></name><etal/></person-group>. <article-title>Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Sci Rep.</source> (<year>2016</year>) <volume>6</volume>:<fpage>25837</fpage>. <pub-id pub-id-type="doi">10.1038/srep25837</pub-id><pub-id pub-id-type="pmid">27173443</pub-id><pub-id pub-id-type="pmcid">PMC4865829</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Flynn</surname><given-names>JL</given-names></name><name name-style="western"><surname>Gideon</surname><given-names>HP</given-names></name><name name-style="western"><surname>Mattila</surname><given-names>JT</given-names></name><name name-style="western"><surname>Lin</surname><given-names>PL</given-names></name></person-group>. <article-title>Immunology studies in non-human primate models of tuberculosis</article-title>. <source>Immunol Rev.</source> (<year>2015</year>) <volume>264</volume>:<fpage>60</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12258</pub-id><pub-id pub-id-type="pmid">25703552</pub-id><pub-id pub-id-type="pmcid">PMC4339213</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharpe</surname><given-names>SA</given-names></name><name name-style="western"><surname>McShane</surname><given-names>H</given-names></name><name name-style="western"><surname>Dennis</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Basaraba</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Gleeson</surname><given-names>F</given-names></name><name name-style="western"><surname>Hall</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Establishment of an aerosol challenge model of tuberculosis in rhesus macaques and an evaluation of endpoints for vaccine testing</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2010</year>) <volume>17</volume>:<fpage>1170</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00079-10</pub-id><pub-id pub-id-type="pmid">20534795</pub-id><pub-id pub-id-type="pmcid">PMC2916246</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed <italic toggle="yes">Mycobacterium leprae</italic> vaccine for prevention of leprosy and tuberculosis in Malawi.</collab></person-group><article-title>Karonga Prevention Trial Group</article-title>. <source>Lancet.</source> (<year>1996</year>) <volume>348</volume>:<fpage>17</fpage>&#8211;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(96)02166-6</pub-id><pub-id pub-id-type="pmid">8691924</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>LC</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>SS</given-names></name><name name-style="western"><surname>Genser</surname><given-names>B</given-names></name><name name-style="western"><surname>Ichihara</surname><given-names>MY</given-names></name><name name-style="western"><surname>de Brito</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial</article-title>. <source>Lancet.</source> (<year>2005</year>) <volume>366</volume>:<fpage>1290</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(05)67145-0</pub-id><pub-id pub-id-type="pmid">16214599</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Leung</surname><given-names>CC</given-names></name><name name-style="western"><surname>Tam</surname><given-names>CM</given-names></name><name name-style="western"><surname>Chan</surname><given-names>SL</given-names></name><name name-style="western"><surname>Chan-Yeung</surname><given-names>M</given-names></name><name name-style="western"><surname>Chan</surname><given-names>CK</given-names></name><name name-style="western"><surname>Chang</surname><given-names>KC</given-names></name></person-group>. <article-title>Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong</article-title>. <source>Int J Tuberc Lung Dis.</source> (<year>2001</year>) <volume>5</volume>:<fpage>717</fpage>&#8211;<lpage>23</lpage>. Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ingentaconnect.com/content/iuatld/ijtld">https://www.ingentaconnect.com/content/iuatld/ijtld</ext-link><pub-id pub-id-type="pmid">11495262</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nemes</surname><given-names>E</given-names></name><name name-style="western"><surname>Geldenhuys</surname><given-names>H</given-names></name><name name-style="western"><surname>Rozot</surname><given-names>V</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>KT</given-names></name><name name-style="western"><surname>Ratangee</surname><given-names>F</given-names></name><name name-style="western"><surname>Bilek</surname><given-names>N</given-names></name><etal/></person-group><article-title>Prevention of <italic toggle="yes">M. tuberculosis</italic> Infection with H4:IC31 Vaccine or BCG Revaccination</article-title>. <source>N Engl J Med.</source> (<year>2018</year>) <volume>379</volume>:<fpage>138</fpage>&#8211;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa1714021</pub-id><pub-id pub-id-type="pmid">29996082</pub-id><pub-id pub-id-type="pmcid">PMC5937161</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mangtani</surname><given-names>P</given-names></name><name name-style="western"><surname>Abubakar</surname><given-names>I</given-names></name><name name-style="western"><surname>Ariti</surname><given-names>C</given-names></name><name name-style="western"><surname>Beynon</surname><given-names>R</given-names></name><name name-style="western"><surname>Pimpin</surname><given-names>L</given-names></name><name name-style="western"><surname>Fine</surname><given-names>PE</given-names></name><etal/></person-group>. <article-title>Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials</article-title>. <source>Clin Infect Dis.</source> (<year>2014</year>) <volume>58</volume>:<fpage>470</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit790</pub-id><pub-id pub-id-type="pmid">24336911</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kashyap</surname><given-names>RS</given-names></name><name name-style="western"><surname>Husain</surname><given-names>AA</given-names></name><name name-style="western"><surname>Morey</surname><given-names>SH</given-names></name><name name-style="western"><surname>Panchbhai</surname><given-names>MS</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>PS</given-names></name><name name-style="western"><surname>Purohit</surname><given-names>HJ</given-names></name><etal/></person-group>. <article-title>Assessment of immune response to repeat stimulation with BCG vaccine using <italic toggle="yes">in vitro</italic> PBMC model</article-title>. <source>J Immune Based Ther Vaccines.</source> (<year>2010</year>) <volume>8</volume>:<fpage>3</fpage>. <pub-id pub-id-type="doi">10.1186/1476-8518-8-3</pub-id><pub-id pub-id-type="pmid">20509931</pub-id><pub-id pub-id-type="pmcid">PMC2890520</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>P</given-names></name><name name-style="western"><surname>Doherty</surname><given-names>TM</given-names></name></person-group>. <article-title>The success and failure of BCG - implications for a novel tuberculosis vaccine</article-title>. <source>Nat Rev Microbiol.</source> (<year>2005</year>) <volume>3</volume>:<fpage>656</fpage>&#8211;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro1211</pub-id><pub-id pub-id-type="pmid">16012514</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Monteiro-Maia</surname><given-names>R</given-names></name><name name-style="western"><surname>de Pinho</surname><given-names>RT</given-names></name></person-group>. <article-title>Oral bacillus Calmette-Gu&#233;rin vaccine against tuberculosis: why not?</article-title><source>Mem&#243;rias do Instituto Oswaldo Cruz.</source> (<year>2014</year>) <volume>109</volume>:<fpage>838</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1590/0074-0276140091</pub-id><pub-id pub-id-type="pmid">25317714</pub-id><pub-id pub-id-type="pmcid">PMC4238780</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gheorghiu</surname><given-names>M</given-names></name></person-group>. <article-title>BCG-induced mucosal immune responses</article-title>. <source>Int J Immunopharmacol.</source> (<year>1994</year>) <volume>16</volume>:<fpage>435</fpage>&#8211;<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/0192-0561(94)90033-7</pub-id><pub-id pub-id-type="pmid">7927990</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoft</surname><given-names>DF</given-names></name><name name-style="western"><surname>Brown</surname><given-names>RM</given-names></name><name name-style="western"><surname>Belshe</surname><given-names>RB</given-names></name></person-group>. <article-title>Mucosal bacille calmette-Guerin vaccination of humans inhibits delayed-type hypersensitivity to purified protein derivative but induces mycobacteria-specific interferon-gamma responses</article-title>. <source>Clin Infect Dis</source>. (<year>2000</year>) <volume>30</volume> (<issue>Suppl. 3</issue>):<fpage>S217</fpage>&#8211;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1086/313864</pub-id><pub-id pub-id-type="pmid">10875787</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>LG</given-names></name></person-group>. <article-title>Rabies virus vaccines</article-title>. <source>Dev Biol Standard.</source> (<year>1995</year>) <volume>84</volume>:<fpage>49</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="pmid">7796967</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beltran-Beck</surname><given-names>B</given-names></name><name name-style="western"><surname>de la Fuente</surname><given-names>J</given-names></name><name name-style="western"><surname>Garrido</surname><given-names>JM</given-names></name><name name-style="western"><surname>Aranaz</surname><given-names>A</given-names></name><name name-style="western"><surname>Sevilla</surname><given-names>I</given-names></name><name name-style="western"><surname>Villar</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Oral vaccination with heat inactivated <italic toggle="yes">Mycobacterium bovis</italic> activates the complement system to protect against tuberculosis</article-title>. <source>PLoS ONE.</source> (<year>2014</year>) <volume>9</volume>:<fpage>e98048</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0098048</pub-id><pub-id pub-id-type="pmid">24842853</pub-id><pub-id pub-id-type="pmcid">PMC4026474</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manjaly Thomas</surname><given-names>ZR</given-names></name><name name-style="western"><surname>McShane</surname><given-names>H</given-names></name></person-group>. <article-title>Aerosol immunisation for TB: matching route of vaccination to route of infection</article-title>. <source>Trans R Soc Trop Med Hyg.</source> (<year>2015</year>) <volume>109</volume>:<fpage>175</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1093/trstmh/tru206</pub-id><pub-id pub-id-type="pmid">25636950</pub-id><pub-id pub-id-type="pmcid">PMC4321022</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Falero-Diaz</surname><given-names>G</given-names></name><name name-style="western"><surname>Challacombe</surname><given-names>S</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>D</given-names></name><name name-style="western"><surname>Douce</surname><given-names>G</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A</given-names></name><name name-style="western"><surname>Ivanyi</surname><given-names>J</given-names></name></person-group>. <article-title>Intranasal vaccination of mice against infection with <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Vaccine.</source> (<year>2000</year>) <volume>18</volume>:<fpage>3223</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(00)00134-1</pub-id><pub-id pub-id-type="pmid">10869767</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lyadova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Vordermeier</surname><given-names>HM</given-names></name><name name-style="western"><surname>Eruslanov</surname><given-names>EB</given-names></name><name name-style="western"><surname>Khaidukov</surname><given-names>SV</given-names></name><name name-style="western"><surname>Apt</surname><given-names>AS</given-names></name><name name-style="western"><surname>Hewinson</surname><given-names>RG</given-names></name></person-group>. <article-title>Intranasal BCG vaccination protects BALB/c mice against virulent <italic toggle="yes">Mycobacterium bovis</italic> and accelerates production of IFN-gamma in their lungs</article-title>. <source>Clin Exp Immunol.</source> (<year>2001</year>) <volume>126</volume>:<fpage>274</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2249.2001.01667.x</pub-id><pub-id pub-id-type="pmid">11703371</pub-id><pub-id pub-id-type="pmcid">PMC1906185</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tree</surname><given-names>JA</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name><name name-style="western"><surname>Clark</surname><given-names>S</given-names></name><name name-style="western"><surname>Hall</surname><given-names>G</given-names></name><name name-style="western"><surname>Marsh</surname><given-names>PD</given-names></name><name name-style="western"><surname>Ivanyi</surname><given-names>J</given-names></name></person-group>. <article-title>Intranasal bacille Calmette&#8211;Gu&#233;rin (BCG) vaccine dosage needs balancing between protection and lung pathology</article-title>. <source>Clin Exp Immunol.</source> (<year>2004</year>) <volume>138</volume>:<fpage>405</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.2004.02648.x</pub-id><pub-id pub-id-type="pmid">15544615</pub-id><pub-id pub-id-type="pmcid">PMC1809232</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mutsch</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Rhodes</surname><given-names>P</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>RT</given-names></name><name name-style="western"><surname>Linder</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland</article-title>. <source>N Engl J Med.</source> (<year>2004</year>) <volume>350</volume>:<fpage>896</fpage>&#8211;<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa030595</pub-id><pub-id pub-id-type="pmid">14985487</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lewis</surname><given-names>DJM</given-names></name><name name-style="western"><surname>Huo</surname><given-names>Z</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>S</given-names></name><name name-style="western"><surname>Kromann</surname><given-names>I</given-names></name><name name-style="western"><surname>Giemza</surname><given-names>R</given-names></name><name name-style="western"><surname>Galiza</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of <italic toggle="yes">Escherichia coli</italic> heat labile toxin</article-title>. <source>PLoS ONE.</source> (<year>2009</year>) <volume>4</volume>:<fpage>e6999</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0006999</pub-id><pub-id pub-id-type="pmid">19756141</pub-id><pub-id pub-id-type="pmcid">PMC2737308</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dilraj</surname><given-names>A</given-names></name><name name-style="western"><surname>Sukhoo</surname><given-names>R</given-names></name><name name-style="western"><surname>Cutts</surname><given-names>FT</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>JV</given-names></name></person-group>. <article-title>Aerosol and subcutaneous measles vaccine: measles antibody responses 6 years after re-vaccination</article-title>. <source>Vaccine.</source> (<year>2007</year>) <volume>25</volume>:<fpage>4170</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.03.003</pub-id><pub-id pub-id-type="pmid">17408818</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Markowitz</surname><given-names>LE</given-names></name><name name-style="western"><surname>Albrecht</surname><given-names>P</given-names></name><name name-style="western"><surname>Orenstein</surname><given-names>WA</given-names></name><name name-style="western"><surname>Lett</surname><given-names>SM</given-names></name><name name-style="western"><surname>Pugliese</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Farrell</surname><given-names>D</given-names></name></person-group>. <article-title>Persistence of measles antibody after revaccination</article-title>. <source>J Infect Dis.</source> (<year>1992</year>) <volume>166</volume>:<fpage>205</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/166.1.205</pub-id><pub-id pub-id-type="pmid">1607699</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barclay</surname><given-names>WR</given-names></name><name name-style="western"><surname>Busey</surname><given-names>WM</given-names></name><name name-style="western"><surname>Dalgard</surname><given-names>DW</given-names></name><name name-style="western"><surname>Good</surname><given-names>RC</given-names></name><name name-style="western"><surname>Janicki</surname><given-names>BW</given-names></name><name name-style="western"><surname>Kasik</surname><given-names>JE</given-names></name><etal/></person-group>. <article-title>Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin</article-title>. <source>Am Rev Respir Dis.</source> (<year>1973</year>) <volume>107</volume>:<fpage>351</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="pmid">4632221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/arrd.1973.107.3.351</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Contreras</surname><given-names>L</given-names></name><name name-style="western"><surname>Wong</surname><given-names>YL</given-names></name><name name-style="western"><surname>Muttil</surname><given-names>P</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>D</given-names></name><name name-style="western"><surname>Sadoff</surname><given-names>J</given-names></name><name name-style="western"><surname>Derousse</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Immunization by a bacterial aerosol</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2008</year>) <volume>105</volume>:<fpage>4656</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0800043105</pub-id><pub-id pub-id-type="pmid">18344320</pub-id><pub-id pub-id-type="pmcid">PMC2290758</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenthal</surname><given-names>SR</given-names></name><name name-style="western"><surname>McEnery</surname><given-names>JT</given-names></name><name name-style="western"><surname>Raisys</surname><given-names>N</given-names></name></person-group>. <article-title>Aerogenic BCG vaccination against tuberculosis in animal and human subjects</article-title>. <source>J Asthma Res.</source> (<year>1968</year>) <volume>5</volume>:<fpage>309</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.3109/02770906809100348</pub-id><pub-id pub-id-type="pmid">5666107</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Satti</surname><given-names>I</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>J</given-names></name><name name-style="western"><surname>Harris</surname><given-names>SA</given-names></name><name name-style="western"><surname>Manjaly Thomas</surname><given-names>ZR</given-names></name><name name-style="western"><surname>Griffiths</surname><given-names>K</given-names></name><name name-style="western"><surname>Antrobus</surname><given-names>RD</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial</article-title>. <source>Lancet Infect Dis.</source> (<year>2014</year>) <volume>14</volume>:<fpage>939</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(14)70845-X</pub-id><pub-id pub-id-type="pmid">25151225</pub-id><pub-id pub-id-type="pmcid">PMC4178237</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aguilo</surname><given-names>N</given-names></name><name name-style="western"><surname>Toledo</surname><given-names>AM</given-names></name><name name-style="western"><surname>Lopez-Roman</surname><given-names>EM</given-names></name><name name-style="western"><surname>Perez-Herran</surname><given-names>E</given-names></name><name name-style="western"><surname>Gormley</surname><given-names>E</given-names></name><name name-style="western"><surname>Rullas-Trincado</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Pulmonary <italic toggle="yes">Mycobacterium bovis</italic> BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination</article-title>. <source>Clin Vaccine Immunol.</source> (<year>2014</year>) <volume>21</volume>:<fpage>594</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00700-13</pub-id><pub-id pub-id-type="pmid">24501340</pub-id><pub-id pub-id-type="pmcid">PMC3993116</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Deng</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name></person-group>. <article-title>Roles of Mucosal Immunity against <italic toggle="yes">Mycobacterium tuberculosis</italic> infection</article-title>. <source>Tuberculosis Res Treat.</source> (<year>2012</year>) <volume>2012</volume>:<fpage>791728</fpage>. <pub-id pub-id-type="doi">10.1155/2012/791728</pub-id><pub-id pub-id-type="pmid">23213508</pub-id><pub-id pub-id-type="pmcid">PMC3504404</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mazanec</surname><given-names>MB</given-names></name><name name-style="western"><surname>Nedrud</surname><given-names>JG</given-names></name><name name-style="western"><surname>Kaetzel</surname><given-names>CS</given-names></name><name name-style="western"><surname>Lamm</surname><given-names>ME</given-names></name></person-group>. <article-title>A three-tiered view of the role of IgA in mucosal defense</article-title>. <source>Immunol Today.</source> (<year>1993</year>) <volume>14</volume>:<fpage>430</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/0167-5699(93)90245-G</pub-id><pub-id pub-id-type="pmid">8216720</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>RC</given-names></name><name name-style="western"><surname>Gibbons</surname><given-names>RJ</given-names></name></person-group>. <article-title>Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal</article-title>. <source>Science.</source> (<year>1972</year>) <volume>177</volume>:<fpage>697</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.177.4050.697</pub-id><pub-id pub-id-type="pmid">5054144</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurono</surname><given-names>Y</given-names></name><name name-style="western"><surname>Shigemi</surname><given-names>H</given-names></name><name name-style="western"><surname>Shimamura</surname><given-names>K</given-names></name><name name-style="western"><surname>Mogi</surname><given-names>G</given-names></name></person-group>. <article-title>Inhibition of bacterial adherence by nasopharyngeal secretions</article-title>. <source>Ann Otol Rhinol Laryngol.</source> (<year>1991</year>) <volume>100</volume>:<fpage>455</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1177/000348949110000605</pub-id><pub-id pub-id-type="pmid">2058985</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tjarnlund</surname><given-names>A</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>A</given-names></name><name name-style="western"><surname>Cardona</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Guirado</surname><given-names>E</given-names></name><name name-style="western"><surname>Ivanyi</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice</article-title>. <source>Int Immunol.</source> (<year>2006</year>) <volume>18</volume>:<fpage>807</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1093/intimm/dxl017</pub-id><pub-id pub-id-type="pmid">16569672</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharpe</surname><given-names>S</given-names></name><name name-style="western"><surname>White</surname><given-names>A</given-names></name><name name-style="western"><surname>Sarfas</surname><given-names>C</given-names></name><name name-style="western"><surname>Sibley</surname><given-names>L</given-names></name><name name-style="western"><surname>Gleeson</surname><given-names>F</given-names></name><name name-style="western"><surname>McIntyre</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Alternative BCG delivery strategies improve protection against <italic toggle="yes">Mycobacterium tuberculosis</italic> in non-human primates: protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations</article-title>. <source>Tuberculosis.</source> (<year>2016</year>) <volume>101</volume>:<fpage>174</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2016.09.004</pub-id><pub-id pub-id-type="pmid">27865390</pub-id><pub-id pub-id-type="pmcid">PMC5120991</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anacker</surname><given-names>RL</given-names></name><name name-style="western"><surname>Brehmer</surname><given-names>W</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>WR</given-names></name><name name-style="western"><surname>Leif</surname><given-names>WR</given-names></name><name name-style="western"><surname>Ribi</surname><given-names>E</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Superiority of intravenously administered BCG and BCG cell walls in protecting rhesus monkeys (Macaca mulatta) against airborne tuberculosis</article-title>. <source>Z Immunitatsforsch Exp Klin Immunol.</source> (<year>1972</year>) <volume>143</volume>:<fpage>363</fpage>&#8211;<lpage>76</lpage>. <pub-id pub-id-type="pmid">4282920</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barclay</surname><given-names>WR</given-names></name><name name-style="western"><surname>Anacker</surname><given-names>RL</given-names></name><name name-style="western"><surname>Brehmer</surname><given-names>W</given-names></name><name name-style="western"><surname>Leif</surname><given-names>W</given-names></name><name name-style="western"><surname>Ribi</surname><given-names>E</given-names></name></person-group>. <article-title>Aerosol-induced tuberculosis in subhuman primates and the course of the disease after intravenous BCG vaccination</article-title>. <source>Infect Immun.</source> (<year>1970</year>) <volume>2</volume>:<fpage>574</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="pmid">16557880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.2.5.574-582.1970</pub-id><pub-id pub-id-type="pmcid">PMC416053</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribi</surname><given-names>E</given-names></name><name name-style="western"><surname>Anacker</surname><given-names>RL</given-names></name><name name-style="western"><surname>Barclay</surname><given-names>WR</given-names></name><name name-style="western"><surname>Brehmer</surname><given-names>W</given-names></name><name name-style="western"><surname>Harris</surname><given-names>SC</given-names></name><name name-style="western"><surname>Leif</surname><given-names>WR</given-names></name><etal/></person-group>. <article-title>Efficacy of mycobacterial cell walls as a vaccine against airborne tuberculosis in the Rheusus monkey</article-title>. <source>J Infect Dis.</source> (<year>1971</year>) <volume>123</volume>:<fpage>527</fpage>&#8211;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/123.5.527</pub-id><pub-id pub-id-type="pmid">5000470</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Muller</surname><given-names>J</given-names></name><name name-style="western"><surname>Matsumiya</surname><given-names>M</given-names></name><name name-style="western"><surname>Snowden</surname><given-names>M</given-names></name><name name-style="western"><surname>Landry</surname><given-names>B</given-names></name><name name-style="western"><surname>Satti</surname><given-names>I</given-names></name><name name-style="western"><surname>Harris</surname><given-names>S</given-names></name><etal/></person-group><source>Cytomegalovirus infection is a risk factor for TB disease in infants</source>. <publisher-name>BioRxiv</publisher-name> (<year>2017</year>). <pub-id pub-id-type="doi">10.1101/222646</pub-id><pub-id pub-id-type="pmcid">PMC6962026</pub-id><pub-id pub-id-type="pmid">31697647</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elias</surname><given-names>D</given-names></name><name name-style="western"><surname>Britton</surname><given-names>S</given-names></name><name name-style="western"><surname>Aseffa</surname><given-names>A</given-names></name><name name-style="western"><surname>Engers</surname><given-names>H</given-names></name><name name-style="western"><surname>Akuffo</surname><given-names>H</given-names></name></person-group>. <article-title>Poor immunogenicity of BCG in helminth infected population is associated with increased <italic toggle="yes">in vitro</italic> TGF-beta production</article-title>. <source>Vaccine.</source> (<year>2008</year>) <volume>26</volume>:<fpage>3897</fpage>&#8211;<lpage>902</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.04.083</pub-id><pub-id pub-id-type="pmid">18554755</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kozak</surname><given-names>R</given-names></name><name name-style="western"><surname>Behr</surname><given-names>MA</given-names></name></person-group>. <article-title>Divergence of immunologic and protective responses of different BCG strains in a murine model</article-title>. <source>Vaccine.</source> (<year>2011</year>) <volume>29</volume>:<fpage>1519</fpage>&#8211;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.012</pub-id><pub-id pub-id-type="pmid">21184855</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritz</surname><given-names>N</given-names></name><name name-style="western"><surname>Hanekom</surname><given-names>WA</given-names></name><name name-style="western"><surname>Robins-Browne</surname><given-names>R</given-names></name><name name-style="western"><surname>Britton</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name></person-group>. <article-title>Influence of BCG vaccine strain on the immune response and protection against tuberculosis</article-title>. <source>FEMS Microbiol Rev.</source> (<year>2008</year>) <volume>32</volume>:<fpage>821</fpage>&#8211;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-6976.2008.00118.x</pub-id><pub-id pub-id-type="pmid">18616602</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>M</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wan</surname><given-names>K</given-names></name></person-group>. <article-title>Comparative analysis of human B cell epitopes based on BCG genomes</article-title>. <source>Biomed Res Int.</source> (<year>2016</year>) <volume>2016</volume>:<fpage>3620141</fpage>. <pub-id pub-id-type="doi">10.1155/2016/3620141</pub-id><pub-id pub-id-type="pmid">27382565</pub-id><pub-id pub-id-type="pmcid">PMC4921132</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petricevich</surname><given-names>VL</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>C</given-names></name><name name-style="western"><surname>Alves</surname><given-names>RCB</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>MA</given-names></name><name name-style="western"><surname>Moreno</surname><given-names>C</given-names></name><name name-style="western"><surname>Melo</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>A single strain of <italic toggle="yes">Mycobacterium bovis</italic> bacillus Calmette-Gu&#233;rin (BCG) grown in two different media evokes distinct humoral immune responses in mice</article-title>. <source>Brazil J Med Biol Res.</source> (<year>2001</year>) <volume>34</volume>:<fpage>81</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1590/S0100-879X2001000100010</pub-id><pub-id pub-id-type="pmid">11151032</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sani</surname><given-names>M</given-names></name><name name-style="western"><surname>Houben</surname><given-names>EN</given-names></name><name name-style="western"><surname>Geurtsen</surname><given-names>J</given-names></name><name name-style="western"><surname>Pierson</surname><given-names>J</given-names></name><name name-style="western"><surname>de Punder</surname><given-names>K</given-names></name><name name-style="western"><surname>van Zon</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Direct visualization by cryo-EM of the mycobacterial capsular layer: a labile structure containing ESX-1-secreted proteins</article-title>. <source>PLoS Pathog.</source> (<year>2010</year>) <volume>6</volume>:<fpage>e1000794</fpage>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1000794</pub-id><pub-id pub-id-type="pmid">20221442</pub-id><pub-id pub-id-type="pmcid">PMC2832766</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prados-Rosales</surname><given-names>R</given-names></name><name name-style="western"><surname>Carreno</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Weinrick</surname><given-names>B</given-names></name><name name-style="western"><surname>Batista-Gonzalez</surname><given-names>A</given-names></name><name name-style="western"><surname>Glatman-Freedman</surname><given-names>A</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>The type of growth medium affects the presence of a mycobacterial capsule and is associated with differences in protective efficacy of BCG vaccination against <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>J Infect Dis.</source> (<year>2016</year>) <volume>214</volume>:<fpage>426</fpage>&#8211;<lpage>37</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiw153</pub-id><pub-id pub-id-type="pmid">27234419</pub-id><pub-id pub-id-type="pmcid">PMC4936643</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biering-S&#248;rensen</surname><given-names>S</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Monterio</surname><given-names>I</given-names></name><name name-style="western"><surname>Ravn</surname><given-names>H</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P</given-names></name><name name-style="western"><surname>Benn</surname><given-names>CS</given-names></name></person-group>. <article-title>Rapid protective effects of early BCG on neonatal mortality among low birth weight boys: observations from randomized trials</article-title>. <source>J Infect Dis.</source> (<year>2018</year>) <volume>217</volume>:<fpage>759</fpage>&#8211;<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jix612</pub-id><pub-id pub-id-type="pmid">29216358</pub-id><pub-id pub-id-type="pmcid">PMC5853955</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Castro</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Pardo-Seco</surname><given-names>J</given-names></name><name name-style="western"><surname>Martinon-Torres</surname><given-names>F</given-names></name></person-group>. <article-title>Nonspecific (Heterologous) protection of neonatal BCG vaccination against hospitalization due to respiratory infection and sepsis</article-title>. <source>Clin Infect Dis.</source> (<year>2015</year>) <volume>60</volume>:<fpage>1611</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ144</pub-id><pub-id pub-id-type="pmid">25725054</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garly</surname><given-names>ML</given-names></name><name name-style="western"><surname>Martins</surname><given-names>CL</given-names></name><name name-style="western"><surname>Bale</surname><given-names>C</given-names></name><name name-style="western"><surname>Balde</surname><given-names>MA</given-names></name><name name-style="western"><surname>Hedegaard</surname><given-names>KL</given-names></name><name name-style="western"><surname>Gustafson</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa. A non-specific beneficial effect of BCG?</article-title><source>Vaccine</source>. (<year>2003</year>) <volume>21</volume>:<fpage>2782</fpage>&#8211;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(03)00181-6</pub-id><pub-id pub-id-type="pmid">12798618</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nankabirwa</surname><given-names>V</given-names></name><name name-style="western"><surname>Tumwine</surname><given-names>JK</given-names></name><name name-style="western"><surname>Mugaba</surname><given-names>PM</given-names></name><name name-style="western"><surname>Tyllesk&#228;r</surname><given-names>T</given-names></name><name name-style="western"><surname>Sommerfelt</surname><given-names>H</given-names></name></person-group>. <article-title>Child survival and BCG vaccination: a community based prospective cohort study in Uganda</article-title>. <source>BMC Public Health.</source> (<year>2015</year>) <volume>15</volume>:<fpage>175</fpage>. <pub-id pub-id-type="doi">10.1186/s12889-015-1497-8</pub-id><pub-id pub-id-type="pmid">25886062</pub-id><pub-id pub-id-type="pmcid">PMC4342809</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clark</surname><given-names>IA</given-names></name><name name-style="western"><surname>Allison</surname><given-names>AC</given-names></name><name name-style="western"><surname>Cox</surname><given-names>FE</given-names></name></person-group>. <article-title>Protection of mice against Babesia, and Plasmodium with BCG</article-title>. <source>Nature.</source> (<year>1976</year>) <volume>259</volume>:<fpage>309</fpage>. <pub-id pub-id-type="doi">10.1038/259309a0</pub-id><pub-id pub-id-type="pmid">765838</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senterfitt</surname><given-names>VC</given-names></name><name name-style="western"><surname>Shands</surname><given-names>JW</given-names></name></person-group>. <article-title>Salmonellosis in mice infected with <italic toggle="yes">Mycobacterium bovis</italic> BCG II. Resistance to infection</article-title>. <source>Infect Immunity.</source> (<year>1970</year>) <volume>1</volume>:<fpage>583</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="pmid">16557779</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.1.6.583-586.1970</pub-id><pub-id pub-id-type="pmcid">PMC415945</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goodridge</surname><given-names>HS</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>SS</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name><name name-style="western"><surname>Kollmann</surname><given-names>TR</given-names></name><name name-style="western"><surname>Levy</surname><given-names>O</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Harnessing the beneficial heterologous effects of vaccination</article-title>. <source>Nat Rev Immunol.</source> (<year>2016</year>) <volume>16</volume>:<fpage>392</fpage>&#8211;<lpage>400</lpage>. <pub-id pub-id-type="doi">10.1038/nri.2016.43</pub-id><pub-id pub-id-type="pmid">27157064</pub-id><pub-id pub-id-type="pmcid">PMC4931283</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stensballe</surname><given-names>LG</given-names></name><name name-style="western"><surname>Ravn</surname><given-names>H</given-names></name><name name-style="western"><surname>Benn</surname><given-names>CS</given-names></name><name name-style="western"><surname>Jeppesen</surname><given-names>DL</given-names></name><name name-style="western"><surname>Birk</surname><given-names>NM</given-names></name><name name-style="western"><surname>Pryds</surname><given-names>O</given-names></name><etal/></person-group><article-title>BCG vaccination at birth and rate of hospitalization for infection until 15 months of age in danish children: A Randomized Clinical Multicenter Trial</article-title>. <source>J Pediatric Infect Dis Soc.</source> (<year>2018</year>) <volume>102</volume>:<fpage>224</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1093/jpids/piy029</pub-id><pub-id pub-id-type="pmid">29635419</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berendsen</surname><given-names>ML</given-names></name><name name-style="western"><surname>Smits</surname><given-names>J</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>van der Ven</surname><given-names>A</given-names></name></person-group>. <article-title>Non-specific Effects of Vaccines and Stunting: timing may be essential</article-title>. <source>EBioMedicine.</source> (<year>2016</year>) <volume>8</volume>:<fpage>341</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2016.05.010</pub-id><pub-id pub-id-type="pmid">27428443</pub-id><pub-id pub-id-type="pmcid">PMC4919612</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>A</given-names></name><name name-style="western"><surname>Fisker</surname><given-names>AB</given-names></name><name name-style="western"><surname>Martins</surname><given-names>CL</given-names></name><name name-style="western"><surname>Garly</surname><given-names>M-L</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>A</given-names></name><name name-style="western"><surname>Benn</surname><given-names>CS</given-names></name><etal/></person-group>. <article-title>Measles vaccination in the presence or absence of maternal measles antibody: impact on child survival</article-title>. <source>Clin Infect Dis.</source> (<year>2014</year>) <volume>59</volume>:<fpage>484</fpage>&#8211;<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu354</pub-id><pub-id pub-id-type="pmid">24829213</pub-id><pub-id pub-id-type="pmcid">PMC4111916</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mawa</surname><given-names>PA</given-names></name><name name-style="western"><surname>Webb</surname><given-names>EL</given-names></name><name name-style="western"><surname>Filali-Mouhim</surname><given-names>A</given-names></name><name name-style="western"><surname>Nkurunungi</surname><given-names>G</given-names></name><name name-style="western"><surname>Sekaly</surname><given-names>R-P</given-names></name><name name-style="western"><surname>Lule</surname><given-names>SA</given-names></name><etal/></person-group>. <article-title>Maternal BCG scar is associated with increased infant proinflammatory immune responses</article-title>. <source>Vaccine.</source> (<year>2017</year>) <volume>35</volume>:<fpage>273</fpage>&#8211;<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2016.11.079</pub-id><pub-id pub-id-type="pmid">27914741</pub-id><pub-id pub-id-type="pmcid">PMC5357573</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Freyne</surname><given-names>B</given-names></name><name name-style="western"><surname>Donath</surname><given-names>S</given-names></name><name name-style="western"><surname>Germano</surname><given-names>S</given-names></name><name name-style="western"><surname>Gardiner</surname><given-names>K</given-names></name><name name-style="western"><surname>Casalaz</surname><given-names>D</given-names></name><name name-style="western"><surname>Robins-Browne</surname><given-names>RM</given-names></name><etal/></person-group>. <article-title>Neonatal BCG vaccination influences cytokine responses to toll-like receptor ligands and heterologous antigens</article-title>. <source>J Infect Dis.</source> (<year>2018</year>) <volume>217</volume>:<fpage>1798</fpage>&#8211;<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiy069</pub-id><pub-id pub-id-type="pmid">29415180</pub-id><pub-id pub-id-type="pmcid">PMC11491830</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bree</surname><given-names>Cd</given-names></name><name name-style="western"><surname>Crevel</surname><given-names>Rv</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name></person-group><article-title>H4: IC31 Vaccine or BCG revaccination for tuberculosis</article-title>. <source>N Engl J Med</source>. (<year>2018</year>) <volume>379</volume>:<fpage>1969</fpage><pub-id pub-id-type="doi">10.1056/NEJMc1811046</pub-id><pub-id pub-id-type="pmid">30428296</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>MO</given-names></name><name name-style="western"><surname>Vekemans</surname><given-names>J</given-names></name><name name-style="western"><surname>Schlegel-Haueter</surname><given-names>SE</given-names></name><name name-style="western"><surname>Fielding</surname><given-names>K</given-names></name><name name-style="western"><surname>Sanneh</surname><given-names>M</given-names></name><name name-style="western"><surname>Kidd</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Influence of <italic toggle="yes">Mycobacterium bovis</italic> bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination</article-title>. <source>J Immunol.</source> (<year>2002</year>) <volume>168</volume>:<fpage>919</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.168.2.919</pub-id><pub-id pub-id-type="pmid">11777990</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ritz</surname><given-names>N</given-names></name><name name-style="western"><surname>Mui</surname><given-names>M</given-names></name><name name-style="western"><surname>Balloch</surname><given-names>A</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name></person-group>. <article-title>Non-specific effect of Bacille Calmette-Gu&#233;rin vaccine on the immune response to routine immunisations</article-title>. <source>Vaccine.</source> (<year>2013</year>) <volume>31</volume>:<fpage>3098</fpage>&#8211;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2013.03.059</pub-id><pub-id pub-id-type="pmid">23583897</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nissen</surname><given-names>TN</given-names></name><name name-style="western"><surname>Birk</surname><given-names>NM</given-names></name><name name-style="western"><surname>Smits</surname><given-names>G</given-names></name><name name-style="western"><surname>Jeppesen</surname><given-names>DL</given-names></name><name name-style="western"><surname>Stensballe</surname><given-names>LG</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><etal/></person-group>. <article-title>Bacille Calmette-Gu&#233;rin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial</article-title>. <source>Vaccine.</source> (<year>2017</year>) <volume>35</volume>:<fpage>2084</fpage>&#8211;<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.02.048</pub-id><pub-id pub-id-type="pmid">28318766</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strachan</surname><given-names>DP</given-names></name></person-group>. <article-title>Family size, infection and atopy: the first decade of the &#8220;hygiene hypothesis&#8221;</article-title>. <source>Thorax</source>. (<year>2000</year>) <volume>55</volume>(<issue>Suppl. 1</issue>):<fpage>S2</fpage>&#8211;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1136/thorax.55.suppl_1.S2</pub-id><pub-id pub-id-type="pmid">10943631</pub-id><pub-id pub-id-type="pmcid">PMC1765943</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirakawa</surname><given-names>T</given-names></name><name name-style="western"><surname>Enomoto</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimazu</surname><given-names>S</given-names></name><name name-style="western"><surname>Hopkin</surname><given-names>JM</given-names></name></person-group>. <article-title>The inverse association between tuberculin responses and atopic disorder</article-title>. <source>Science.</source> (<year>1997</year>) <volume>275</volume>:<fpage>77</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.275.5296.77</pub-id><pub-id pub-id-type="pmid">8974396</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cavallo</surname><given-names>GP</given-names></name><name name-style="western"><surname>Elia</surname><given-names>M</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>D</given-names></name><name name-style="western"><surname>Baldi</surname><given-names>C</given-names></name><name name-style="western"><surname>Cammarota</surname><given-names>R</given-names></name></person-group>. <article-title>Decrease of specific and total IgE levels in allergic patients after BCG vaccination: preliminary report</article-title>. <source>Arch Otolaryngol Head Neck Surg.</source> (<year>2002</year>) <volume>128</volume>:<fpage>1058</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1001/archotol.128.9.1058</pub-id><pub-id pub-id-type="pmid">12220212</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barlan</surname><given-names>IB</given-names></name><name name-style="western"><surname>Tukenmez</surname><given-names>F</given-names></name><name name-style="western"><surname>Bahceciler</surname><given-names>NN</given-names></name><name name-style="western"><surname>Basaran</surname><given-names>MM</given-names></name></person-group>. <article-title>The impact of <italic toggle="yes">in vivo</italic> Calmette-Guerin Bacillus administration on <italic toggle="yes">in vitro</italic> IgE secretion in atopic children</article-title>. <source>J Asthma.</source> (<year>2002</year>) <volume>39</volume>:<fpage>239</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1081/JAS-120002473</pub-id><pub-id pub-id-type="pmid">12043855</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Aaby Shaheen Heyes Goudiaby Hall Shiell</collab><etal/></person-group><article-title>Early BCG vaccination and reduction in atopy in Guinea-Bissau</article-title>. <source>Clin Exp Allergy.</source> (<year>2000</year>) <volume>30</volume>:<fpage>644</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2222.2000.00803.x</pub-id><pub-id pub-id-type="pmid">10792355</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herz</surname><given-names>U</given-names></name><name name-style="western"><surname>Gerhold</surname><given-names>K</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>C</given-names></name><name name-style="western"><surname>Braun</surname><given-names>A</given-names></name><name name-style="western"><surname>Wahn</surname><given-names>U</given-names></name><name name-style="western"><surname>Renz</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>BCG infection suppresses allergic sensitization and development of increased airway reactivity in an animal model</article-title>. <source>J Allergy Clin Immunol.</source> (<year>1998</year>) <volume>102</volume>:<fpage>867</fpage>&#8211;<lpage>74</lpage>. <pub-id pub-id-type="doi">10.1016/S0091-6749(98)70030-2</pub-id><pub-id pub-id-type="pmid">9819307</pub-id></mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bakir</surname><given-names>M</given-names></name><name name-style="western"><surname>T&#252;kenmez</surname><given-names>F</given-names></name><name name-style="western"><surname>Bah&#231;eciler</surname><given-names>NN</given-names></name><name name-style="western"><surname>Barlan</surname><given-names>IB</given-names></name><name name-style="western"><surname>Ba&#351;aran</surname><given-names>MM</given-names></name></person-group>. <article-title>Heat-Killed <italic toggle="yes">Mycobacterium bovis</italic> -Bacillus calmette guerin-suppressed total serum IgE response in ovalbumin-sensitized newborn mice</article-title>. <source>J Asthma.</source> (<year>2000</year>) <volume>37</volume>:<fpage>329</fpage>&#8211;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.3109/02770900009055456</pub-id><pub-id pub-id-type="pmid">10883743</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nahori</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lagranderie</surname><given-names>M</given-names></name><name name-style="western"><surname>Lefort</surname><given-names>J</given-names></name><name name-style="western"><surname>Thouron</surname><given-names>F</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>D</given-names></name><name name-style="western"><surname>Winter</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Effects of <italic toggle="yes">Mycobacterium bovis</italic> BCG on the development of allergic inflammation and bronchial hyperresponsiveness in hyper-IgE BP2 mice vaccinated as newborns</article-title>. <source>Vaccine.</source> (<year>2001</year>) <volume>19</volume>:<fpage>1484</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1016/S0264-410X(00)00345-5</pub-id><pub-id pub-id-type="pmid">11163672</pub-id></mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YH</given-names></name><name name-style="western"><surname>Shen</surname><given-names>HD</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SH</given-names></name><name name-style="western"><surname>Han</surname><given-names>SH</given-names></name></person-group>. <article-title>Prevention of Der p2-induced allergic airway inflammation by <italic toggle="yes">Mycobacterium-bacillus</italic> Calmette Guerin</article-title>. <source>J Microbiol Immunol Infect.</source> (<year>2002</year>) <volume>35</volume>:<fpage>152</fpage>&#8211;<lpage>8</lpage>. Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.journals.elsevier.com/journal-of-microbiology-immunology-and-infection">https://www.journals.elsevier.com/journal-of-microbiology-immunology-and-infection</ext-link><pub-id pub-id-type="pmid">12380787</pub-id></mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gruber</surname><given-names>C</given-names></name><name name-style="western"><surname>Kulig</surname><given-names>M</given-names></name><name name-style="western"><surname>Bergmann</surname><given-names>R</given-names></name><name name-style="western"><surname>Guggenmoos-Holzmann</surname><given-names>I</given-names></name><name name-style="western"><surname>Wahn</surname><given-names>U</given-names></name></person-group>. <article-title>Delayed hypersensitivity to tuberculin, total immunoglobulin E, specific sensitization, and atopic manifestation in longitudinally followed early Bacille Calmette-Guerin-vaccinated and nonvaccinated children</article-title>. <source>Pediatrics.</source> (<year>2001</year>) <volume>107</volume>:<fpage>E36</fpage>. <pub-id pub-id-type="doi">10.1542/peds.107.3.e36</pub-id><pub-id pub-id-type="pmid">11230617</pub-id></mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas</surname><given-names>MH</given-names></name><name name-style="western"><surname>Bernal-Alcantara</surname><given-names>DA</given-names></name><name name-style="western"><surname>Vaca</surname><given-names>MA</given-names></name><name name-style="western"><surname>Franco-Marina</surname><given-names>F</given-names></name><name name-style="western"><surname>Lascurain</surname><given-names>R</given-names></name></person-group>. <article-title>Effect of BCG vaccination in asthmatic schoolchildren</article-title>. <source>Pediatr Allergy Immunol.</source> (<year>2004</year>) <volume>15</volume>:<fpage>415</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-3038.2004.00198.x</pub-id><pub-id pub-id-type="pmid">15482516</pub-id></mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alm</surname><given-names>JS</given-names></name><name name-style="western"><surname>Lilja</surname><given-names>G</given-names></name><name name-style="western"><surname>Pershagen</surname><given-names>G</given-names></name><name name-style="western"><surname>Scheynius</surname><given-names>A</given-names></name></person-group>. <article-title>Early BCG vaccination and development of atopy</article-title>. <source>Lancet.</source> (<year>1997</year>) <volume>350</volume>:<fpage>400</fpage>&#8211;<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(97)02207-1</pub-id><pub-id pub-id-type="pmid">9259654</pub-id></mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ota</surname><given-names>MO</given-names></name><name name-style="western"><surname>van der Sande</surname><given-names>MA</given-names></name><name name-style="western"><surname>Walraven</surname><given-names>GE</given-names></name><name name-style="western"><surname>Jeffries</surname><given-names>D</given-names></name><name name-style="western"><surname>Nyan</surname><given-names>OA</given-names></name><name name-style="western"><surname>Marchant</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Absence of association between delayed type hypersensitivity to tuberculin and atopy in children in The Gambia</article-title>. <source>Clin Exp Allergy.</source> (<year>2003</year>) <volume>33</volume>:<fpage>731</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2222.2003.01599.x</pub-id><pub-id pub-id-type="pmid">12801305</pub-id></mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Steenhuis</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Van Aalderen</surname><given-names>WMC</given-names></name><name name-style="western"><surname>Bloksma</surname><given-names>N</given-names></name><name name-style="western"><surname>Nijkamp</surname><given-names>FP</given-names></name><name name-style="western"><surname>Van Der Laag</surname><given-names>J</given-names></name><name name-style="western"><surname>Van Loveren</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Bacille&#8211;Calmette&#8211;Guerin vaccination and the development of allergic disease in children: a randomized, prospective, single-blind study</article-title>. <source>Clin Exp Allergy.</source> (<year>2008</year>) <volume>38</volume>:<fpage>79</fpage>&#8211;<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2222.2007.02859.x</pub-id><pub-id pub-id-type="pmid">17956585</pub-id></mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Th&#248;stesen</surname><given-names>LM</given-names></name><name name-style="western"><surname>Kj&#230;rgaard</surname><given-names>J</given-names></name><name name-style="western"><surname>Pihl</surname><given-names>GT</given-names></name><name name-style="western"><surname>Birk</surname><given-names>NM</given-names></name><name name-style="western"><surname>Nissen</surname><given-names>TN</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Neonatal BCG vaccination and atopic dermatitis before 13 months of age: a randomized clinical trial</article-title>. <source>Allergy.</source> (<year>2018</year>) <volume>73</volume>:<fpage>498</fpage>&#8211;<lpage>504</lpage>. <pub-id pub-id-type="doi">10.1111/all.13314</pub-id><pub-id pub-id-type="pmid">28929567</pub-id></mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yuxin</surname><given-names>W</given-names></name><name name-style="western"><surname>Yuzhi</surname><given-names>L</given-names></name><name name-style="western"><surname>Shuhui</surname><given-names>Z</given-names></name></person-group><article-title>Consecutive 5-year observation of predominant deactivated BCG in treatment of pediatric indolent bronchioasthma</article-title>. <source>Tian Jin Med.</source> (<year>1987</year>) <volume>3</volume>:<fpage>155</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhizhen</surname><given-names>H</given-names></name><name name-style="western"><surname>Zuoxiong</surname><given-names>L</given-names></name><name name-style="western"><surname>Youbin</surname><given-names>W</given-names></name><name name-style="western"><surname>Yanhong</surname><given-names>X</given-names></name></person-group><article-title>Inactivated BCG injection in the management of asthma (100 cases report)</article-title>. <source>Guangzhou Med J.</source> (<year>1984</year>) <volume>15</volume>:<fpage>16</fpage>&#8211;<lpage>8</lpage>.</mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loubei</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dihua</surname><given-names>S</given-names></name><name name-style="western"><surname>Jiening</surname><given-names>W</given-names></name></person-group><article-title>Prophylactic effect of BCG vaccination on the recurrence of children asthma</article-title>. <source>Chin J Paediatr.</source> (<year>1991</year>) <volume>39</volume>:<fpage>165</fpage>&#8211;<lpage>7</lpage>.</mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shirtcliffe</surname><given-names>PM</given-names></name><name name-style="western"><surname>Easthope</surname><given-names>SE</given-names></name><name name-style="western"><surname>Weatherall</surname><given-names>M</given-names></name><name name-style="western"><surname>Beasley</surname><given-names>R</given-names></name></person-group>. <article-title>Effect of repeated intradermal injections of heat-inactivated <italic toggle="yes">Mycobacterium bovis</italic> bacillus Calmette&#8211;Gu&#233;rin in adult asthma</article-title>. <source>Clin Exp Allergy.</source> (<year>2004</year>) <volume>34</volume>:<fpage>207</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2222.2004.01861.x</pub-id><pub-id pub-id-type="pmid">14987299</pub-id></mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Omenaas</surname><given-names>E</given-names></name><name name-style="western"><surname>Jentoft</surname><given-names>HF</given-names></name><name name-style="western"><surname>Vollmer</surname><given-names>WM</given-names></name><name name-style="western"><surname>Buist</surname><given-names>AS</given-names></name><name name-style="western"><surname>Gulsvik</surname><given-names>A</given-names></name></person-group>. <article-title>Absence of relationship between tuberculin reactivity and atopy in BCG vaccinated young adults</article-title>. <source>Thorax.</source> (<year>2000</year>) <volume>55</volume>:<fpage>454</fpage>. <pub-id pub-id-type="doi">10.1136/thorax.55.6.454</pub-id><pub-id pub-id-type="pmid">10817791</pub-id><pub-id pub-id-type="pmcid">PMC1745773</pub-id></mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yoneyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>M</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>K</given-names></name><name name-style="western"><surname>Odajima</surname><given-names>Y</given-names></name></person-group>. <article-title>The effect of DPT and BCG vaccinations on atopic disorders</article-title>. <source>Arerugi=[Allergy].</source> (<year>2000</year>) <volume>49</volume>:<fpage>585</fpage>&#8211;<lpage>92</lpage>. Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.jstage.jst.go.jp/browse/arerugi">https://www.jstage.jst.go.jp/browse/arerugi</ext-link><pub-id pub-id-type="pmid">10944825</pub-id></mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Marks</surname><given-names>GB</given-names></name><name name-style="western"><surname>Ng</surname><given-names>K</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>J</given-names></name><name name-style="western"><surname>Toelle</surname><given-names>BG</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>W</given-names></name><name name-style="western"><surname>Belousova</surname><given-names>EG</given-names></name><etal/></person-group>. <article-title>The effect of neonatal BCG vaccination on atopy and asthma at age 7 to 14 years: an historical cohort study in a community with a very low prevalence of tuberculosis infection and a high prevalence of atopic disease</article-title>. <source>J Allergy Clin Immunol.</source> (<year>2003</year>) <volume>111</volume>:<fpage>541</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1067/mai.2003.171</pub-id><pub-id pub-id-type="pmid">12642835</pub-id></mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alm</surname><given-names>JS</given-names></name><name name-style="western"><surname>Sanjeevi</surname><given-names>CB</given-names></name><name name-style="western"><surname>Miller</surname><given-names>EN</given-names></name><name name-style="western"><surname>Dabadghao</surname><given-names>P</given-names></name><name name-style="western"><surname>Lilja</surname><given-names>G</given-names></name><name name-style="western"><surname>Pershagen</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Atopy in children in relation to BCG vaccination and genetic polymorphisms at SLC11A1 (formerly NRAMP1) and D2S1471</article-title>. <source>Genes Immunity.</source> (<year>2002</year>) <volume>3</volume>:<fpage>71</fpage>. <pub-id pub-id-type="doi">10.1038/sj.gene.6363834</pub-id><pub-id pub-id-type="pmid">11960304</pub-id></mixed-citation></ref><ref id="B180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahrens</surname><given-names>B</given-names></name><name name-style="western"><surname>Gruber</surname><given-names>C</given-names></name><name name-style="western"><surname>Rha</surname><given-names>RD</given-names></name><name name-style="western"><surname>Freund</surname><given-names>T</given-names></name><name name-style="western"><surname>Quarcoo</surname><given-names>D</given-names></name><name name-style="western"><surname>Awagyan</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>BCG priming of dendritic cells enhances T regulatory and Th1 function and suppresses allergen-induced Th2 function <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic></article-title>. <source>Int Arch Allergy Immunol.</source> (<year>2009</year>) <volume>150</volume>:<fpage>210</fpage>&#8211;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1159/000222673</pub-id><pub-id pub-id-type="pmid">19494518</pub-id></mixed-citation></ref><ref id="B181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lindqvist</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>RE</given-names></name><name name-style="western"><surname>Osterland</surname><given-names>CK</given-names></name></person-group>. <article-title>Autoantibodies in chronic pulmonary tuberculosis</article-title>. <source>J Chronic Dis.</source> (<year>1970</year>) <volume>22</volume>:<fpage>717</fpage>&#8211;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/0021-9681(70)90047-0</pub-id><pub-id pub-id-type="pmid">4191378</pub-id></mixed-citation></ref><ref id="B182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Valentini</surname><given-names>D</given-names></name><name name-style="western"><surname>Rao</surname><given-names>M</given-names></name><name name-style="western"><surname>Rane</surname><given-names>L</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>S</given-names></name><name name-style="western"><surname>Axelsson-Robertson</surname><given-names>R</given-names></name><name name-style="western"><surname>Heuchel</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette&#8211;Gu&#233;rin vaccination</article-title>. <source>Int J Infect Dis.</source> (<year>2017</year>) <volume>56</volume>:<fpage>140</fpage>&#8211;<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2017.01.027</pub-id><pub-id pub-id-type="pmid">28161459</pub-id></mixed-citation></ref><ref id="B183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name><name name-style="western"><surname>Vilner</surname><given-names>Y</given-names></name><name name-style="western"><surname>Coates</surname><given-names>AR</given-names></name><name name-style="western"><surname>Rauch</surname><given-names>J</given-names></name><name name-style="western"><surname>Lavie</surname><given-names>G</given-names></name><name name-style="western"><surname>Shaul</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Monoclonal anti-tuberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with <italic toggle="yes">Mycobacterium tuberculosis</italic></article-title>. <source>Clin Exp Immunol</source>. (<year>1986</year>) <volume>66</volume>:<fpage>255</fpage>. <pub-id pub-id-type="pmid">3102132</pub-id><pub-id pub-id-type="pmcid">PMC1542527</pub-id></mixed-citation></ref><ref id="B184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glynn</surname><given-names>P</given-names></name><name name-style="western"><surname>Weedon</surname><given-names>D</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J</given-names></name><name name-style="western"><surname>Suckling</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Cuzner</surname><given-names>ML</given-names></name></person-group>. <article-title>Humoral immunity in chronic relapsing experimental autoimmune encephalomyelitis: the major oligoclonal IgG bands are antibodies to mycobacteria</article-title>. <source>J Neurol Sci.</source> (<year>1982</year>) <volume>57</volume>:<fpage>369</fpage>&#8211;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/0022-510X(82)90042-9</pub-id><pub-id pub-id-type="pmid">6186775</pub-id></mixed-citation></ref><ref id="B185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baxter</surname><given-names>AG</given-names></name><name name-style="western"><surname>Horsfall</surname><given-names>AC</given-names></name><name name-style="western"><surname>Healey</surname><given-names>D</given-names></name><name name-style="western"><surname>Ozegbe</surname><given-names>P</given-names></name><name name-style="western"><surname>Day</surname><given-names>S</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DG</given-names></name><etal/></person-group>. <article-title>Mycobacteria precipitate an SLE-like syndrome in diabetes-prone NOD mice</article-title>. <source>Immunology.</source> (<year>1994</year>) <volume>83</volume>:<fpage>227</fpage>&#8211;<lpage>31</lpage>. <pub-id pub-id-type="pmid">7835939</pub-id><pub-id pub-id-type="pmcid">PMC1414944</pub-id></mixed-citation></ref><ref id="B186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>HY</given-names></name><name name-style="western"><surname>Singh</surname><given-names>B</given-names></name></person-group>. <article-title>BCG vaccination prevents insulin-dependent diabetes mellitus (IDDM) in NOD mice after disease acceleration with cyclophosphamide</article-title>. <source>J Autoimmun.</source> (<year>1997</year>) <volume>10</volume>:<fpage>271</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1006/jaut.1997.0136</pub-id><pub-id pub-id-type="pmid">9218754</pub-id></mixed-citation></ref><ref id="B187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harada</surname><given-names>M</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>Y</given-names></name><name name-style="western"><surname>Makino</surname><given-names>S</given-names></name></person-group>. <article-title>Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination</article-title>. <source>Diabetes Res Clin Pract.</source> (<year>1990</year>) <volume>8</volume>:<fpage>85</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/0168-8227(90)90017-N</pub-id><pub-id pub-id-type="pmid">2307094</pub-id></mixed-citation></ref><ref id="B188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shehadeh</surname><given-names>N</given-names></name><name name-style="western"><surname>Calcinaro</surname><given-names>F</given-names></name><name name-style="western"><surname>Bradley</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Bruchim</surname><given-names>I</given-names></name><name name-style="western"><surname>Vardi</surname><given-names>P</given-names></name><name name-style="western"><surname>Lafferty</surname><given-names>KJ</given-names></name></person-group>. <article-title>Effect of adjuvant therapy on development of diabetes in mouse and man</article-title>. <source>Lancet.</source> (<year>1994</year>) <volume>343</volume>:<fpage>706</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(94)91583-0</pub-id><pub-id pub-id-type="pmid">7907682</pub-id></mixed-citation></ref><ref id="B189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#252;htreiber</surname><given-names>WM</given-names></name><name name-style="western"><surname>Tran</surname><given-names>L</given-names></name><name name-style="western"><surname>Kim</surname><given-names>T</given-names></name><name name-style="western"><surname>Dybala</surname><given-names>M</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>B</given-names></name><name name-style="western"><surname>Plager</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Long-term reduction in hyperglycemia in advanced type 1 diabetes: the value of induced aerobic glycolysis with BCG vaccinations</article-title>. <source>NPJ Vaccines</source>. (<year>2018</year>) <volume>3</volume>:<fpage>23</fpage>. <pub-id pub-id-type="doi">10.1038/s41541-018-0062-8</pub-id><pub-id pub-id-type="pmid">29951281</pub-id><pub-id pub-id-type="pmcid">PMC6013479</pub-id></mixed-citation></ref><ref id="B190"><label>190.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Faustman</surname><given-names>DL</given-names></name></person-group><article-title>Chapter 2 - The potential of TNF induction from BCG for the treatment of type 1 diabetes</article-title>. In: <person-group person-group-type="editor"><name name-style="western"><surname>Faustman</surname><given-names>DL</given-names></name></person-group> editor. <source>The Value of BCG and TNF in Autoimmunity Second Edition.</source><publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Academic Press</publisher-name> (<year>2018</year>). p. <fpage>11</fpage>&#8211;<lpage>24</lpage>.</mixed-citation></ref><ref id="B191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanjeevi</surname><given-names>CB</given-names></name><name name-style="western"><surname>Das</surname><given-names>AK</given-names></name><name name-style="western"><surname>Shtauvere-Brameus</surname><given-names>A</given-names></name></person-group>. <article-title>BCG vaccination and GAD65 and IA-2 autoantibodies in autoimmune diabetes in southern India</article-title>. <source>Ann N Y Acad Sci.</source> (<year>2002</year>) <volume>958</volume>:<fpage>293</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.2002.tb02990.x</pub-id><pub-id pub-id-type="pmid">12021127</pub-id></mixed-citation></ref><ref id="B192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huppmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Baumgarten</surname><given-names>A</given-names></name><name name-style="western"><surname>Ziegler</surname><given-names>AG</given-names></name><name name-style="western"><surname>Bonifacio</surname><given-names>E</given-names></name></person-group>. <article-title>Neonatal Bacille Calmette-Guerin vaccination and type 1 diabetes</article-title>. <source>Diabetes Care.</source> (<year>2005</year>) <volume>28</volume>:<fpage>1204</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.2337/diacare.28.5.1204</pub-id><pub-id pub-id-type="pmid">15855590</pub-id></mixed-citation></ref><ref id="B193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahlberg</surname><given-names>J</given-names></name><name name-style="western"><surname>Fredriksson</surname><given-names>J</given-names></name><name name-style="western"><surname>Vaarala</surname><given-names>O</given-names></name><name name-style="western"><surname>Ludvigsson</surname><given-names>J</given-names></name></person-group>. <article-title>Vaccinations may induce diabetes-related autoantibodies in one-year-old children</article-title>. <source>Ann N Y Acad Sci</source>. (<year>2006</year>) <volume>1005</volume>:<fpage>404</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1196/annals.1288.068</pub-id><pub-id pub-id-type="pmid">14679101</pub-id></mixed-citation></ref><ref id="B194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Faustman</surname><given-names>DL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Okubo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Burger</surname><given-names>D</given-names></name><name name-style="western"><surname>Ban</surname><given-names>L</given-names></name><name name-style="western"><surname>Man</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes</article-title>. <source>PLoS One.</source> (<year>2012</year>) <fpage>7</fpage>:<lpage>e41756-e</lpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0041756</pub-id><pub-id pub-id-type="pmid">22905105</pub-id><pub-id pub-id-type="pmcid">PMC3414482</pub-id></mixed-citation></ref><ref id="B195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>J</given-names></name><name name-style="western"><surname>Reinke</surname><given-names>EK</given-names></name><name name-style="western"><surname>Zozulya</surname><given-names>AL</given-names></name><name name-style="western"><surname>Sandor</surname><given-names>M</given-names></name><name name-style="western"><surname>Fabry</surname><given-names>Z</given-names></name></person-group>. <article-title><italic toggle="yes">Mycobacterium bovis</italic> bacille Calmette-Guerin infection in the CNS suppresses experimental autoimmune encephalomyelitis and Th17 responses in an IFN-gamma-independent manner</article-title>. <source>J Immunol.</source> (<year>2008</year>) <volume>181</volume>:<fpage>6201</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.181.9.6201</pub-id><pub-id pub-id-type="pmid">18941210</pub-id><pub-id pub-id-type="pmcid">PMC2735452</pub-id></mixed-citation></ref><ref id="B196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ristori</surname><given-names>G</given-names></name><name name-style="western"><surname>Romano</surname><given-names>S</given-names></name><name name-style="western"><surname>Cannoni</surname><given-names>S</given-names></name><name name-style="western"><surname>Visconti</surname><given-names>A</given-names></name><name name-style="western"><surname>Tinelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Mendozzi</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Effects of bacille calmette-guerin after the first demyelinating event in the CNS</article-title>. <source>Neurology.</source> (<year>2013</year>) <volume>82</volume>:<fpage>41</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1212/01.wnl.0000438216.93319.ab</pub-id><pub-id pub-id-type="pmid">24306002</pub-id><pub-id pub-id-type="pmcid">PMC3873620</pub-id></mixed-citation></ref><ref id="B197"><label>197.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cossu</surname><given-names>D</given-names></name><name name-style="western"><surname>Masala</surname><given-names>S</given-names></name><name name-style="western"><surname>Sechi</surname><given-names>LA</given-names></name></person-group>. <article-title>A Sardinian map for multiple sclerosis</article-title>. <source>Fut Microbiol.</source> (<year>2013</year>) <volume>8</volume>:<fpage>223</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.2217/fmb.12.135</pub-id><pub-id pub-id-type="pmid">23374127</pub-id></mixed-citation></ref><ref id="B198"><label>198.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cossu</surname><given-names>D</given-names></name><name name-style="western"><surname>Mameli</surname><given-names>G</given-names></name><name name-style="western"><surname>Masala</surname><given-names>S</given-names></name><name name-style="western"><surname>Cocco</surname><given-names>E</given-names></name><name name-style="western"><surname>Frau</surname><given-names>J</given-names></name><name name-style="western"><surname>Marrosu</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Evaluation of the humoral response against mycobacterial peptides, homologous to MOG35&#8211;55, in multiple sclerosis patients</article-title>. <source>J Neurol Sci.</source> (<year>2014</year>) <volume>347</volume>:<fpage>78</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2014.09.023</pub-id><pub-id pub-id-type="pmid">25271190</pub-id></mixed-citation></ref><ref id="B199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahr</surname><given-names>GM</given-names></name><name name-style="western"><surname>Rook</surname><given-names>GA</given-names></name><name name-style="western"><surname>Al-Saffar</surname><given-names>M</given-names></name><name name-style="western"><surname>Van Embden</surname><given-names>JDA</given-names></name><name name-style="western"><surname>Stanford</surname><given-names>JL</given-names></name><name name-style="western"><surname>Behbehani</surname><given-names>K</given-names></name></person-group>. <article-title>Antibody levels to mycobacteria in relation to HLA type: evidence for non-HLA-linked high levels of antibody to the 65 kD heat shock protein of M. bovis in rheumatoid arthritis</article-title>. <source>Clin Exp Immunol.</source> (<year>1988</year>) <volume>74</volume>:<fpage>211</fpage>. <pub-id pub-id-type="pmid">3147153</pub-id><pub-id pub-id-type="pmcid">PMC1541803</pub-id></mixed-citation></ref><ref id="B200"><label>200.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsoulfa</surname><given-names>G</given-names></name><name name-style="western"><surname>Rook</surname><given-names>GA</given-names></name><name name-style="western"><surname>Van-Embden</surname><given-names>JD</given-names></name><name name-style="western"><surname>Young</surname><given-names>DB</given-names></name><name name-style="western"><surname>Mehlert</surname><given-names>A</given-names></name><name name-style="western"><surname>Isenberg</surname><given-names>DA</given-names></name><etal/></person-group>. <article-title>Raised serum IgG and IgA antibodies to mycobacterial antigens in rheumatoid arthritis</article-title>. <source>Ann Rheumatic Dis.</source> (<year>1989</year>) <volume>48</volume>:<fpage>118</fpage>&#8211;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1136/ard.48.2.118</pub-id><pub-id pub-id-type="pmid">2930263</pub-id><pub-id pub-id-type="pmcid">PMC1003696</pub-id></mixed-citation></ref><ref id="B201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Worthington</surname><given-names>J</given-names></name><name name-style="western"><surname>Rigby</surname><given-names>AS</given-names></name><name name-style="western"><surname>MacGregor</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Silman</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Carthy</surname><given-names>D</given-names></name><name name-style="western"><surname>Ollier</surname><given-names>WE</given-names></name></person-group>. <article-title>Lack of association of increased antibody levels to mycobacterial hsp65 with rheumatoid arthritis: results from a study of disease discordant twin pairs</article-title>. <source>Ann Rheumatic Dis.</source> (<year>1993</year>) <volume>52</volume>:<fpage>542</fpage>&#8211;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1136/ard.52.7.542</pub-id><pub-id pub-id-type="pmid">8346983</pub-id><pub-id pub-id-type="pmcid">PMC1005096</pub-id></mixed-citation></ref><ref id="B202"><label>202.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panchapakesan</surname><given-names>J</given-names></name><name name-style="western"><surname>Daglis</surname><given-names>M</given-names></name><name name-style="western"><surname>Gatenby</surname><given-names>P</given-names></name></person-group>. <article-title>Antibodies to 65 kDa and 70 kDa heat shock proteins in rheumatoid arthritis and systemic lupus erythematosus</article-title>. <source>Immunol Cell Biol.</source> (<year>1992</year>) <volume>70</volume>:<fpage>295</fpage>&#8211;<lpage>300</lpage>. <pub-id pub-id-type="doi">10.1038/icb.1992.37</pub-id><pub-id pub-id-type="pmid">1478694</pub-id></mixed-citation></ref><ref id="B203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tinazzi</surname><given-names>E</given-names></name><name name-style="western"><surname>Ficarra</surname><given-names>V</given-names></name><name name-style="western"><surname>Simeoni</surname><given-names>S</given-names></name><name name-style="western"><surname>Artibani</surname><given-names>W</given-names></name><name name-style="western"><surname>Lunardi</surname><given-names>C</given-names></name></person-group>. <article-title>Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review</article-title>. <source>Rheumatol Int.</source> (<year>2006</year>) <volume>26</volume>:<fpage>481</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s00296-005-0059-2</pub-id><pub-id pub-id-type="pmid">16220289</pub-id></mixed-citation></ref><ref id="B204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shoenfeld</surname><given-names>Y</given-names></name><name name-style="western"><surname>Aron-Maor</surname><given-names>A</given-names></name><name name-style="western"><surname>Tanai</surname><given-names>A</given-names></name><name name-style="western"><surname>Ehrenfeld</surname><given-names>M</given-names></name></person-group>. <article-title>BCG and Autoimmunity: another two-edged sword</article-title>. <source>J Autoimmunity.</source> (<year>2001</year>) <volume>16</volume>:<fpage>235</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1006/jaut.2000.0494</pub-id><pub-id pub-id-type="pmid">11334488</pub-id></mixed-citation></ref><ref id="B205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Da Gama Duarte</surname><given-names>J</given-names></name><name name-style="western"><surname>Parakh</surname><given-names>S</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>MC</given-names></name><name name-style="western"><surname>Woods</surname><given-names>K</given-names></name><name name-style="western"><surname>Pasam</surname><given-names>A</given-names></name><name name-style="western"><surname>Tutuka</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Autoantibodies may predict immune-related toxicity: results from a phase I study of intralesional bacillus calmette-guerin followed by ipilimumab in patients with advanced metastatic melanoma</article-title>. <source>Front Immunol.</source> (<year>2018</year>) <volume>9</volume>:<fpage>411</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00411</pub-id><pub-id pub-id-type="pmid">29552014</pub-id><pub-id pub-id-type="pmcid">PMC5840202</pub-id></mixed-citation></ref><ref id="B206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Raymond</surname><given-names>P</given-names></name></person-group><article-title>On the pathological relations between cancer and tuberculosis</article-title>. <source>Proc Soc Exp Biol Med.</source> (<year>1928</year>) <volume>26</volume>:<fpage>73</fpage>&#8211;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.3181/00379727-26-4143</pub-id></mixed-citation></ref><ref id="B207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Old</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>DA</given-names></name><name name-style="western"><surname>Benacerraf</surname><given-names>B</given-names></name></person-group>. <article-title>Effect of Bacillus Calmette-Guerin infection on transplanted tumours in the mouse</article-title>. <source>Nature.</source> (<year>1959</year>) <volume>184</volume>(<issue>Suppl. 5</issue>):<fpage>291</fpage>&#8211;<lpage>2</lpage>. <pub-id pub-id-type="doi">10.1038/184291a0</pub-id><pub-id pub-id-type="pmid">14428599</pub-id></mixed-citation></ref><ref id="B208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carswell</surname><given-names>EA</given-names></name><name name-style="western"><surname>Old</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Kassel</surname><given-names>RL</given-names></name><name name-style="western"><surname>Green</surname><given-names>S</given-names></name><name name-style="western"><surname>Fiore</surname><given-names>N</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>B</given-names></name></person-group>. <article-title>An endotoxin-induced serum factor that causes necrosis of tumors</article-title>. <source>Proc Natl Acad Sci USA.</source> (<year>1975</year>) <volume>72</volume>:<fpage>3666</fpage>&#8211;<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.72.9.3666</pub-id><pub-id pub-id-type="pmid">1103152</pub-id><pub-id pub-id-type="pmcid">PMC433057</pub-id></mixed-citation></ref><ref id="B209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alexandroff</surname><given-names>AB</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>AM</given-names></name><name name-style="western"><surname>O'Donnell</surname><given-names>MA</given-names></name><name name-style="western"><surname>James</surname><given-names>K</given-names></name></person-group>. <article-title>BCG immunotherapy of bladder cancer: 20 years on</article-title>. <source>Lancet.</source> (<year>1999</year>) <volume>353</volume>:<fpage>1689</fpage>&#8211;<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(98)07422-4</pub-id><pub-id pub-id-type="pmid">10335805</pub-id></mixed-citation></ref><ref id="B210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Redelman-Sidi</surname><given-names>G</given-names></name><name name-style="western"><surname>Glickman</surname><given-names>MS</given-names></name><name name-style="western"><surname>Bochner</surname><given-names>BH</given-names></name></person-group>. <article-title>The mechanism of action of BCG therapy for bladder cancer&#8212;a current perspective</article-title>. <source>Nat Rev Urol.</source> (<year>2014</year>) <volume>11</volume>:<fpage>153</fpage>. <pub-id pub-id-type="doi">10.1038/nrurol.2014.15</pub-id><pub-id pub-id-type="pmid">24492433</pub-id></mixed-citation></ref><ref id="B211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wile</surname><given-names>AG</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>FC</given-names></name><name name-style="western"><surname>Morton</surname><given-names>DL</given-names></name></person-group>. <article-title>Monitoring immunotherapy with Bacillus Calmette-Guerin by antibody titer</article-title>. <source>Cancer Res.</source> (<year>1977</year>) <volume>37</volume>(7 Pt 1):<fpage>2251</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="pmid">324610</pub-id></mixed-citation></ref><ref id="B212"><label>212.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Winters</surname><given-names>WD</given-names></name><name name-style="western"><surname>Lamm</surname><given-names>DL</given-names></name></person-group>. <article-title>Antibody responses to Bacillus Calmette-Guerin during immunotherapy in bladder cancer patients</article-title>. <source>Cancer Res.</source> (<year>1981</year>) <volume>41</volume>:<fpage>2672</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="pmid">7018669</pub-id></mixed-citation></ref><ref id="B213"><label>213.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lamm</surname><given-names>DL</given-names></name><name name-style="western"><surname>Thor</surname><given-names>DE</given-names></name><name name-style="western"><surname>Winters</surname><given-names>WD</given-names></name><name name-style="western"><surname>Stogdill</surname><given-names>VD</given-names></name><name name-style="western"><surname>Radwin</surname><given-names>HM</given-names></name></person-group>. <article-title>BCG immunotherapy of bladder cancer: inhibition of tumor recurrence and associated immune responses</article-title>. <source>Cancer.</source> (<year>1981</year>) <volume>48</volume>:<fpage>82</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/1097-0142(19810701)48:1&amp;#x0003c;82::AID-CNCR2820480117&amp;#x0003e;3.0.CO;2-Z</pub-id><pub-id pub-id-type="pmid">7016300</pub-id></mixed-citation></ref><ref id="B214"><label>214.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van der Meijden</surname><given-names>APM</given-names></name><name name-style="western"><surname>Steerenberg</surname><given-names>PA</given-names></name><name name-style="western"><surname>Van Hoogstraaten</surname><given-names>IMW</given-names></name><name name-style="western"><surname>Kerckhaert</surname><given-names>JA</given-names></name><name name-style="western"><surname>Schreinemachers</surname><given-names>LMH</given-names></name><name name-style="western"><surname>Harthoorn-Lasthuizen</surname><given-names>EJ</given-names></name><etal/></person-group>. <article-title>Immune reactions in patients with superficial bladder cancer after intradermal and intravesical treatment with bacillus Calmette-Guerin</article-title>. <source>Cancer Immunol Immunother</source>. (<year>1989</year>) <volume>28</volume>:<fpage>287</fpage>&#8211;<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1007/BF00205239</pub-id><pub-id pub-id-type="pmid">2784716</pub-id><pub-id pub-id-type="pmcid">PMC11038704</pub-id></mixed-citation></ref><ref id="B215"><label>215.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zlotta</surname><given-names>AR</given-names></name><name name-style="western"><surname>Drowart</surname><given-names>A</given-names></name><name name-style="western"><surname>Huygen</surname><given-names>K</given-names></name><name name-style="western"><surname>De Bruyn</surname><given-names>J</given-names></name><name name-style="western"><surname>Shekarsarai</surname><given-names>H</given-names></name><name name-style="western"><surname>Decock</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Humoral response against heat shock proteins and other mycobacterial antigens after intravesical treatment with bacille Calmette&#8211;Guerin (BCG) in patients with superficial bladder cancer</article-title>. <source>Clin Exp Immunol</source>. (<year>1997</year>) <volume>109</volume>:<fpage>157</fpage>&#8211;<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2249.1997.4141313.x</pub-id><pub-id pub-id-type="pmid">9218839</pub-id><pub-id pub-id-type="pmcid">PMC1904703</pub-id></mixed-citation></ref><ref id="B216"><label>216.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Biot</surname><given-names>C</given-names></name><name name-style="western"><surname>Rentsch</surname><given-names>CA</given-names></name><name name-style="western"><surname>Gsponer</surname><given-names>JR</given-names></name><name name-style="western"><surname>Birkhauser</surname><given-names>FD</given-names></name><name name-style="western"><surname>Jusforgues-Saklani</surname><given-names>H</given-names></name><name name-style="western"><surname>Lemaitre</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer</article-title>. <source>Sci Transl Med.</source> (<year>2012</year>) <volume>4</volume>:<fpage>137ra72</fpage>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3003586</pub-id><pub-id pub-id-type="pmid">22674550</pub-id></mixed-citation></ref><ref id="B217"><label>217.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borsos</surname><given-names>T</given-names></name><name name-style="western"><surname>Rapp</surname><given-names>HJ</given-names></name></person-group>. <article-title>Antigenic relationship between <italic toggle="yes">Mycobacterium bovis</italic> (BCG) and a guinea pig hepatoma</article-title>. <source>J Natl Cancer Institute.</source> (<year>1973</year>) <volume>51</volume>:<fpage>1085</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1093/jnci/51.3.1085</pub-id><pub-id pub-id-type="pmid">4355214</pub-id></mixed-citation></ref><ref id="B218"><label>218.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufmann</surname><given-names>SHE</given-names></name></person-group>. <article-title>Heat shock proteins and the immune response</article-title>. <source>Immunol Today.</source> (<year>1990</year>) <volume>11</volume>:<fpage>129</fpage>&#8211;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/0167-5699(90)90050-J</pub-id><pub-id pub-id-type="pmid">2187470</pub-id></mixed-citation></ref><ref id="B219"><label>219.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hara</surname><given-names>I</given-names></name><name name-style="western"><surname>Sato</surname><given-names>N</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kamidono</surname><given-names>S</given-names></name></person-group>. <article-title>Immune response against BCG 65 kDa protein antigen in bladder cancer with BCG instillation therapy. Analyses carried out with the gene of this protein to develop a monoclonal antibody</article-title>. <source>Nihon Hinyokika Gakkai zasshi Japan J Urol</source>. (<year>1991</year>) <volume>82</volume>:<fpage>24</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.5980/jpnjurol1989.82.24</pub-id><pub-id pub-id-type="pmid">1710676</pub-id></mixed-citation></ref><ref id="B220"><label>220.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishibashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>H</given-names></name><name name-style="western"><surname>Harada</surname><given-names>S</given-names></name><name name-style="western"><surname>Harada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Takamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>K</given-names></name></person-group>. <article-title>Inhibition and promotion of tumor growth by BCG: evidence for stimulation of humoral enhancing factors by BCG</article-title>. <source>Int J Cancer.</source> (<year>1978</year>) <volume>21</volume>:<fpage>67</fpage>&#8211;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1002/ijc.2910210112</pub-id><pub-id pub-id-type="pmid">624600</pub-id></mixed-citation></ref><ref id="B221"><label>221.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name></person-group>. <article-title>Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle</article-title>. <source>Infect Immunity.</source> (<year>2003</year>) <volume>71</volume>:<fpage>4225</fpage>&#8211;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.71.8.4225-4228.2003</pub-id><pub-id pub-id-type="pmid">12874297</pub-id><pub-id pub-id-type="pmcid">PMC166024</pub-id></mixed-citation></ref><ref id="B222"><label>222.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lund</surname><given-names>FE</given-names></name><name name-style="western"><surname>Randall</surname><given-names>TD</given-names></name></person-group>. <article-title>Effector and regulatory B cells: modulators of CD4<sup>+</sup> T cell immunity</article-title>. <source>Nat Rev Immunol.</source> (<year>2010</year>) <volume>10</volume>:<fpage>236</fpage>&#8211;<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1038/nri2729</pub-id><pub-id pub-id-type="pmid">20224569</pub-id><pub-id pub-id-type="pmcid">PMC3038334</pub-id></mixed-citation></ref><ref id="B223"><label>223.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>A</given-names></name><name name-style="western"><surname>Tj&#228;rnlund</surname><given-names>A</given-names></name><name name-style="western"><surname>Ivanji</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>I</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Role of IgA in the defense against respiratory infections: IgA deficient mice exhibited increased susceptibility to intranasal infection with <italic toggle="yes">Mycobacterium bovis</italic> BCG</article-title>. <source>Vaccine.</source> (<year>2005</year>) <volume>23</volume>:<fpage>2565</fpage>&#8211;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2004.11.032</pub-id><pub-id pub-id-type="pmid">15780438</pub-id></mixed-citation></ref><ref id="B224"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balu</surname><given-names>S</given-names></name><name name-style="western"><surname>Reljic</surname><given-names>R</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Pleass</surname><given-names>RJ</given-names></name><name name-style="western"><surname>McIntosh</surname><given-names>R</given-names></name><name name-style="western"><surname>van Kooten</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>A novel human IgA monoclonal antibody protects against tuberculosis</article-title>. <source>J Immunol.</source> (<year>2011</year>) <volume>186</volume>:<fpage>3113</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1003189</pub-id><pub-id pub-id-type="pmid">21257971</pub-id><pub-id pub-id-type="pmcid">PMC3115510</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>